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Platelets play pivotal roles in thrombosis and hemostasis. Upon vascular injury, they 
acutely respond by forming a plug or aggregate, and thereby prevent further blood loss. 
Following activation of the coagulation cascade, a fibrin mesh is formed, which stabilizes 
the platelet plug. This process of clot formation is referred to as hemostasis.1 When platelet 
activation or coagulation is impaired due to either genetic or environmental factors, 
hemostatic clot formation is hampered, which leads to an increased risk of hemorrhage. 
On the contrary, enhanced platelet activation or coagulation relates to a higher risk of 
thrombosis, which is the pathological process where aberrant clot formation results in 
occlusion of a blood vessel. While platelets are considered to have a predominant role in 
arterial thrombosis, venous thrombosis is more dependent on the coagulation process.2,3 
In the present chapter, a general overview is given of platelet functions and of 
thrombus formation, as far as relevant for the present thesis. Furthermore, a brief 
description is provided on acquired clinical conditions that are linked to either bleeding 
or thrombosis.
Regulation of platelet functions and thrombus formation
 The formation of new platelets takes place mainly, but not exclusively, in the 
bone marrow.4,5 Proplatelets are shed from the precursor megakaryocytes in a process 
called thrombopoiesis.6 These proplatelets further divide to form the individual platelets 
that stay in circulation. In man, platelets circulate for 7-10 days on average, meaning 
that a continuous production of new platelets is needed to maintain a constant platelet 
count.7
Newly formed platelets contain measurable amounts of mRNA that is inherited 
from the precursor megakaryocytes; hence they are named ‘reticulated platelets’.8 As 
the platelet mRNA degrades over time, the older circulating platelets are essentially 
devoid of these linear ribonucleotides, although they still contain circular RNA forms.9 
The presence of mRNA is often used as a feature to identify newly formed platelets.10 
In the literature, it has been suggested that reticulated platelets are larger and more 
reactive than the older ones.11,12 However, conclusive evidence for this suggestion is 
still missing,13,14 partly due to the lack of methods that enable a proper detection of 
reticulated platelets. Characterization of these platelet types in terms of structure and 
function thus requires more investigation.
Circulating platelets are capable of responding quickly to vascular damage, since 
they are equipped with a multitude of signaling receptors on the plasma membrane.1,15 
Under conditions of high shear rate, such as present in the arteries and arterioles, red 
blood cells normally accumulate in the central part of the vessel lumen, whereby they 
push the platelets outwards to come in close proximity to the vascular wall.16,17 One 
of the first events, upon vascular damage, is the shear-dependent interaction of these 
platelets with von Willebrand factor, derived from endothelial cells, that is bound to 
the exposed collagen fibers.18 The platelet glycoprotein Ib-V-IX complexes are primarily 
responsible for the interaction with von Willebrand factor. It causes platelets to roll, which 
then triggers their firm binding to collagen itself via the receptors glycoprotein VI and 
integrin α2β1.
1,19,20 The collagen-attached platelets become activated, primarily through 
1General Introduction 
CHAPTER 1
9
glycoprotein VI, and respond by granule secretion, in which they release cargo molecules 
from the α and dense granules. Depending on the strength of the stimulus, platelets 
will secrete more or less of this granular cargo.21 The secretory granules contain many 
autocrine and paracrine molecules. Large molecules, such as fibrinogen and factor V, are 
packed in the α granules, while the dense granules are loaded among others with ADP, 
ATP and polyphosphates.22 Once secreted, ATP and ADP serve as autacoids to activate 
nearby platelets via the purinergic receptors P2X1 (for ATP) and P2Y1 plus P2Y12 (for ADP). 
Along with secretion, the autacoid thromboxane A2 is produced via the cyclooxygenase/
thromboxane synthase complex, which similarly activates nearby platelets via the 
TP receptors. Together, these autocrine agents provide a potent amplification loop to 
enhance effects of initial triggers of platelet activation, e.g. provided by collagen or 
thrombin traces.23,24 Another important platelet response is the conformation change 
of integrin α
IIb
β
3
, which is a glycoprotein complex abundantly expressed on the platelet 
surface. Activation of α
IIb
β
3
 integrin enables the binding of fibrinogen, a protein that is 
necessary for platelet-platelet interactions and thus for stable platelet aggregation.25 The 
eventual size and activity of a platelet aggregate or a thrombus formed on collagen is 
furthermore influenced by the presence of other platelet-adhesive proteins in the vessel 
wall and by local shear stress.26
 There is evidence indicating that platelets remain active for a certain time, also 
after being incorporated into a thrombus. For instance, the platelets in a thrombus 
formed on collagen secrete matrix metalloproteinases, enzymes which gradually 
degrade the underlying collagen fibers.27 In addition, these platelets can undergo 
proteolytic cleavage of several glycoproteins.28 Glycoprotein Ibα and glycoprotein VI 
can be cleaved by members of the A Disintegrin And Metalloprotease family, namely 
by ADAM17 and ADAM10, respectively, in a process called receptor shedding.29 Both 
ADAM10 and 17 are membrane-bound proteases, which remove the entire extracellular 
domain of their target membrane proteins.30 Although shedding of glycoprotein Ibα and 
glycoprotein VI will theoretically impair the ability of platelets to bind von Willebrand 
factor and collagen, the physiological role of receptor shedding has remained elusive. 
So far, only the suggestion has been made that shedding is a mechanism to shut down 
platelet adhesion and activation.31 Another suggestion is that the shedding of especially 
glycoprotein Ibα serves to clear platelets from the circulation in the liver.32
Platelet heterogeneity within thrombi
It has been established in earlier work from our laboratory that the platelets that 
are incorporated in a thrombus can undergo different types of responses, and thereby 
show different phenotypes.1 Accordingly, the composition of an average thrombus 
is quite heterogeneous, containing multiple platelet phenotypes (Figure 1). How 
individual platelets decide which phenotype to adapt is largely unknown. The immediate 
environment of a platelet is considered to be important, but also the composition of a 
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platelet may contribute to the heterogeneity.33,34 It can be hypothesized that the content 
of cytoplasm and membranes that is inherited from a given precursor megakaryocyte 
predispose platelets to assume a certain phenotype.
Phenotypes that can be distinguished are adherent platelets – platelets that 
directly interact with the damaged vessel wall – and aggregating platelets, which in 
particular interact with each other. The majority of these aggregating platelets, which 
form the bulk of the thrombus, show high activation of integrin α
IIb
β
3
, required for 
platelet aggregation and show significant levels of secretion.33,35 Upon strong activation 
with sustained, high intracellular Ca2+ levels, collagen-interacting platelets assume a 
different, procoagulant phenotype.35,36 The procoagulant platelets are characterized 
by the presence of negatively charged phosphatidylserine at the outer leaflet of the 
plasma membrane.37 Phosphatidylserine exposure is mediated by the ion channel 
and phospholipid scramblase anoctamin-6 (previously designated as TMEM16F), 
causing transbilayer movement of phospholipids over the membrane.38,39 The exposed 
phosphatidylserine supports assembly of the coagulation complexes, tenase and 
prothrombinase, and thereby catalyzes the formation of thrombin.35,40
Tissue factor that comes into contact with blood upon vascular damage triggers the 
extrinsic pathway of coagulation, by forming a complex with coagulation factor VII(a) and 
factor X.41 Once initial traces of factor Xa and subsequently thrombin are formed, these 
cleave other coagulation factors, including factor V. In the prothrombinase complexes 
at the surface of procoagulant platelets, the formed factor Xa assembles with factor 
Va, which then strongly stimulates the conversion of prothrombin to thrombin.42,43 The 
local generation of thrombin enhances platelet activation, and also converts fibrinogen 
to fibrin.34 The so-called coated platelets form a specific subset of the procoagulant 
platelets.44 These coated platelets require co-activation with thrombin, and show high 
levels of fibrin(ogen) binding, despite integrin α
IIb
β
3
 closure and contain high activity 
of the transglutaminase factor XIIIa, which assists in platelet-dependent fibrin fiber 
formation.45 Consequently, a fibrin network is formed which extends from the thrombus. 
In vivo models of thrombosis have shown that the fibrin network is distributed in and 
around a thrombus in a non-homogeneous way.46,47 In spite of this knowledge, it is still 
unclear how the platelet activation state and local shear stress determine the spatial 
distribution of fibrin.
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Platelets and thrombosis
The most common cause of arterial thrombosis is rupture or erosion of an 
atherosclerotic plaque.3 For example, in the coronary arteries this results in partial or 
full occlusion, with myocardial infarction as a consequence. Patients with obstructed 
coronary arteries are often treated by percutaneous coronary intervention, followed 
by stent placement. In order to prevent recurrent ischemic events, e.g. due to in-stent 
thrombosis, patients receive dual antiplatelet therapy.48 The therapeutic regimen consists 
of a daily intake of a P2Y12 inhibitor for the period of one year, in combination with aspirin 
that is recommended to be taken life-long.49 The P2Y12 inhibitors that are currently 
prescribed include the irreversible inhibitors, clopidogrel or prasugrel, or alternatively 
the reversible inhibitor, ticagrelor.23 The irreversible inhibitors form an active metabolite 
in the liver which, once released into the blood stream, specifically binds and inactivates 
the platelet P2Y12 receptors.
50 Aspirin, on the other hand, irreversibly abolishes the 
synthesis of thromboxane A2, and thereby blocks the reinforcement of platelet response 
by this autacoid.51 An important drawback of the dual inhibition of both ADP/P2Y12 and 
thromboxane A2 responses is a significantly increased risk of bleeding.
23 Since after one 
year of treatment, the beneficial antithrombotic effect equalizes the negative effect of 
bleeding, it is advised to stop administration of the P2Y12 inhibitors at this time point. 
There are indications that, during the offset period, patients are at increased risk of a 
recurrent ischemic event.52-55 Speculations are that this is possibly a consequence of 
hyperreactivity of the platelets, which are formed after treatment cessation, but this has 
not been studied in detail.
Bleeding
Under conditions where platelet or coagulation activation is impaired, hemostatic 
clot formation becomes hampered, leading to an increased risk of bleeding. As of today, 
the most common treatment option to prevent or treat hemorrhages is the transfusion 
of blood products.56 In the Netherlands, platelet transfusion is commonly performed 
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Figure 1: An overview of platelet heterogeneity in thrombus formation. Detailed explanation of the roles of 
different platelet agonists, receptors and platelet subtypes is given in the text.
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with concentrates consisting of platelets pooled from five donors, suspended in plasma 
to which ‘PAS’ (platelet-additive solution) medium can be added. These pooled platelet 
concentrates can be stored for up to 7 days.57 Although platelet transfusions temporarily 
increases the platelet count and hence improves hemostasis, this treatment also has 
potential risks, such as allergic reactions, infectious diseases and, incidentally, acute lung 
injury.56
Currently, a substantial part of platelet concentrates is administered to patients, who 
have been diagnosed with a hematological malignancy and who were therefore treated 
with chemotherapy.58 As a consequence of disease and foremost chemotherapeutic 
treatment, these patients develop severe thrombocytopenia.58 Normal platelet count 
ranges from 150-400 x 109 plts/L, but severely thrombocytopenic patients have a platelet 
count lower than 50 x 109 plts/L. Besides a low count, it has been reported that the 
platelets of these patients before onset of chemotherapy can show impairments in 
P-selectin expression and thromboxane B2 production, which might explain an increased 
bleeding risk.59,60 However, the severity and etiology of such a platelet dysfunction is 
unclear.
Another clinical condition in which bleeding is common is that of dilutional 
coagulopathy. As a consequence of major blood loss due to trauma or surgery (e.g. 
the cardiopulmonary bypass procedure) patients will receive fluid infusion (crystalloids 
and colloids) to maintain normal fluid and electrolyte homeostasis.61 As a consequence 
of both the blood loss and the blood dilution, coagulation factors will become diluted 
and thrombocytopenia will occur. In order to prevent anemia and preserve hemostasis, 
transfusion protocols have been developed, in which packed red blood cells, plasma and 
coagulation factors, and platelet concentrates are given.62,63 However, as it is desired to 
reduce unnecessary use of blood products,63 a better understanding of the individual and 
combined effects of these blood products is necessary.
Experimental models for thrombosis and hemostasis
To understand the roles of different platelet and coagulation proteins in thrombosis 
and bleeding, genetic mouse models have been developed, in which a specific platelet 
or coagulation protein is missing or defective.64 Experimentally, arterial damage can be 
induced in these mice to trigger thrombus formation,65 and the tail tip can be cut to 
monitor the bleeding phenotype.64 Taking into account specific differences between 
the human and mouse hemostatic systems, these genetic mouse models have provided 
useful insight into the process of thrombus formation, and guided in the development 
of new antiplatelet and anticoagulant therapies.66 As a way to reduce and refine such 
animal experiments, in vitro studies can be performed with isolated whole blood and 
microfluidic flow chambers.67,68 From a translational point of view, using such flow 
chambers, it is possible to study thrombus formation on multiple thrombogenic surfaces 
in the absence or presence of coagulation with either mouse or human blood samples.26,68 
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By systematically comparing the consequences of a genetic deficiency in various in vivo 
and in vitro approaches, a broader understanding of the roles of the individual genes in 
thrombosis and hemostasis can be gained.
Aims and outline of this thesis
The chapters of this thesis have as a common aim to better understand the 
consequences of an acquired impairment or recovery of platelet functions. In Chapter 1, 
a general introduction is presented in order to provide relevant background information 
on platelet physiology and mechanisms of platelet activation during thrombus 
formation. Chapter 2 provides a new concept regarding the formation of different 
platelet populations in a physiological environment, and extends this to altered platelet 
phenotypes in a pathological environment. Chapter 3 describes how newly formed, 
juvenile platelets contribute to a recovery of function in patients, who stopped intake 
of the P2Y12 receptor inhibitor prasugrel at one year after myocardial infarction. This 
chapter furthermore presents a novel methodology to identify the juvenile platelets, 
such in comparison to established methods. Chapter 4 focuses on the dynamic processes 
of platelet adhesion, aggregation and fibrin clot formation under flow conditions. It is 
examined how immobilized collagen and tissue factor steer the formation of different 
types of thrombi with a specific micro-elastic structure. Thrombus phenotype and 
architecture are also characterized in Chapter 5. Here, a new feature of the population of 
procoagulant platelets is examined, namely the loss of glycoprotein Ibα and glycoprotein 
VI. It is studied how extracellular shedding of these receptors, mediated by the proteases 
ADAM10 and 17, affects the platelet coagulant activity. This chapter also identifies the 
main signaling pathways, which regulate ADAM activity in activated platelets. The central 
theme of Chapter 6 is identification and characterization of platelet dysfunction, which 
occurs in leukemia, multiple myeloma and lymphoma patients, who are treated with 
chemotherapy and develop thrombocytopenia as a consequence. This work focusses on 
the role of platelet mitochondria in relation to the dysfunction. How platelet transfusion 
alters the overall platelet responsiveness in these patients is studied as well. Chapter 
7 examines the means for recovery of coagulant activity in patients with dilutional 
coagulopathy. A central question is how the supplementation of platelets and fibrinogen 
can alter elastic clot formation and, hence, improve the acquired hemostatic dysfunction. 
Chapter 8 presents a comprehensive literature synthesis, aiming to develop a method 
to systematically compare the consequences of genetic deficiencies in mice for arterial 
thrombosis and hemostasis. A scoring system is proposed allowing the calibration and 
comparison of multiple heterogeneous studies using different in vivo and in vitro models 
of arterial thrombus formation. These scores are used to construct a network of proteins 
in thrombosis and hemostasis, allowing the identification of new genes involved in these 
processes. In the last Chapter 9, the principal findings of this thesis are critically discussed 
in the light of the current literature.
CHAPTER 1
Chapter 1
14
References
1. Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 
2013;93(1):327-358.
2. Tan KT, Lip GY. Red vs white thrombi: treating the right clot is crucial. Arch Intern Med. 2003;163(20):2534-
2535.
3. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.
4. Stegner D, van Eeuwijk JMM, Angay O, et al. Thrombopoiesis is spatially regulated by the bone marrow 
vasculature. Nat Commun. 2017;8(1):127.
5. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir 
for haematopoietic progenitors. Nature. 2017;544(7648):105-109.
6. Thon JN, Italiano JEJ. Does size matter in platelet production? Blood. 2012;120(8):1552-1561.
7. Lebois M, Josefsson EC. Regulation of platelet lifespan by apoptosis. Platelets. 2016;27(6):497-504.
8. Schubert S, Weyrich AS, Rowley JW. A tour through the transcriptional landscape of platelets. Blood. 
2014;124(4):493-502.
9. Alhasan AA, Izuogu OG, Al-Balool HH, et al. Circular RNA enrichment in platelets is a signature of 
transcriptome degradation. Blood. 2016;127(9):e1-e11.
10. Harrison P, Goodall AH. “Message in the platelet”-- more than just vestigial mRNA! Platelets. 
2008;19(6):395-404.
11. Rinder HM, Tracey JB, Recht M, et al. Differences in platelet alpha-granule release between normals 
and immune thrombocytopenic patients and between young and old platelets. Thromb Haemost. 
1998;80(3):457-462.
12. McBane RDn, Gonzalez C, Hodge DO, Wysokinski WE. Propensity for young reticulated platelet 
recruitment into arterial thrombi. J Thromb Thrombolysis. 2014;37(2):148-154.
13. Robinson MS, Mackie IJ, Khair K, et al. Flow cytometric analysis of reticulated platelets: evidence for a large 
proportion of non-specific labelling of dense granules by fluorescent dyes. Br J Haematol. 1998;100(2):351-
357.
14. Hoffmann JJ, van den Broek NM, Curvers J. Reference intervals of reticulated platelets and other platelet 
parameters and their associations. Arch Pathol Lab Med. 2013;137(11):1635-1640.
15. Swieringa F, Kuijpers MJ, Heemskerk JW, van der Meijden PE. Targeting platelet receptor function in 
thrombus formation: the risk of bleeding. Blood Rev. 2014;28(1):9-21.
16. Aarts PA, van den Broek SA, Prins GW, et al. Blood platelets are concentrated near the wall and red blood 
cells, in the center in flowing blood. Arteriosclerosis. 1988;8(6):819-824.
17. Zwaginga JJ, Nash G, King MR, et al. Flow-based assays for global assessment of hemostasis. Part 1: 
Biorheologic considerations. J Thromb Haemost. 2006;4(11):2486-2487.
18. Ruggeri ZM, Mendolicchio GL. Interaction of von Willebrand factor with platelets and the vessel wall. 
Hamostaseologie. 2015;35(3):211-224.
19. Siljander PR, Munnix IC, Smethurst PA, et al. Platelet receptor interplay regulates collagen-induced 
thrombus formation in flowing human blood. Blood. 2004;103(4):1333-1341.
20. Auger JM, Kuijpers MJ, Senis YA, Watson SP, Heemskerk JW. Adhesion of human and mouse platelets to 
collagen under shear: a unifying model. FASEB J. 2005;19(7):825-827.
21. Eckly A, Rinckel JY, Proamer F, et al. Respective contributions of single and compound granule fusion to 
secretion by activated platelets. Blood. 2016;128(21):2538-2549.
22. Joshi S, Whiteheart SW. The nuts and bolts of the platelet release reaction. Platelets. 2017;28(2):129-
137.
23. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced 
defects. Blood. 2011;117(7):2102-2112.
24. Jones S, Evans RJ, Mahaut-Smith MP. Ca2+ influx through P2X1 receptors amplifies P2Y1 receptor-evoked 
Ca2+ signaling and ADP-evoked platelet aggregation. Mol Pharmacol. 2014;86(3):243-251.
25. Cosemans JM, Iserbyt BF, Deckmyn H, Heemskerk JW. Multiple ways to switch platelet integrins on and 
off. J Thromb Haemost. 2008;6(8):1253-1261.
26. de Witt SM, Swieringa F, Cavill R, et al. Identification of platelet function defects by multi-parameter 
assessment of thrombus formation. Nat Commun. 2014;16(5):4257.
27. Mastenbroek TG, Feijge MA, Kremers RM, et al. Platelet-associated matrix metalloproteinases regulate 
1General Introduction 
CHAPTER 1
15
thrombus formation and exert local collagenolytic activity. Arterioscler Thromb Vasc Biol. 2015;35(12):2554-
2561.
28. Fong KP, Barry C, Tran AN, et al. Deciphering the human platelet sheddome. Blood. 2011;117(1):e15-e26.
29. Gardiner EE, Karunakaran D, Shen Y, et al. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-
IX-V by ADAM family metalloproteinases. J Thromb Haemost. 2007;5(7):1530-1537.
30. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A. The role of ADAM-mediated shedding in vascular 
biology. Eur J Cell Biol. 2012;91(6-7):472-485.
31. Gardiner EE, Andrews RK. Platelet receptor expression and shedding: glycoprotein Ib-IX-V and 
glycoprotein VI. Transfus Med Rev. 2014;28(2):56-60.
32. Jansen AJ, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after 
refrigeration and initiates GPIba metalloproteinase-mediated cleavage in mice. Blood. 2012;119(5):1263-
1273.
33. Munnix IC, Cosemans JM, Auger JM, Heemskerk JW. Platelet response heterogeneity in thrombus 
formation. Thromb Haemost. 2009;102(6):1149-1156.
34. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different 
functions. J Thromb Haemost. 2013;11(1):2-16.
35. Munnix IC, Kuijpers MJ, Auger JM, et al. Segregation of platelet aggregatory and procoagulant 
microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc 
Biol. 2007;27(11):2484-2490.
36. Jackson SP, Schoenwaelder SM. Procoagulant platelets: are they necrotic? Blood. 2010;116(12):2011-
2018.
37. Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity 
and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982;122(2):429-
436.
38. van Kruchten R, Mattheij NJ, Saunders C, et al. Both TMEM16F-dependent and TMEM16F-independent 
pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood. 
2013;121(10):1850-1857.
39. Lhermusier T, Chap H, Payrastre B. Platelet membrane phospholipid asymmetry; from the characterization 
of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. J Thromb 
Haemost. 2011;9(10):1883-1891.
40. Berny MA, Munnix IC, Auger JM, et al. Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on 
thrombi at venous shear. PLoS One. 2010;5(4):e10415.
41. Ruf W, Riewald M. Regulation of tissue factor expression: Landes Bioscience; 2000-2013.
42. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and 
thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-1693.
43. Hoffman M, Monroe DMr. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958-965.
44. Alberio L, Ravanat C, Hechler B, et al. Delayed-onset of procoagulant signalling revealed by kinetic 
analysis of COAT platelet formation. Thromb Haemost. 2017;117(6):1101-1114.
45. Mattheij NJ, Swieringa F, Mastenbroek TG, et al. Coated platelets function in platelet-dependent fibrin 
formation via integrin αIIbβ3 and transglutaminase factor XIII. Haematologica. 2016;101(4):427-436.
46. Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. Par4 is required for platelet thrombus 
propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A. 
2007;104(1):288-292.
47. Stalker TJ, Welsh J, Tomaiuolo M, et al. A systems approach to hemostasis: 3. Thrombus consolidation 
regulates intrathrombus solute transport and local thrombin activity. Blood. 2014;124(11):1824-1831.
48. Ten Berg JM, Zwart B, van ‘t Hof AW, et al. Optimal duration of dual antiplatelet therapy after percutaneous 
coronary intervention or after acute coronary syndrome: Practical lessons from a review. Neth Heart J. 
2017;Epub ahead of print.
49. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in 
patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-2619.
50. Floyd CN, Passacquale G, Ferro A. Comparative pharmacokinetics and pharmacodynamics of 
platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet. 
2012;51(7):429-442.
51. Schrör K. Why we should not skip aspirin in cardiovascular prevention. Hamostaseologie. 2016;36(1):33-
43.
CHAPTER 1
Chapter 1
16
52. Ho PM, Tsai TT, Wang TY, et al. Adverse events after stopping clopidogrel in post-acute coronary syndrome 
patients: Insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes. 
2010;3(3):303-308.
53. Mylotte D, Peace AJ, Tedesco AT, et al. Clopidogrel discontinuation and platelet reactivity following 
coronary stenting. J Thromb Haemost. 2011;9(1):24-32.
54. Charlot M, Nielsen LH, Lindhardsen J, et al. Clopidogrel discontinuation after myocardial infarction and 
risk of thrombosis: a nationwide cohort study. Eur Heart J. 2012;33(20):2527-2534.
55. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting 
stents. N Engl J Med. 2014;371(23):2155-2166.
56. Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ. Alternatives to allogeneic platelet transfusion. 
Br J Haematol. 2016;175(3):381-392.
57. van der Meer PF. PAS or plasma for storage of platelets? A concise review. Transfus Med. 2016;26(5):339-
342.
58. Apelseth TO, Hervig T, Bruserud O. Current practice and future directions for optimization of platelet 
transfusions in patients with severe therapy-induced cytopenia. Blood Rev. 2011;25(3):113-122.
59. Woodcock BE, Cooper PC, Brown PR, et al. The platelet defect in acute myeloid leukaemia. J Clin Pathol. 
1984;37(12):1339-1342.
60. Leinoe EB, Hoffmann MH, Kjaersgaard E, Johnsen HE. Multiple platelet defects identified by flow 
cytometry at diagnosis in acute myeloid leukaemia. Br J Haematol. 2004;127(1):76-84.
61. Kozek-Langenecher S. Fluids and coagulation. Curr Opin Crit Care. 2015;21(4):285-291.
62. Bollinger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive 
hemorrhage and hemodilution. Anesthesiology. 2010;113(5):1205-1219.
63. Kozek-Langenecher SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: 
guidelines from the European Society of Anaesthesiolofy: First update 2016. Eur J Anaesthesiol. 
2017;34(6):332-395.
64. Jirouskova M, Shet AS, Johnson GJ. A guide to murine platelet structure, function, assays, and genetic 
alterations. J Thromb Haemost. 2007;5(4):661-669.
65. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis (Eitzman series). Arterioscler 
Thromb Vasc Biol. 2007;27(10):2079-2093.
66. Jagadeeswaran P, Cooley BC, Gross PL, Mackman N. Animal models of thrombosis from zebrafish 
to nonhuman primates: Use in the elucidation of new pathologic pathways and the development of 
antithrombotic drugs. Circ Res. 2016;118(9):1363-1379.
67. van Kruchten R, Cosemans JM, Heemskerk JW. Measurement of whole blood thrombus formation using 
parallel-plate flow chambers - a practical guide. Platelets. 2012;23(3):229-242.
68. Nagy M, Heemskerk JW, Swieringa F. Use of microfluidics to assess the platelet-based control of 
coagulation. Platelets. 2017;Epub ahead of print:1-8.


Chapter 2
Platelet populations and priming in hematological 
diseases
Baaten CC, Ten Cate H, van der Meijden PE*, Heemskerk JW* 
(*equal contribution)
Blood Rev. 2017; 31(6):389-399 
Reprinted with permission
CHAPTER 1
Chapter 2
20
Abstract
In healthy subjects and patients with hematological diseases, platelet 
populations can be distinguished with different response spectra in hemostatic and 
vascular processes. These populations partly overlap, and are less distinct than those 
of leukocytes. The platelet heterogeneity is linked to structural properties, and is 
enforced by inequalities in the environment. Contributing factors are variability between 
megakaryocytes, platelet ageing, and positive or negative priming of platelets during 
their time in circulation. Within a hemostatic plug or thrombus, platelet heterogeneity is 
enhanced by unequal exposure to agonists, with populations of contracted platelets in 
the thrombus core, discoid platelets at the thrombus surface, patches of ballooned and 
procoagulant platelets forming thrombin, and coated platelets binding fibrin. Several 
pathophysiological hematological conditions can positively or negatively prime the 
responsiveness of platelet populations. As a consequence, in vivo and in vitro markers of 
platelet activation can differ in thrombotic and hematological disorders.
1. Introduction
Individual platelets interact in numerous ways with the vessel wall or adherent 
blood cells. This versatility is fundamental to the role of platelets in a wide range of 
(patho)physiological processes, ranging from vascular repair, hemostasis and thrombosis, 
to inflammation progression, innate immunity and tumor metastasis. In the past years, 
evidence has been accumulating that circulating platelets are markedly heterogeneous 
in properties, which has led to the suggestion that identifiable populations of platelets 
with specialized response spectra are best suited for specific roles. In the present paper, 
we resume the current evidence for heterogeneity in terms of composition and functions 
of platelets during their formation from megakaryocytes, when circulating over time in 
the circulation, and once adhered to a vessel wall. We further describe how various 
physiological and pathophysiological conditions can change or prime the responsiveness 
of circulating platelets, and hence alter the distribution of platelet populations. We finally 
define how in vitro and in vivo markers of platelet activation phenotypes can be judged in 
relation to thrombotic and hematological disorders.
2. Intrinsic factors of platelet heterogeneity
Platelets from a given subject, healthy or diseased, greatly vary in receptor 
expression levels and markedly diverge in responsiveness once activated. Different 
populations of activated platelets can be distinguished, which can differently interact 
with the inflamed or injured vessel wall and differently support hematological processes. 
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This heterogeneity is explained by several intrinsic factors, including variability of 
clonal megakaryocytes, unequal division of megakaryocyte-derived proplatelets, and 
modifications upon ageing of the newly formed platelets.
 
2.1. Heterogeneity between megakaryocytes and platelets
Heterogeneity between megakaryocytes, whether or not linked to a specific niche 
in the bone marrow or lungs, is a likely cause of inter-platelet variability, although there 
is only limited literature available on this subject. Several authors have described that 
polyploid megakaryocytes, either cultured from CD34+ hematopoietic stem cells or 
derived from immortalized cell lines, considerably differ from cell to cell, in terms of levels 
of cytoplasmic and membrane proteins, as well as in agonist-induced Ca2+ transients.1-3 
Recently, this was demonstrated also for megakaryocytes derived from single-cell clones 
of forward-programmed human pluripotent stem cells. After re-programming, individual 
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Figure 1. Intrinsic heterogeneity in platelet composition and functions. (A, B) Differential expression of key 
adhesive receptors in the total platelet population, immunologically stained for GPIbα or GPVI. Indicated 
in the flow cytometric histograms are the estimated copy numbers, based on proteome analysis.128 (C, D) 
Platelets stimulated with a GPVI agonist immunologically stained for CD62P in combination with CD63; 
or CD62P in combination with a marker for activated integrin α
IIb
β
3
. Shown is the presence of different 
platelet populations with alpha granule secretion (CD62P+) with or without dense granule secretion or α
IIb
β
3
 
activation. (E) Two apoptotic platelet populations after stimulation with BH3 mimetic ABT-737, displaying 
low or high phosphatidylserine (PS) exposure.
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megakaryocytes of the same clone showed a 100-fold difference in expression levels 
of common receptor proteins, such as glycoprotein (GP)Ibα, GPVI and integrin α
IIb
β
3
, as 
assessed by flow cytometry.4 No studies are yet available to demonstrate whether distinct 
megakaryocytes (in the bone marrow) also yield different types of platelets. However, 
one can expect that single platelets ‘inherit’ at least in part their expression profiles of 
receptors and other signaling molecules from the precursor megakaryocyte. It has been 
shown that when the environment of megakaryocytes changes (e.g. upon inflammation 
or diabetes), the transcriptome of platelets is influenced as well.5, 6 For instance, patients 
diagnosed with the autoimmune disease systemic lupus erythematosus (SLE) may have 
an altered platelet transcriptome. The changes in platelet mRNA and protein levels 
were linked to increased procoagulant activity and platelet-monocyte interactions in SLE 
patients.7  
 Proplatelets are formed from the demarcation compartment of megakaryocytes 
by pinching off the cytosol containing cell membrane compartment and organelles.8 
Although studies are lacking, it can be conceived that part of the heterogeneity between 
platelets may come from unequal retention or re-distribution of the cellular components 
from the mother cell, including surface receptors, actin and tubulin cytoskeletons, 
signalosomes, internal membrane vesicles, secretory granules, ribosomes, and 
mitochondria.
Clear evidence for heterogeneity in platelet size and volume comes from flow 
cytometric profiles and blood count histograms. Forward side scatter plots (flow 
cytometry) point to a considerable variation in size, which is in agreement with the relative 
large distribution width of the platelet volume (blood cell count). Sizable heterogeneity 
between platelets is also detectable by quantifying the abundantly expressed receptors. 
Thus, flow cytometric profiles of platelets that are stained with fluorescent antibodies 
against integrin β
3
 (CD61) point to a large inter-platelet variation in expression levels 
of this integrin.9, 10 Similarly, staining for GPIbα or GPVI gives histograms, which show 
an about 10-fold difference in fluorescence intensity (indicative of expression level) of 
platelets in the lower and upper 10% percentiles (Figure 1A-B). Evidence for signaling 
heterogeneity comes from recordings of the Ca2+ responses of single platelets from an 
arbitrary donor, which appear to vary greatly in the type of transient Ca2+ fluxes after 
stimulation via ADP, thrombin or collagen receptors.11
2.2. Populations of activated platelets
Platelets, upon activation by agonists, are known to form populations with 
different surface properties.10 For instance, platelets stimulated with a maximal dose of 
a GPVI agonist showing CD62P expression (marker of α-granule secretion) only display 
CD63 expression to a certain degree (marker of δ-granule and lysosome release), while 
the majority of platelets that express CD62P do have activated integrin α
IIb
β
3
 (Figure 1C-
D). Inter-platelet heterogeneity in granule release has also been observed by electron 
microscopy.12 Thus, secretion of granule content can occur in two different ways: single 
granule secretion (both α and δ granules), or secretion of multiple granules fused into 
one large compartment (mainly α granules).12 Dependent on the strength of an activation 
trigger, secretion of the granule content appears to be regulated differently and can 
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result in different secretion patterns (Figure 1C-D).12, 13 Another consistent observation is 
that, regardless of the agonist used, a fraction of 10-20% of the platelets fails to stain for 
CD62P,14 suggesting that some platelets are refractory to α-granule secretion.
A striking heterogeneity is observed when platelets in suspension are stimulated 
with combinations of collagen and thrombin receptor agonists. In addition to an 
population showing integrin α
IIb
β
3
 activation and granule secretion, another population 
of swollen platelets appears with exposed phosphatidylserine at their outer membrane 
surface, inactivated/closed integrins, and capability of coagulation factor binding.15, 16 
Depending on the activating conditions, the majority of the latter platelets also have a 
transglutaminase-dependent fibrin coat at their surface,17 which is in agreement with the 
early description of coated or COAT platelets.18 As described below, the various platelet 
populations are considered to have different roles, in supporting platelet aggregation, 
procoagulant activity and fibrin formation. The formation of phosphatidylserine-
exposing, procoagulant platelets is linked to a prolonged, high cytosolic Ca2+ level 19, 20 i.e. 
a condition required for swelling and phospholipid scrambling via the Ca2+-dependent 
anoctamin-6 channel (gene ANO6 or TMEM16F).21, 22 It can be speculated that, in single 
platelets, differences in both receptor expression levels and in activity of the Ca2+-flux 
machinery determine the formation of the platelet populations.
Populations of platelets with different surface properties are also formed after 
stimulation with the proapoptotic BH3 mimetic ABT-737.23 Typically, platelets with low 
and high phosphatidylserine exposure are formed in this case (Figure 1E).
2.3. Changes with platelet maturation, ageing and apoptosis
Early studies supposed that platelet activity correlates with platelet size and, 
hence, receptor and granule numbers.24, 25. Later papers have focused on platelet age, 
considering that newly formed platelets are larger in size and therefore more active than 
older platelets.26, 27 However, there is still not much support for the idea that platelet size 
is the only or main factor determining platelet responsiveness to agonists. Association 
studies do not suggest such a relation. For instance, in a cohort of healthy individuals, 
mean platelet volume negatively correlated with the amount of newly formed platelets, 
suggesting that young platelets are not necessarily the largest ones.28
 A consistent finding is that newly formed platelets are enriched in mRNA, as 
observed by specific mRNA-staining and cell counting analyses.29 Young platelets 
with detectable mRNA in the cytoplasm have been termed as reticulated platelets30, 
31 or immature platelet fraction.32 The latter fraction, with a normal reference range 
of 1-5%, is considered to reflect the rate of platelet production in the bone marrow. 
Given that platelets have overall lost >90% of the mRNA of their progenitor cells - 
while retaining the stable circular RNAs -,33 it is clear that the residual mRNA levels in 
reticulated platelets reflect incomplete mRNA maturation. Interestingly, subject age 
does not seem to be an important modifier of reticulated platelets, as in older subjects 
only ~2% of all >6000 identified mRNA and miRNA species were found to be changed 
in expression levels.34 On the other hand, a Spanish hemophilia study showed that the 
reticulated platelet fraction has a high heritability component.35 Recent papers describe 
that certain combinations of mRNA and miRNA correlate with platelet phenotype, 
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raising the possibility to use these RNA species as biomarkers of platelet function.36, 37 
 With a circulation time of 7-10 days and a remarkably constant platelet count 
over time, the daily turnover (production and removal) of platelets is extremely well 
regulated, being estimated at about 1011 platelets per day.8, 38. Platelet removal from 
the circulation occurs via both clearance and “consumption” (at the enormous vascular 
bed in the human body). Clearance can be triggered by prior platelet activation and an 
apoptotic process, e.g. resulting in the surface exposure of PS,39 or by other still unknown 
causes.
Evidence for a link between platelet ageing and apoptosis comes from 
experiments with mice, lacking the pro-apoptotic proteins Bax/Bak, in which platelet 
survival is greatly extended.40 Because aged, Bak-deficient platelets showed a reduced 
capability of thrombin- and collagen-induced secretion, these were designated as 
exhausted platelets.41 On the other hand, in mice lacking the anti-apoptotic protein 
Bcl-xL, platelet lifetime was shortened and platelet function was also reduced.40 The 
interpretation was that a loss of Bcl-xL leads to activation of Bax/Bak to induce a pro-
apoptotic condition. In patients with malignancies, who were treated with the Bcl-xL-
degrading drug Navitoclax (a BH-3 mimetic also known as ABT-263), platelet lifetime was 
also shortened, thus resulting in mild thrombocytopenia.39 Characteristics of apoptotic 
platelets are mitochondrial dysfunction, caspase proteolytic activity, refractoriness to 
integrin activation, and surface exposure of phosphatidylserine.42, 43
 Another finding was that aged platelets gradually loose sialic acid residues 
from their surface membrane glycoproteins.38 Desialylated platelets were found to be 
recognized by Ashwell-Morell receptors in the liver, mediating platelet clearance and, 
interestingly, also mediating release of thrombopoietin, which is the main cytokine 
regulating platelet formation from megakaryocytes.44 These data are suggestive for a 
gradual, ongoing formation of the population of (pro)apoptotic platelets.
3. Environmental factors of platelet heterogeneity
Platelets can interact with a large variety of glycoproteins in the inflamed or damaged 
vessel wall. The adhesive interactions include: activated endothelial cells expressing 
von Willebrand factor (VWF); subendothelial matrix components such as laminins, 
collagens, thrombospondins; adhered plasma proteins, such as VWF, fibrin(ogen), 
fibronectin and vitronectin; leukocytes under inflammatory conditions; lymphatic wall 
components like podoplanin; tumor cells; and other platelets via fibrinogen bridges. 
Given that these adhesive ligands all induce different signaling pathways, the response 
of an adhered platelet will vary with the precise location and substrate of adhesion. Well 
studied is the environmental directed heterogeneity in responses of platelets adhering 
to collagen and assembling into a thrombus.10, 16 The formation of platelet populations 
in thrombus formation is further stimulated by the local generation of thrombin.45, 46 
 
3.1. Platelet heterogeneity upon adhesion and activation
Platelets will respond differently, when interacting with specific vascular wall-
derived proteins. This response heterogeneity is studied most extensively for platelets 
adhering to fibrillar collagen via the receptors GPVI and integrin α2β1.
16, 47 Both receptors 
2 Platelet populations in hematological diseases 
CHAPTER 1
25
act in synergy to immobilize and thereby activate platelets via the GPVI signalosome, 
resulting in Ca2+ elevation, integrin activation and granular secretion.48, 49 Collagen 
fibrils allowing platelet adhesion to both receptors are most strongly activating, and 
form the largest platelet aggregates. A population of the collagen-adhered platelets – 
subjected to the highest Ca2+ fluxes –, responds by surface exposure of procoagulant 
phosphatidylserine.50 This so-called procoagulant response is accomplished via the ion 
channel anoctamin-6,22 and accompanied by marked morphological changes involving 
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Figure 2. Heterogeneity of platelet responses. (A) Distinct calcium fluxes of single platelets adhered under 
flow to collagen. Based on the time between adhesion and increase in calcium signal, platelets were 
classified as having a fast, delayed or absent activation response. (B) Platelet populations in thrombi formed 
on collagen: aggregating platelets characterized by integrin activation and CD62P expression (green) and 
procoagulant platelets forming blebs/balloons and exposing PS (red). 
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swelling, bleb and balloon formation.51, 52 Phosphatidylserine exposure facilitates 
the binding of multiple coagulation factors and promotes thrombin generation.19, 20 
Remarkably, the majority of collagen-bound platelets is refrained from phosphatidylserine 
exposure and swelling.
3.2. Platelet heterogeneity within a thrombus
Heterogeneity in platelet activation properties progresses during collagen-
dependent thrombus formation in flowing blood, both in vitro and in vivo. At high, arterial 
wall-shear rates, platelet adhesion to collagen/VWF is accomplished via GPVI, integrin 
α2β1 and the VWF receptor, GPIb-V-IX.
53, 54 Single-cell studies of adhered platelets from 
flowing blood again show marked differences in Ca2+ fluxes (Figure 2A).55 Thrombi formed 
under high-shear flow show clusters of aggregated platelets (staining for activated integrin 
α
IIb
β
3
 and P-selectin), alternated with patches of ballooned phosphatidylserine-exposing 
platelets (binding annexin A5 and coagulation factors) (Figure 2B).56, 57 The population of 
aggregated platelets also undergoes contraction.58, 59 It is not quite clear how platelets 
‘decide’ to either aggregate or expose phosphatidylserine. Given that adjacent platelets 
can form gap junctions,60 and communicate with each other,61 it is possible that cross-
communication in the aggregate protects against anoctamin-6-dependent procoagulant 
activity. In a study where platelet adhesion to multiple surfaces was examined, the 
response heterogeneity in thrombus formation with different populations of platelets 
formed was a constant finding, regardless of the surface type and adhesive receptors 
involved (GPIb-V-IX, GPVI, CLEC-2, α
6
β1, αIIbβ3 or CD36).
62
Recent in vivo studies with mice, where laser-induced injury was applied to 
cremaster or femoral arterioles, have pointed to another level of platelet heterogeneity 
within thrombi, i.e. an inner core of aggregated and contracted platelets, surrounded by 
an outer shell of loosely adhered platelets.63, 64 Two specific platelet populations were 
distinguished, i.e. platelets in the thrombus core having undergone secretion and CD62P 
expression, and platelets in the outer shell without secretion.63, 64 Several factors may 
contribute to the heterogeneous thrombus buildup, including local levels of soluble 
platelet agonists (ADP, thromboxane A2) and the local wall shear gradients.
65 Also, this 
type of platelet heterogeneity in thrombi is likely to be influenced by the type of injury, 
vascular bed location and the physiological or pathological state of the vessel.
3.3. Coagulation and thrombus heterogeneity
Under conditions favoring coagulation, e.g. with tissue factor present, the 
formation of thrombin and fibrin in a thrombus appear to be highly localized processes. 
In mouse microvascular thrombosis models, thrombin activity and fibrin deposits 
appeared to be concentrated at the thrombus base, i.e. close to the vascular localization 
of tissue factor.66 In vitro models of thrombus formation showed that the population 
of phosphatidylserine-exposing platelets was responsible for the binding of coagulation 
factors (prothrombin, factors Va, IXa and Xa), and also for the formation of thrombin and 
fibrin.46, 57 A potent feedback loop was identified, in that the local formation of thrombin 
enhanced thrombin-mediated phosphatidylserine exposure of nearby platelets, thus 
increasing the population of procoagulant platelets.46 Fibrin formation appeared to be 
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initially linked to PS exposure, and secondarily dependent on integrin α
IIb
β
3
 activation and 
transglutaminase-dependent fibrin cross-linking.17, 67 In vitro models further indicated 
that fibrin preferentially localized near the sites of tissue factor and on procoagulant 
(coated) platelets.68 Other identified elements of heterogeneity in a thrombus are the local 
secretion of polyphosphate clusters (activating factor XII)69, and the phosphatidylserine-
dependent accumulation of plasmin (activating the fibrinolytic system).70 Taken together, 
during thrombus formation, the coagulation process appears to enhance the formation 
of distinct platelet populations, and increase the heterogeneity in platelet functions.
4. Positive and negative priming of platelets
Multiple bioactive molecules in the blood can enhance or suppress platelet 
functionality. In psychological and neurobiological sciences, the implicit memory effect 
by which exposure to the first stimulus influences the response to the next stimulus, is 
called ‘priming’.71 By analogy, we can consider the exposure of platelets to enhancing or 
suppressing agents as positive or negative priming events. Figure 3 gives an illustration 
of potential priming biomolecules that are either derived from the vascular wall or found 
in plasma.
4.1. Positive priming: key roles of plasma derived factors
Several hormones enhance platelet activation processes (shape change, secretion, 
aggregation), when applied in combination with other agonists. Epinephrine, binding to 
the Gi-coupled α2-adrenergic receptor, reduces intracellular cyclic AMP levels which, 
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Figure 3. Concept of negative and positive priming of platelets. The indicated factors can cause negative or 
positive priming of platelet activation processes, either plasma-derived or from the vessel wall.
CHAPTER 1
Chapter 2
28
e.g. enhances Ca2+ fluxes raised by agonists like ADP and thrombin.16, 72 Thrombopoietin, 
a growth factor for megakaryocytes, also sensitizes platelets to agonists at threshold 
concentrations,73, 74 and at shear stress.75 Similarly, insulin-like growth factor-1 (IGF1) 
greatly enhances platelet activation provided that other agonists are present.76 In vitro 
studies indicate that positive priming of platelets with thrombopoietin or insulin-like 
growth factor-1 can overcome the inhibitory effects on platelet function by aspirin or 
P2Y12 receptor treatment.
77 This suggests that positive priming of platelets can be a 
mechanism of resistance to antiplatelet therapy.
 Other positive priming molecules are Gas6 (plasma-derived) and soluble CD40L 
(platelet-derived), both of which stabilize and extend platelet aggregation.78, 79 TNFα, a 
pro-inflammatory cytokine which is synthesized in high amounts during inflammatory 
conditions, is capable of inducing platelet activation mainly indirectly via endothelial 
activation,80  although some authors report an enhancing effect of TNFα on collagen-
induced aggregation.81 
 Besides the positive enforcement of such plasma molecules on platelet function, 
wall shear stress is of great influence as well. Rapid changes in laminar blood flow and 
shear rate, which occur at sites of stenosis, promote platelet aggregate formation.58, 
65, 82 This wall-shear effect is highly dependent on VWF activity and autocrine platelet 
stimulation.65 As such, disturbances in blood flow can be considered as a positive priming 
condition.
Several dietary nutrients are known to positively modulate platelet responsiveness. 
In addition, gut microbes may contribute to platelet hyperreactivity via the generation 
of trimethylamine N-oxide (TMAO) from dietary sources of trimethylamine, present in a 
western diet. The generated TMAO is proposed to prime platelet activation by enhancing 
Ca2+ release from intracellular stores.83 
4.2. Negative priming: key roles of endothelial mediators
Not all platelets are freely circulating, as part of the platelets are kept in the spleen 
and lungs.84, 85 In mice, the lungs also significantly contribute to platelet biogenesis.86 
Whether this also applies to the human situation, remains to be explored. Clearly, 
these pools of marginated platelets in the lungs and spleen are exposed to different 
environments. Unclear is at which rate and to what extent the platelet pools exchange, 
as well as how these different locations alter the activation properties. Adaptions in 
properties can also arise when platelets are flowing through the micro- and macro-
vascular beds lined with specialized endothelial cells. 
At least three endothelial-derived substances – likely there are more – are 
accountable for the major negative priming effect of the vessel wall on platelet activation. 
These are prostacyclin, nitric oxide and CD39/CD73.87 Prostacyclin (prostaglandin I2), a 
short-lived eicosanoid produced by endothelial cells, binds to the platelet IP receptor, 
which couples to the Gs GTP-binding protein, stimulates adenylate cyclase and thereby 
elevates the inhibitory second messenger cyclic AMP.88 Continuous exposure of circulating 
platelets to prostacyclin leads to cyclic AMP elevation and thereby platelet inhibition. In 
freshly isolated platelets, supra-basal levels of cyclic AMP have indeed been measured.72 
However, IP receptors can desensitize and the functional effects of prostacyclin on 
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platelets may be most prominent locally, i.e. after platelet adhesion.87 Prostaglandin E2 
(EP receptor agonist), also has an inhibitory though more complex action mechanism.88 
The effect of PGE2 depends on the receptor isotype that is activated. Activation of EP3 
isoforms by PGE2 leads to sensitization of platelets, while binding of PGE2 to EP2 or EP4 
receptors causes platelet inhibition. It has been proposed that specifically the blocking of 
EP3 could be beneficial for the prevention of atherothrombosis.89 
The unstable free radical nitric oxide is membrane-permeable, and interacts with 
intracellular guanylate cyclase, raising the inhibitory second messenger cyclic GMP in 
platelets.90 Nitric oxide is produced by endothelial nitric oxide synthase isoforms in 
response to the pulsatile flow of blood. Together, elevated levels of cyclic AMP and 
cyclic GMP accomplish strong platelet inhibition via a flood of protein phosphorylation 
reactions, mediated by the protein kinases A and G, respectively.91, 92 The levels of both 
cyclic nucleotides are balanced via cyclic nucleotide-dependent phosphodiesterases. The 
hormone insulin can also affect platelet reactivity via cyclic AMP and GMP elevation. In 
diabetic patients, who are resistant to insulin, a loss of these inhibitory pathways might 
contribute to platelet hyperreactivity.93, 94
 The endothelial-expressed ecto-nucleotidases CD39 and CD73 degrade intra-
vascular ATP/ADP and AMP, respectively, to ultimately produce adenosine.87 These 
activities convert potent platelet-activating autacoids (ATP, ADP) into a platelet inhibitor 
(adenosine, activating Gs).87 Both mouse and human studies point towards a modulating 
role of ecto-nucleotidases in thrombus formation and thrombosis. In addition to the 
inhibitory A2-adenosine receptor, platelets possess receptors linked to protein-tyrosine 
phosphatases, which also suppress activation processes.95 The physiological ligands 
of these are mostly unknown. Indirectly, also the thrombin-inactivating activity of 
endothelial thrombomodulin contributes to platelet suppression, i.e. by preventing 
thrombin-induced activation.96 Some nutritional components can contribute to negative 
priming, e.g. a mild to moderate alcohol consumption may lower platelet reactivity by 
inhibiting thromboxane formation.97
Given that circulating platelets are exposed to a plethora of positive and negative 
priming molecules, their net effect must be prevention of platelet adhesion and activation, 
unless positive stimuli prevail, such as at a damaged vessel wall. The implicit assumption is 
that a shift or disturbance in the balance of positive and negative priming molecules causes 
a change in the threshold of platelet activation. This could for example explain why the 
population of coated platelets increased in a variety of pathophysiological conditions.18 
5. Pathology induced alterations in platelet populations
Considering that multiple bioactive mediators present in the blood or derived 
from the vessel wall influence the tendency of platelet activation, it can be expected that 
disease conditions associated with vascular abnormalities or blood changes enhance the 
positive priming of platelets. An increasing number of reports points to such increased 
priming events, often ascribed to the formation of different ‘types’ of platelets, especially 
in patients with high-burden inflammatory, prothrombotic or hematological diseases 
(Table 1). Albeit different terms are used to annotate the platelet changes, the majority of 
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Clinical 
condition
Hemostatic 
balance
Type of plt Plt activation 
markers in vivo
Platelet 
activation 
testing in vitro
Refs
Negatively primed (low responsive)
Congenital 
defects: Scott 
syndrome
mild bleed-
ing
procoagulant n.d. PS ↓
fibrin formation 
↓
22,68
Hematological 
malignancies
bleeding hypo-respon-
sive
Plt count ↓
TPO ↑
αIIbβ3, CD62P, 
CD63, GPIb ↓
100,
101
Renal failure 
and uremia
bleeding 
(thrombosis)
dysfunctional NO ↑ CD62P, Ca2+ ↓ 
PS, caspase  ↑
102,
103
Positively primed (high responsive)
Diabetes type 
2
prothrom-
botic
angry sCD62P, sCD40L, 
PF4, MPV ↑
NO ↓
GPIb, CD41, 
GPVI↑ CD63, 
CD62P, CAT↑
104,
105,
129,
130
Hypercholes-
terolemia
prothrom-
botic
hyper-reactive PLT turnover, MPV 
↑
LTA ↑ 108,
109,
131-
133
Myelopro-
liferative 
neoplasms (ET, 
PCV)
prothrom-
botic
hyper-reactive PLT count ↑ LTA, CD62P, CAT 
↑
110,
111
Positively primed and secondarily inactive (low responsive)
Cancers (solid 
tumors)
prothrom-
botic
hyper-reactive 
(exhausted)
sCD62P, PEV ↑ 
PLT count ↑
CD62P, CD63, 
GPIb↑
TxB2 ↓
112-
115
Sepsis thrombosis, 
bleeding
hyper-reac-
tive/
exhausted
PLT count ↓
sCD62P, sTLT, PEV ↑
CD62P ↑ 
LTA, fibrinogen 
binding ↓ 
(severe sepsis)
116,
119
Stroke bleeding exhausted sCD62P, βTG ↑ 
TxB2 (urine) ↑
CD62P, CD63 ↓ 
mepacrine ↓
120-
122
Major trauma 
(brain)
bleeding hypo-respon-
sive
PEV↑
CD62P, PAC mAb ↑ 
(unstimulated)
LTA ↓ 123,
124
Viral hemor-
rhagic fever
thrombosis 
(bleeding)
exhausted/
reticulated
sCD62P, sGPVI ↑
TPO, IPF, MPV ↑
αIIbβ3, CD62P, 
CD63 ↓
125,
126
Table 1: Platelet phenotypes and activation markers in hematological and other diseases, 
induced by negative or positive priming. Representative examples from the literature are given.
Abbreviations: CAT, calibrated automated thrombin generation in PRP; ET, essential thrombocytopenia; IPF, 
immature platelet fraction; LTA, light transmission aggregometry; MPV, mean platelet volume; NO, 
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papers refer to either a gain-of-function (high-responsive platelets) or a loss-of-function 
(low-responsive platelets). A still unresolved question is how these functional changes 
relate to the formation of specific platelet populations.  
5.1. Negatively primed platelets in disease
The genetic makeup of a subject co-determines platelet responsiveness. Rare 
genetic modifications of over 25 different platelet proteins have been described that 
result in low-responsive platelets, and associate with bleeding disorders.98, 99 Loss-of-
function mutations, often accompanied by thrombocytopenia, in particular concern 
genes of transcription factors, the actin-myosin and tubulin cytoskeletons, signaling 
proteins, and granule secretion-regulating proteins.98, 99 Genetic polymorphisms in these 
and other genes may also influence platelet responsiveness. 
A clear example how a genetic deficiency can imbalance the formation of platelet 
populations is the Scott syndrome, a mild bleeding disorder. Herein, mutations in the 
ANO6 gene result in the near absence of the procoagulant, phosphatidylserine-exposing 
platelet population due to inability of phospholipid scrambling,21, 22 resulting in a severely 
compromised fibrin formation.68
In addition to genetics, there is accumulating evidence for acquired forms of low-
responsive platelets. A primary loss-of-function is observed in patients with hematological 
malignancies and thrombocytopenia. For instance, platelets from patients with acute 
leukemia can be impaired in adhesion, aggregation and secretion. These functional 
defects are likely a consequence of dysfunctional megakaryocytopoiesis.100, 101
In patients with renal failure and associated uremia, it is considered that impaired 
platelet adhesion to the vessel wall is the main cause of bleeding. Several indicators 
of low platelet responsiveness are described, including impaired Ca2+ fluxes, reduced 
secretion and low platelet aggregation.102 On the other hand, also impaired platelet 
adhesion to the vessel wall due to anemia may explain the hemorrhagic complications in 
these patients. A low hematocrit limits the margination of platelets towards the vessel 
wall, and might furthermore restrict the availability of red blood cell-derived ADP and 
the scavenging effect of hemoglobin on nitric oxide as a platelet inhibitor.102 Other papers 
report that renal failure increases the risk of thrombosis, e.g. by increasing the population 
of apoptotic, phosphatidylserine-exposing platelets.103
 
5.2. Positively primed platelets in disease
Diabetes has often been associated with platelet hyperreactivity, i.e. enhanced 
platelet adhesion, activation, aggregation and platelet-dependent thrombin 
generation.104 This increased responsiveness of platelets is explained by high blood-
glucose levels, oxidative stress and increased vascular shear stress.105 Under these 
hyperglycemic conditions, advanced glycation end products (AGEs) are generated, which 
nitric oxide; PCV, polycythemia vera; PEV, platelet-derived extracellular vesicles; PF4, platelet factor 4; PLT, 
platelet; PS, phosphatidylserine; s, soluble; β-TG, β-thromboglobulin; s, soluble; TLT, TREM-like transcript-1; 
TPO, thrombopoietin.
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activate platelets via the CD36 pathway.106 Further, activation of the receptor of AGEs 
(RAGE) by S100A8/A9 may lead to enhanced production of TPO, thereby increasing 
platelet production from megakaryocytes upon hyperglycemia.107 In diabetic patients, 
antiplatelet treatment strategies were shown to be effective for the secondary prevention 
of ischemic complications.104
Plasma cholesterol levels can positively prime platelets, such as manifested 
by the enhanced activity and larger size of platelets from patients with familial 
hypercholesterolemia, in whom total lipid and low-density lipoprotein levels are severely 
elevated. Accumulation of cholesterol in the platelet membrane enhances platelet 
aggregation by influencing the membrane structure and signaling via surface receptors.108, 
109 Hypercholesterolemia is also linked to increased platelet production and turnover.108 
Similarly, oxidation of low-density lipoproteins in the intima of atherosclerotic lesions is 
considered to result in enhanced platelet activation.108
In the myeloproliferative neoplasms, essential thrombocytosis and polycythemia 
vera, quantitative as well as qualitative platelet abnormalities have been identified. 
Particularly in patients carrying the JAK2V617F mutation, for whom aspirin treatment 
is recommended, platelet responsiveness is increased (secretion, aggregation and 
procoagulant activity), which effect is in part associated with thromboembolic 
complications.110, 111
Platelet population Markers
Reticulated mRNA (immature platelet fraction)
Secretory PF4, βTG release
CD62P, CD63 expression
TxB2 formation, serotonin
Aggregating fibrinogen binding
PAC1 mAb binding (activated α
IIb
β
3
 integrin)
platelet-leukocyte aggregate formation
Procoagulant PS exposure, coagulation factor binding
extracellular vesicle formation
Coated PS exposure,
fibrin binding, transglutaminase activity
extracellular vesicle formation
Apoptotic PS exposure,
extracellular vesicle formation
Table 2. Markers of the different platelet populations. For abbreviations and explanation, see text 
and Table 1. 
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5.3. Positively primed and secondarily inactivated platelets in disease
Despite the presence of positive priming molecules in vivo, platelet activation in 
vitro may appear to be impaired. This can be a direct consequence of prior activation in 
the circulation resulting in secondary loss of function. In such cases, authors describe the 
dysfunctional platelets often as exhausted platelets.
In patients with different types of solid tumors, apart from a high platelet count, 
platelet activation can be enhanced in vivo, as deduced from the presence of platelet-
derived soluble (s)CD62P in the blood plasma.112 This associates in vitro with a low-level 
of platelet activation, leading to the assumption that these platelets are ‘exhausted’, 
i.e. displaying a secondarily down-regulated responsiveness to agonists (CD62P, CD63 
expression), although the primarily enhanced activation may predispose patients to 
an increased risk of thromboembolic complications.113, 114 Another marker of ongoing 
platelet activation in cancer patients is the accumulation of platelet-derived extracellular 
vesicles, interestingly, with almost no effect on mean platelet volume.115 Strikingly, in 
those patients a high mean platelet volume associates (though with low odds ratio) with 
a decreased risk of venous thromboembolism.113
In sepsis, as a life-threatening condition of systemic inflammation, platelets are 
positively primed as a result of endothelial damage or activation in combination with 
enhanced coagulant activity. This leads to increased plasma levels of platelet secretion 
products as well as platelet-derived extracellular vesicles.116 It has been demonstrated 
that several pathogens can interact with platelets via Toll-like receptors, FcγRIIa and/
Platelet activity
in vivo
activation markers
in vitro
activation
in vitro
activation
low
responsiveness
high
responsiveness
high
responsiveness
normal exhausted
negative priming positive priming
Bleeding risk Bleeding riskHemostasis Thrombotic risk
normal increaseddecreased increaseddecreased
normal increased
Figure 4. Concept of negative and positive platelet priming resulting in changed platelet activation markers 
in vivo and altered platelet activities in vitro. Flow chart for assessing changes in platelet functions in 
patients with thrombosis or bleeding risk. 
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or integrin α
IIb
β
3
, thus inducing platelet activation.116-118 In severe sepsis, also secondary 
defects in platelet function have been observed, often concomitantly with a lowering in 
platelet count.116, 119
Papers studying patients who suffered a stroke, report increased levels in 
the circulation of platelet activation markers, including sCD62P, β-thromboglobulin 
and thromboxane B2, in those patients with a high risk of bleeding.
120, 121 Since this is 
accompanied by an impaired platelet activation tendency in vitro, the authors type such 
platelets as exhausted.122 A similar platelet phenotype is expected in patients with acute 
coronary syndrome before the initiation of antiplatelet therapy. An exhausted platelet 
type has also been observed after major trauma, in particular brain injury, where 
plasma markers of platelet activation are elevated, while the platelets after isolation 
are hypo-responsive in terms of aggregation.123, 124 The suggestion was made that sub-
endothelial tissue exposure upon injury causes a low level of platelet activation, resulting 
in dysfunctional circulating platelets with an activation history.
Higher fractions (populations) of reticulated platelets have been detected in 
patients with viral hemorrhagic fever due to hantaviral disease, which was accompanied 
by increased levels of activation markers such as sCD62P and sGPVI, followed by a 
secondary loss in platelet activity in vitro.125 A similar phenotype of exhausted platelets 
has been described for patients with a severe dengue infection.126 
It is currently unclear how the different pathologies induce specific changes in 
platelet function. The pathological environment may alter one specific platelet population 
or it rather affects all circulating platelets and thereby elicits a shift in the distribution 
of the different platelet populations. It can be reasonably presumed that this change 
is specific for the pathological environment. Furthermore, the impact of a pathological 
condition on platelet function may be multifactorial (e.g. diabetes) and therefore even 
more complex. 
6. Platelet heterogeneity and risk assessment for bleeding and 
thrombosis: recommendations
For diagnosing a known or suspected risk of thrombosis or bleeding, current 
routine measurements include (i) platelet count and mean volume, (ii) plasma markers of 
in vivo platelet activation, and (iii) in vitro platelet activation tests. Particularly, the latter 
tests are used for the monitoring of anti-platelet therapy. Table 2 presents an outline of 
how different test outcomes relate to distinct platelet populations, provided that sample 
processing is up to standards. 
The proposed concept of partly overlapping platelet populations that are 
subjected to positive/negative priming can shed new light on the often paradoxical 
information obtained from different diagnostic platelet function and activity tests. 
Figure 4 shows a flow chart aiming to structure the information obtained from such tests 
for a risk estimate of hemorrhage or thrombosis. From the figure, it will be clear that 
information on both activation markers in vivo and platelet responsiveness in vitro is 
needed to obtain a complete picture. It is noted though that platelets are deprived of 
endothelial inhibitors when performing in vitro measurements, which influences their 
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responsiveness. Assay measurements should preferably include markers of different 
platelet populations, given their specific contribution to hemostasis or thrombosis. 
Understanding of the redistribution of platelet populations in patients with particular 
hemorrhagic or thrombotic tendencies will also aid in designing an optimized treatment. 
One such an example is the administration of DDAVP to patients with a mild congenital 
platelet function defect which selectively augments the formation of coated platelets by 
enhancing Na+/Ca2+ mobilization.127
Practice Points
• Platelet heterogeneity can originate from differences between megakaryocytes, 
variation in proplatelet formation, unequal platelet priming and environmental 
conditions, as well as platelet ageing. Changes in the physiological environment 
upon disease can hence influence platelet populations and platelet responses. 
• Combining of both in vivo and in vitro markers of platelet activation and activity 
permits better assessment of a platelet-related thrombotic or hemorrhage risk.
Research agenda
• How the pathophysiological environment affects platelet populations and their 
responsiveness is incompletely understood and warrants further investigation.
• The causes and consequences of platelet heterogeneity have only partly been 
resolved. Characterization of the preferential response spectrum of certain platelet 
populations may contribute to risk factor assessments for prediction of thrombotic 
or hemorrhagic complications.
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Abstract
In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin 
and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated 
how the hemostatic function of platelets recovers after discontinuation of prasugrel 
treatment. Therefore, sixteen patients who suffered from ST-elevation myocardial 
infarction were investigated. Patients were treated with aspirin (100 mg/day, long-
term) and stopped taking prasugrel (10 mg/day) after one year. Blood was collected at 
the last day of prasugrel intake and at 1, 2, 5, 12 and 30 days later. Platelet function in 
response to ADP was normalized between 5 and 30 days after treatment cessation and 
in vitro addition of the reversible P2Y12 receptor antagonist ticagrelor fully suppressed 
the regained activation response. Discontinuation of prasugrel resulted in the formation 
of an emerging subpopulation of ADP-responsive platelets, exhibiting high expression 
of active integrin α
IIb
β
3
. Two different mRNA probes, thiazole orange and the novel 
5’Cy5-oligo-dT probe revealed that this subpopulation consisted of juvenile platelets, 
which progressively contributed to platelet aggregation and thrombus formation under 
flow. During offset, juvenile platelets were overall more reactive than older platelets. 
Interestingly, the responsiveness of both juvenile and older platelets increased in time, 
pointing towards a residual inhibitory effect of prasugrel on the megakaryocyte level. 
In conclusion, the gradual increase in thrombogenicity after cessation of prasugrel 
treatment is due the increased activity of juvenile platelets.
Introduction
The autocrine mediator ADP is a moderately strong platelet agonist, stimulating 
platelet aggregation and thrombus formation and contributing to thrombus 
stabilization.1 At present, the ADP receptor P2Y12 is one of the most effective targets 
for antiplatelet therapy, i.e. by clopidogrel, prasugrel, and ticagrelor.2, 3 Clopidogrel 
in combination with aspirin has been the standard therapy over the last decade to 
prevent recurrent atherothrombotic complications in patients who had a myocardial 
infarction.4 More recently, prescription of prasugrel or ticagrelor instead of clopidogrel 
is increasingly recommended following publication of the TRITON and PLATO studies, 
which demonstrated a net clinical benefit over clopidogrel on top of aspirin, due to a 
higher degree of platelet inhibition.4-9 The thienopyridines clopidogrel and prasugrel 
are both prodrugs, which require metabolic conversion to form an active metabolite 
that irreversibly interacts with the P2Y12 receptors of circulating platelets.
10 In contrast, 
ticagrelor is a reversible, non-competitive P2Y12 antagonist – belonging to the cyto-
pentyl-triazolo class of pyrimidines – interacting with the platelet receptors without 
metabolic conversion.10-12 
Due to the irreversible inhibition of the platelet P2Y12 receptors by the active 
metabolites of clopidogrel and prasugrel, the formation of new platelets is required 
to recover platelet function.7, 9 After ticagrelor treatment, recovery of platelet function 
is only determined by the elimination time of the drug (half-life of 8 hours).10 There is 
limited evidence that during the offset period of irreversible P2Y12 inhibitors (usually 
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prescribed for one year) patients may have an increased risk of a recurrent myocardial 
event.13-17 This may point to hyperactivity of the newly formed platelets in the offset 
period, although the mechanism is unclear.
Previous experiments with rats have indicated that stopping clopidogrel treatment 
resulted in the sudden appearance of a population of fully responsive platelets, whereas 
recovery from ticagrelor treatment led to a more gradual regain in function of all 
platelets.18 The newly formed, juvenile platelets with active P2Y12 receptors seemed to 
preferentially incorporate into thrombi generated under flow conditions.18
Juvenile platelets, also described as reticulated platelets because of the presence 
of reticular-bound mRNA, are those platelets that are shed most recently from the 
megakaryocytes in the bone marrow.19-21 Due to the gradual degradation of mRNA, 
they form only a small part of the entire platelet population. Only little is known about 
the properties of reticulated platelets, although incidental studies report on a larger 
size with more granules,22 and a high reactivity towards platelet agonists.23, 24 With a 
Sysmex analyzer, using cell-permeant fluorescent mRNA dyes containing polymethine 
and oxazine, or using the mRNA probe thiazole orange, evidence has been obtained that 
patients with more reticulated platelets respond less effective to clopidogrel or prasugrel 
medication. 25-27
In the present study, we investigated how the hemostatic function of platelets 
recovers after discontinuation of prasugrel treatment. We hypothesized an immediate 
recovery of newly formed, juvenile platelets to the level of untreated platelets. Our data 
provide evidence for a critical role of the juvenile platelets in the regained aggregation of 
platelets and thrombus formation, and also show that these platelets gradually increase 
in responsiveness.
Methods
For a detailed description of the methods, please see the supplementary material.
Patients and control subjects
This study was approved by the local medical ethics committee (MEC 12-3-075). 
All patients and healthy volunteers gave written informed consent for participation 
according to the Helsinki declaration. Sixteen patients were studied who were treated 
with prasugrel (10 mg/day) for one year and long-term aspirin (80-100 mg/day) due to a 
myocardial infarction with ST elevation. After one year of prasugrel treatment, blood was 
collected on the last treatment day, and at 1, 2, 5 and 30 days later. From two patients, 
blood samples were also collected after 12 days to better understand the delayed regain 
of platelet function. Patients with a malignancy, active infection or a known platelet 
disorder were not included. Blood was obtained by venipuncture into Vacuette tubes, 
containing K2-EDTA, for measurement of hemostatic variables and immature platelet 
fraction (IPF) using a Sysmex XN-9000 analyzer (Sysmex, Chuo-ku Kobe, Japan); 3.2% 
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(w/v) trisodium citrate for platelet function measurements, or hirudin for whole blood 
platelet aggregation. Control experiments were performed with blood drawn from 
healthy volunteers collected in trisodium citrate or acidic citrate dextrose.28
Preparation of platelet-rich plasma, platelets and red cells
Platelet-rich plasma (PRP), platelet-free plasma and washed platelets were 
prepared as described.29 Platelet counts were determined with a thrombocounter XP300 
Sysmex analyzer (Sysmex, Chuo-ku Kobe, Japan). Washed red blood cells were prepared 
as shown before.30
Irreversible P2Y
12
 inhibition in vitro
PRP from healthy donors was treated with lysine aspirin.28 The platelets were 
incubated with the active metabolite of clopidogrel (CAM) or vehicle medium. Mixtures 
of washed CAM-treated and vehicle-treated platelets were used for measurement 
of platelet aggregation, integrin α
IIb
β
3
 activation by flow cytometry and perfusion 
experiments with reconstituted whole blood.
Platelet aggregation
Aggregation of platelets in PRP was measured using a Chronolog aggregometer 
(Stago, Asnières sur Seine Cedex, France).31 Aggregation of platelets in whole blood was 
measured by Multiplate impedance aggregometry (Roche Diagnostics, Basel, Switzerland) 
as described.32 Ticagrelor (1 µM), being more potent than prasugrel 33, was added in vitro 
to block residual P2Y12 activity, where indicated.
Flow cytometric analysis of platelet subpopulations
Flow cytometry was performed on an Accuri C6 flow cytometer with CFlow Plus 
software (Becton-Dickinson Bioscience). To check for integrin α
IIb
β
3
 activation, platelets 
were activated with 2MeS-ADP in the presence of FITC-conjugated PAC-1 antibody against 
the activated α
IIb
β
3 
integrin. Activated platelets were identified as before.31 Ticagrelor (1 
µM) was added, where indicated.
Juvenile platelets were identified using two different methods of mRNA staining, 
i.e. with thiazole orange 34 or by a novel method using Cy5-labeled oligo-dT, which binds to 
the poly-A tail of mRNA species. Thiazole orange (15% in filtered PBS) was added to PRP, 
according to established procedures.34 Samples were activated with 2MeS-ADP in the 
presence of AF647-fibrinogen. For staining with 5’Cy5-oligo-dT, washed platelets were 
activated with 2MeS-ADP in the presence of OG488-fibrinogen. Samples were fixed with 
0.2% formaldehyde, permeabilized with 0.1% saponin and subsequently incubated with 
5’-Cy5-oligo-dT at 37 °C. For all samples, 5’Cy5-oligo-dA was used as a negative control 
probe to check for specificity of the staining. Color compensation was not required as 
fluorescent spectra did not overlap.
The average percentage of juvenile platelets as analyzed by the thiazole orange 
staining and the oligo-dT staining was 6.7% (± 1.9%) and 21.5% (± 5.8%) respectively. 
The discrepancy in the percentage of detected juvenile platelets can be explained by 
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the higher sensitivity of the oligo-dT staining to detect mRNA in comparison to thiazole 
orange. In order to use a uniform definition of juvenile platelets, the threshold for 
juvenile platelets was based on the IPF as determined by the Sysmex XN9000 analyzer, 
which is an internationally validated method in the clinic. An alternative analysis of 
juvenile platelets, based on the negative controls of both stainings, is presented in the 
supplements (Suppl. Fig. 3). 
Thrombus formation in whole blood
Whole blood thrombus formation on microspots in a parallel-plate flow chamber 
was measured, basically as described before.35 Patient blood samples were perfused 
through the chamber for 4 minutes at a wall-shear rate of 1600 s-1, while 2MeS-ADP 
(0.1 μM, f.c.) was co-perfused with a second pump. Ticagrelor was added where 
indicated. Thrombi were stained with AF647-labelled fibrinogen and, when indicated, 
with DiOC
6
.35 Brightfield and fluorescence microscopic images were captured with an 
EVOS fluorescence microscope, equipped with a 60x oil objective. Images were analyzed 
using Metamorph (Molecular Devices, Sunnyvale CA, USA) and ImageJ (open access) 
software.35
For measurement of thrombus formation of reconstituted blood samples from 
healthy controls, mixtures of CAM- and vehicle-treated platelets were added to washed 
red cells and plasma. In these experiments, the CAM-treated and vehicle-treated 
platelets were pre-labeled with the membrane probes CellVue Maroon and PKH26 
respectively. Microscopic  DIC and confocal fluorescent images were taken using a Zeiss 
LSM7 microscope (Oberkochen, Germany).35
Statistical analysis
Statistical analysis was performed using the SPSS Statistics 22 package (Armonk, 
NY, USA). Statistical analysis was performed using a one-way-repeated-measures-ANOVA 
or with a Friedman test with a post hoc Wilcoxon signed rank test. Bonferroni correction 
was applied when comparing multiple groups.
Results
P2Y
12
-inhibited platelets participate less in thrombus formation
In order to determine how platelets with non-responsive P2Y12 receptors interact 
with responsive platelets in aggregation and thrombus formation, platelets from 
control subjects were treated with the clopidogrel active metabolite (CAM) and mixed 
in various proportions with untreated platelets. All platelets were also treated with 
aspirin, in order to mimic conditions as in patients (see below). Flow cytometric analysis 
indicated that, upon stimulation with ADP, these platelet mixtures formed two distinct 
populations in terms of activation of integrin α
IIb
β
3
 and binding of OG488-fibrinogen. The 
population of fibrinogen-binding platelets decreased with increasing fractions of CAM-
treated platelets (Fig. 1A and Suppl. Fig. 1A). Addition of the P2Y12 receptor antagonist 
ticagrelor decreased the population of fibrinogen-binding platelets to the level of 100% 
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CAM-treated platelets (Fig. 1A), indicating that the CAM treatment had fully blocked 
the P2Y12 receptors. Light transmission measurements indicated a gradual decrease in 
ADP-induced platelet aggregation, when the fraction of CAM-treated platelets increased 
(Fig. 1B). Addition of ticagrelor again antagonized the remaining aggregation response. 
Together, these data suggest that the reduced integrin activation of the CAM-treated 
platelets prevented their incorporation into aggregates.
 To investigate this further, we assessed how the CAM-treated platelets participated 
in thrombus formation on immobilized collagen under high-shear flow conditions. 
Therefore, the P2Y12-inhibited platelets were labelled with the red-exciting membrane 
label CellVue Maroon, whereas the untreated platelets were labeled with the green-
exciting membrane label PKH26. This labeling did not affect platelet activation responses 
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Figure 1. Impaired aggregation and contribution to thrombus formation of P2Y12-inhibited platelets. (A, 
B) Different mixtures of uninhibited platelets and CAM-treated platelets were preincubated with vehicle 
or 1 μM ticagrelor, and stimulated with 20 μM 2MeS-ADP. (A) Fractions of OG488-fibrinogen binding 
platelets, representative for uninhibited platelets with activated integrin α
IIb
β
3
 (flow cytometry). (B) Maximal 
aggregation (% change in light transmission) within 5 minutes. (C, D) Reconstituted blood with different 
fractions of CAM-treated platelets was perfused 4 minutes over collagen at 1600 s-1 in the presence of 2MeS-
ADP. Uninhibited platelets were prelabeled with PKH26 and CAM-treated platelets with CellVue Maroon; 
for images see Suppl. Figure 2. (C) Quantification of the surface area covered by the populations of labelled 
platelets. (D) Mean thrombus size. Means ± SD (n = 3), *p < 0.05, **p < 0.01, ***p < 0.001 (ANOVA with 
Bonferroni correction).
3Thrombogenicity of platelets upon prasugrel offset
CHAPTER 1
49
(data not shown). Mixtures with 0%, 50% or 100% of CAM-treated platelets were added 
to red blood cells and plasma from the same donor to obtain reconstituted blood with 
different proportions of P2Y12-inhibited platelets. In comparison to reconstituted blood 
with solely uninhibited platelets, increasing proportions of CAM-treated platelets had 
limited impact on platelet adhesion to the collagen surface, but markedly suppressed 
the formation of large platelet aggregates (Suppl. Fig. 2). As a result, with CAM-treated 
platelets, surface area coverage (Fig. 1C) and mean thrombus size (Fig. 1D) on collagen 
progressively decreased. Strikingly, with 50% of CAM-treated platelets, about 30% of the 
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Figure 2. Partial restoration of platelet aggregation in whole blood upon prasugrel offset. Whole blood 
samples from patients (at indicated days after stopping prasugrel intake) were stimulated with 6.4 µM ADP 
(A), 0.5 mM arachidonic acid (B), 3.2 µg/ml collagen (C), or 32 µM TRAP (D). Measurements by Multiplate 
impedance aggregometry; outcome expressed as the area under the impedance curve (AUC). Grey blocks 
indicate normal ranges, established for healthy subjects. Means ± SD (n = 15-16), *p < 0.05, **p < 0.01, ***p 
< 0.001 vs. day 0 (ANOVA with Bonferroni correction).
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surface area coverage was occupied by the P2Y12 inhibited platelets, while the remaining 
70% was occupied by the P2Y12-responsive platelets. Together, these results indicate that 
P2Y12-inhibited platelets participate less in platelet aggregation and thrombus formation.
Gradual restoration of platelet aggregation in patients upon prasugrel offset
The offset phase of prasugrel medication was studied in 16 patients. The patients 
had a mean age of 59 ± 9 years (mean ± SD); three patients were diagnosed with type II 
diabetes mellitus (Suppl. Table 1). Blood samples taken at day 0 (i.e. last day of prasugrel 
intake) showed a normal hematocrit of 0.435 ± 0.035 l/l and platelet count of 239 ± 81 
x 109/l. Subsequent blood samples were taken at days 1, 2, 5, and 30, and no noticeable 
changes in hematocrit or platelet count were observed.
 Measurements of whole blood aggregation (Multiplate assay) showed a gradual 
increase in ADP-induced aggregation upon offset from days 2 to 30 (Fig. 2A). Interestingly, 
the aggregation response further increased at day 30 in comparison to day 5. Whole 
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Figure 3. Restored ADP- and collagen-induced aggregation of platelets upon prasugrel offset. Patient PRP 
(at indicated days after stopping prasugrel intake) activated with 5-10 μM ADP (A) or 1-4 μg/ml collagen (B), 
in the presence or absence of 1 μM ticagrelor (blocking P2Y12 receptors). Platelet aggregation was assessed 
by light transmission aggregometry (% change in maximal light transmission). Means ± SD (n = 16), *p < 0.05, 
**p < 0.01 and ***p < 0.001 vs. day 0 (ANOVA with Bonferroni correction).
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blood aggregation in response to arachidonic acid remained below the normal range 
(Fig. 2B), thus confirming that all patients still used aspirin during the offset period. The 
aggregation responses to collagen and thrombin receptor-activating peptide (TRAP) 
were within the normal ranges, but slightly increased at later sampling points (Fig. 2C-
D). Similarly, light transmission aggregometry in PRP indicated a restoration in ADP-
induced platelet aggregation from day 2 onward (Fig. 3A). In this test, the aggregation 
response with two ADP concentrations was near maximal already at day 5. Collagen-
induced platelet aggregation also significantly improved, but only at later time points 
(Fig. 3B). Control experiments in the presence of ticagrelor showed that the increase in 
aggregation during prasugrel offset was fully antagonized, confirming that the regained 
platelet reactivity was fully due to increased P2Y12 receptor function (Fig. 3A-B).
Formation of a highly reactive population of juvenile platelets upon prasugrel offset
Based on earlier experiments with rats,18 we expected during the offset phase 
of prasugrel medication the rapid formation of a population of newly formed, fully 
P2Y12-responsive platelets. A pertinent question was how the regained response in 
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Figure 4. Reappearance of ADP-responsive platelets upon prasugrel offset. Whole blood from patients or 
healthy controls was preincubated with vehicle, 1 μM ticagrelor or 50 μM MRS-2179 (as indicated), and then 
stimulated with 1 μM 2MeS-ADP. Activation of α
IIb
β
3
 was assessed by flow cytometric analysis using FITC-
labelled PAC-1 mAb. (A) Representative histograms of PAC-1 mAb binding to patient platelets stimulated with 
ADP (black) or unstimulated (grey) during offset. (B) Quantification of positive platelets. (C) Flow cytometric 
analysis of healthy control platelets. Means ± SD (n = 16), ***p < 0.001 vs. day 0 ADP (ANOVA with Bonferroni 
correction); #n = 15.
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Figure 5. Increased ADP-induced α
IIb
β3 activation of juvenile platelets formed upon prasugrel offset. 
Platelets from 16 patients during offset from prasugrel were activated and analyzed by flow cytometry, 
with per sample a gating for juvenile platelets based on the immature platelet fraction (Sysmex XN-9000 
analyzer). (A) Immature platelet fraction for each of the patients during offset, as determined with a Sysmex 
XN-9000 analyzer. Red dots are from patient with a high immature platelet fraction (IPF = 8.8%). Juvenile 
platelets were identified by staining with thiazole orange or 5’Cy5-oligo-dT. (B) PRP was stained with thiazole 
orange and activated with 1 μM 2MeS-ADP in the presence of AF647-fibrinogen. Shown is extent of activated 
α
IIb
β
3
 of thiazole-positive and -negative platelets, as assessed from fibrinogen binding. (C) Washed platelets 
were activated with 1 μM 2MeS-ADP in the presence of OG488-fibrinogen. The cells were subsequently 
fixed and permeabilized with saponin to allow staining of mRNA by incubation with 5’Cy5-oligo-dT. Negative 
control stains were performed with 5’Cy5-oligo-dA. Shown is extent of α
IIb
β
3
 activation of mRNA-positive 
and -negative platelets, as determined from fibrinogen binding. Medians ± IQR (n = 16), ***p < 0.001 vs. 
corresponding mature platelet fraction (Friedman test).
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P2Y12 receptor activity was linked to the appearance of this new platelet population. To 
investigate this, flow cytometry was used to analyze platelets stimulated with the stable 
(nucleotidase-resistant) ADP analogue, 2MeS-ADP, for binding of FITC-labeled PAC-1 
antibody, indicative of integrin α
IIb
β
3
 activation. At day 0, a limited fraction of 26 ± 9% of 
the platelets showed activated α
IIb
β
3
, and this fraction (recognized as a separate peak in 
the histograms) gradually increased to 56 ± 5% at day 5 and 72 ± 7% at day 30 (Fig. 4A-B). 
In comparison, activation of aspirin-treated platelets from healthy control subjects with 
2MeS-ADP resulted in a similar percentage of platelets with activated α
IIb
β
3
 as platelets 
collected at 30 days after prasugrel cessation (Fig. 4C). In platelets from patients (Fig. 4B) 
and healthy controls (Fig. 4C), the fraction of platelets binding FITC-PAC1 antibody was 
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Figure 6. Restored thrombus formation under flow upon prasugrel offset. Whole blood samples from 
patients (at indicated days after stopping prasugrel intake) were co-perfused with 0.1 μM 2MeS-ADP over 
microspots containing vWF/fibrinogen or collagen type I, at a shear rate of 1600 s-1 for 4 minutes. Vehicle 
(control) or 10 µM ticagrelor was added to the blood. (A) Brightfield images of thrombi from a representative 
patient formed on the two microspots. Bars = 25 μm. Assessment of mean thrombus size for surfaces with 
vWF/fibrinogen (B) or collagen I (C). Means ± SD (n = 16), **p < 0.01, ***p < 0.001 vs. day 0 (ANOVA with 
Bonferroni correction); #n = 15.
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greatly, but incompletely reduced by the addition of ticagrelor. Co-incubations with the 
P2Y1 receptor antagonist MRS-2179 indicated that the residual αIIbβ3 activation was most 
likely due to activation via P2Y1 receptors.
Several assays were performed to determine whether the accumulating platelets 
with activated α
IIb
β
3
 indeed consisted of newly formed, juvenile platelets. Therefore, 
platelet mRNA was quantified using two different mRNA probes: thiazole orange as an 
established, but weak fluorescent mRNA dye22; and 5’Cy5-labeled oligo-dT, binding to 
the platelet mRNA poly-A tails21, which was added to pre-activated and permeabilized 
platelets. Supplemental figure 3 shows typical dotplots of unstimulated and ADP-
activated platelets stained with the 5’Cy5-oligo-dT (Suppl. Fig. 3A-B) or thiazole orange 
(Suppl. Fig. 3C-D). Juvenile and old platelets were discriminated per blood sample, 
based on the negative control and the immature platelet fraction determined by Sysmex 
XN-9000 (Fig 5A). For the majority of the patients, with one noticeable exception, the 
immature platelet fraction was in the normal range, with mean values of 3.6 ± 1.9%, and 
remaining constant per patient during the study (Fig. 5A). Markedly, with either mRNA 
probe (thiazole orange or 5’Cy5-oligo-dT), the fraction of platelets with positive staining 
showed increased fibrinogen binding following ADP stimulation from day 2 on (Fig. 5B-
C). Fibrinogen binding (α
IIb
β
3
 activation) of this juvenile platelet population continued to 
increase from day 5 to day 30. The difference between 5 and 30 days was significant for 
thiazole orange (p = 0.003), and was borderline significant for 5’Cy5-oligo-dT (p = 0.063), 
thus suggesting partial inhibition of these platelets even after 5 days offset. With either 
mRNA probe, the fraction of (older) platelets with negative staining was substantially 
lower in fibrinogen binding, with noticeable increase of activated integrins only from 
day 5 onwards (Fig. 5B-C). The difference in fibrinogen binding between juvenile and 
older platelets was significant at all days (p < 0.001). These results were confirmed using 
an alternative analysis based on the appropriate negative controls (Suppl. Fig 3.) Here 
again, the reactivity of juvenile platelets, expressed as activation ratio, was significantly 
higher in comparison to mature platelets at all days. Moreover, this analysis also shows 
the increasing reactivity of juvenile platelets over time for both stainings (Suppl. Fig 4A). 
Additional platelet measurements with a limited number of patients showed that, after 
12 days of prasugrel discontinuation, the reactivity of juvenile platelets was in between 
the day 5 and 30 values (Suppl. Fig. 4B). Interestingly, in patients with a high immature 
platelet fraction (IPF ≥ 7.0%), the population of juvenile platelets showed a faster increase 
in fibrinogen binding, being near maximal already at day 5 of prasugrel offset (Suppl. Fig. 
4A-B).
Gradual increase in thrombus size upon prasugrel offset
To investigate whether the increased reactivity of juvenile platelets after prasugrel 
cessation translates into enhanced thrombus formation, whole blood was perfused over 
microspots containing vWF/fibrinogen or type I collagen.35 Given the major role of P2Y12 
signaling in thrombus build-up36, we determined thrombus size at the different time 
points. Regardless of the surface, at day 0 many single platelets and small aggregates 
were detected, whilst at later offset days larger aggregates were formed. From the 
recorded brightfield images it was apparent that the thrombi at days 5 and 30 displayed 
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a more contracted morphology (Fig. 6A). Quantification of the feature size showed on 
both microspots a progressive increase in mean thrombus size during offset (Fig. 6B-C). 
On the other hand, platelet adhesion to vWF/fibrinogen or collagen was not changed 
between day 0 and 30, as surface area coverage (by single platelets and aggregates) 
remained similar (Suppl. Fig. 5A-B).
Staining of thrombi with AF647-labeled fibrinogen allowed assessment of integrin 
α
IIb
β
3
 activation. On both the vWF/fibrinogen and collagen microspots, a marked 
increase in fibrinogen binding to the aggregated platelets was detected for the later 
blood samples (Suppl. Fig. 6A-B). Addition of ticagrelor to the blood resulted in a nearly 
complete abolition of platelet aggregation at all offset days, but did not block platelet 
adhesion. With blood samples from a limited number of patients, staining with DiOC
6
 
made it possible to record z-stacks by confocal microscopy for 3D visualization of the 
thrombi. This illustrated the gradual increase in thrombus size from day 0 to day 5 and 
30 (Suppl. Fig. 6C). Taken together, these results indicate that the accumulation of highly 
P2Y12-responsive, juvenile platelets upon prasugrel offset led to a gradual increase in 
formation of large-size thrombi.
Discussion
In this paper, we confirm earlier findings7, 9, 15, 16, 37 that when treatment with 
an irreversible P2Y12 antagonist is stopped, platelet aggregation in response to ADP 
gradually recovers in time, when measured by light transmission aggregometry. Near 
maximal aggregation after stopping prasugrel intake was already reached at day 5, which 
is in line with results from earlier trials, such as Recovery showing recuperation of this 
platelet response after 7-9 days of prasugrel cessation.9 However, we also found that 
other platelet function tests, such as ADP-induced whole blood aggregation and integrin 
α
IIb
β
3
 activation were incompletely recovered at day 5 in comparison to day 30. In vitro 
addition of ticagrelor completely antagonized the time-dependent increase in platelet 
responses, thereby proving that the recuperation was due to regained P2Y12 signaling.
Detailed flow cytometric analysis indicated that the functional recovery during 
prasugrel offset was caused by the appearance of a population of juvenile platelets that 
was increasingly responsive towards ADP. Separation of newly formed and older platelets 
with two mRNA probes, thiazole orange and a new Cy5-conjugated oligo-dT probe, 
revealed increased responsiveness to ADP of the positively stained platelet population 
in terms of integrin α
IIb
β
3
 activation and fibrinogen binding. However, both probes also 
gave unexpected results. First, we observed a marked increase in ADP responsiveness 
of the juvenile platelet population after only two days of offset, and for the older 
platelet population after five days. This suggested that the majority of juvenile platelets 
formed during the first days still had inhibited P2Y12 receptors, taking into account the 
presence of the prasugrel active metabolite in the circulation for 7-8 hours post prasugrel 
administration.38 Second, we found a steady rise in the responsiveness of juvenile platelets 
up to days 12 and 30 of offset. This also points towards residual ADP receptor inhibition 
of new platelets, likely at the megakaryocytic level, for more than 5 days. In agreement 
with this hypothesis, experimental animal models have shown that prasugrel is present 
in the bone marrow.39 An alternative explanation for this phenomenon might be a long-
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term increase in autocrine platelet-stimulating effects due to the larger population of 
P2Y12-responsive platelets.
3, 40 However, flow cytometric analysis did not point to a higher 
extent of integrin α
IIb
β
3
 activation of the ADP-responsive platelet population as a whole.
To determine how the increased reactivity of juvenile platelets translates into 
hemostasis, we studied thrombus formation under flow on two different adhesive 
surfaces using whole blood. Platelet deposition and aggregate formation on the vWF/
fibrinogen and the collagen surfaces restored during the offset and was only maximal at 
day 30. The regained P2Y12 activity was most apparent from thrombus size, with larger 
thrombi towards the end phase of the offset. This is in agreement with earlier work 
showing that signaling via P2Y12 is crucial for thrombus formation and stabilization.
1, 
36 Also others found a relative preponderance of thiazole orange-stained platelets in a 
thrombus.41
In recent years, it has been debated whether the termination of clopidogrel or 
prasugrel intake leads to a rebound effect of recurrent cardiovascular events, perhaps 
related to platelet hyper-reactivity. Several research groups did report a rebound effect 
within 90 days after cessation of clopidogrel,13-17 while other researchers could not confirm 
this.37, 42-44 This discussion has led to clinical trials investigating the effect of tapering 
clopidogrel medication with the idea to prevent platelet hyper-reactivity, but with no 
beneficial effect so far.42, 43, 45 The present work may explain this ambiguity in clinical 
offset effects. On the one hand, cessation of clopidogrel or prasugrel medication will lead 
to the appearance of the newly formed platelets with uninhibited P2Y12 receptors, which 
preferentially partake in thrombus formation. On the other hand, as shown in this study, 
at least during the first few days these juvenile platelets do not appear to be hyperactive, 
possibly due to residual receptor blockage at the megakaryocyte level. When tapering 
the medication, the prolonged time interval between two consecutive dosages will result 
in the alternative formation of uninhibited and inhibited platelets.
The present study has potential limitations, as we have investigated a relative small 
number of patients. Further, in our initial ex vivo studies we used the active metabolite 
of clopidogrel. Although prasugrel is a more potent P2Y12 antagonist in comparison 
to clopidogrel,5 we added the active metabolite of clopidogrel at concentrations high 
enough for maximal inhibition.
Patients on dual antiplatelet therapy who require surgery are recommended to 
stop prasugrel intake 7 days beforehand.9 Our findings that prasugrel can still affect the 
reactivity of juvenile platelets during several days after treatment cessation does not 
plea for a shortening of this period. The compromised reactivity of juvenile platelets 
during the initial days of offset can contribute to a risk of bleeding upon surgery. When 
urgent surgery is required or when bleeding has to be controlled, platelet transfusions 
have shown to be effective in restoring haemostasis at 6 hours after a loading dose of 
prasugrel.46 Altogether, the present study provides clinically relevant detailed insights 
into the mechanisms of prasugrel offset, and thereby provides better insight into the 
optimal treatment regimen of P2Y12 inhibitors.
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Supplemental data
Supplemental methods
Materials
2MeS-ADP and D-Phe-Pro-Arg chloromethyl ketone (PPACK) were from SantaCruz 
Biotechnology (Santa Cruz, CA, USA); fluorescein isothiocyanate (FITC)-conjugated PAC-
1 antibody against active integrin α
IIb
β
3
 and thiazole orange from Becton-Dickinson 
Bioscience (Franklin Lakes NJ, USA), and aspirin was from Sanofi (Paris, France). Ticagrelor 
and the clopidogrel active metabolite (CAM) were kindly provided by AstraZeneca R&D 
(Mölndal, Sweden). 5’-Cy5-conjugated oligo-dA20 and oligo-dT20 were obtained from 
Eurogentec (Maastricht, The Netherlands). Alexa Fluor (AF)-647 and Oregon Green (OG)-
488 conjugated human fibrinogen were from Invitrogen (Bleiswijk, The Netherlands). 
Collagen type I came from Nycomed Pharma (Munich, Germany); 3,3’-dihexyloxa 
carbocyanine iodide (DiOC
6
) from Anaspec (Fremont CA, USA); CellVue Maroon from 
eBioscience (San Diego CA, USA), and iloprost from Bayer Pharma (Berlin, Germany). 
Multiplate test kits were from Roche Diagnostics (Basel, Switzerland). Other compounds 
came from Sigma (St. Louis, MO, USA).
Patients and control subjects
This study was approved by the local medical ethics committee (MEC 12-3-075). 
All patients and healthy volunteers gave written informed consent for participation 
according to the Helsinki declaration. Sixteen patients were studied who were treated 
with prasugrel (10 mg/day) for one year and long-term aspirin (80-100 mg/day) due 
to a myocardial infarction with ST elevation. After one year of prasugrel treatment, 
blood was collected on the last day of prasugrel intake, and at 1, 2, 5 and 30 days after 
the last dose. From two patients, blood samples were also collected after 12 days to 
better understand the delayed regain of platelet function. Patients with a malignancy, 
active infection or a known platelet disorder were not included. Blood was obtained by 
venipuncture with a Vacutainer 21-gauge needle (Becton-Dickinson Bioscience). Blood 
collection was into Vacuette tubes, containing K2-EDTA, for measurement of hemostatic 
variables and immature platelet fraction using a Sysmex XN-9000 analyzer, according 
to protocols of the supplier (Sysmex, Chuo-ku Kobe, Japan). Blood samples were also 
collected into 3.2% (w/v) trisodium citrate for platelet function measurements, and into 
hirudin for whole-blood platelet aggregation. Control experiments were performed with 
blood drawn from healthy volunteers. Collection was into trisodium citrate, or into acidic 
citrate dextrose (ACD, 80 mM trisodium citrate, 52 mM citric acid and 180 mM glucose) 
for the preparation of washed platelets.1
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Preparation of platelet-rich plasma, platelets and red cells
Platelet-rich plasma (PRP) was prepared by centrifuging citrate-anticoagulated 
blood at 240 g for 15 minutes at room temperature. Platelet-free plasma was obtained 
by centrifuging citrate-anticoagulated blood twice at 2630 g for 10 minutes. Washed 
platelets were prepared from ACD-anticoagulated blood, as described2, and were 
suspended in Hepes buffer pH 7.45 (10 mM Hepes, 136 mM NaCl, 2.7 mM KCl, 2 mM 
MgCl2, 0.1% glucose and 0.1% bovine serum albumin). Platelet counts were determined 
with a thrombocounter XP300 Sysmex analyzer (Sysmex, Chuo-ku Kobe, Japan).
Washed red blood cells were prepared by centrifuging citrate-anticoagulated 
blood at 240 g for 15 minutes at room temperature.3 After removal of PRP, Hepes buffer 
pH 7.45 was added in a 1:2 volume ratio. The red blood cells were centrifuged twice 
at 2630 g for 10 minutes, with resuspension in Hepes buffer pH 7.45. This resulted in a 
preparation of >99.9% red cells.
Irreversible P2Y12 inhibition in vitro
PRP from healthy donors was treated with 100 μM lysine aspirin for 30 minutes, 
and platelets were pelleted by centrifugation.1 The resuspended cells were incubated for 
15 minutes with 10 μM CAM or vehicle medium. Residual unbound CAM was removed 
by a second final centrifugation step, where 5 nM iloprost was added to prevent platelet 
activation. Mixtures of the washed CAM-treated and vehicle-treated platelets in Hepes 
buffer pH 7.45 were used for measurement of: platelet aggregation (light transmission 
aggregometry in the presence of 2 mM CaCl2 and 0.1 mg/ml fibrinogen); integrin 
α
IIb
β
3
 activation by flow cytometry in the presence of 75 μg/ml OG488-fibrinogen; and 
perfusion experiments with reconstituted whole blood.
Platelet aggregation
Aggregation of platelets in PRP was measured using a Chronolog aggregometer 
(Stago, Asnières sur Seine Cedex, France).4 Preincubation with ticagrelor or vehicle 
medium was for 5 minutes at 37 °C. Aggregation of platelets in whole blood was measured 
by Multiplate impedance aggregometry (Roche Diagnostics, Basel, Switzerland) as 
described.5 Aggregation was measured in response to ADP (6.4 µM), arachidonic acid 
(0.5 mM), collagen (3.2 µg/ml) or thrombin receptor-activating peptide SFLLRN (TRAP, 
32 µM) at 37 °C during 6 minutes. Ticagrelor (1 µM) was added in vitro to block residual 
P2Y12 activity, where indicated. Extent of platelet aggregation was assessed from the area 
under the impedance curve. 
Flow cytometric analysis of platelet subpopulations
Flow cytometric measurements were performed on an Accuri C6 flow cytometer 
with CFlow Plus software (Becton-Dickinson Bioscience). To check for integrin α
IIb
β
3 
activation, samples of citrated patient blood were diluted (1:20) into Hepes buffer pH 7.45, 
and incubated with 1 µM ticagrelor or vehicle control for 15 minutes at room temperature. 
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Platelets were activated with 1 µM 2MeS-ADP in the presence of FITC-conjugated PAC-1 
antibody (1.25 µg/ml) against the activated α
IIb
β
3
 integrin for 10 minutes. Ticagrelor (1 
µM) was added, where indicated. Activated platelets were identified as before.4
Juvenile platelets were identified using two different methods of mRNA staining, 
i.e. with thiazole orange6 or by a novel method using Cy5-labelled oligo-dT, which binds to 
the poly-A tail of mRNA species. Thiazole orange (15% in filtered PBS: 136 mM NaCl, 2.7 
mM KCl, 1.47 mM KH2PO4, 6.46 mM Na2HPO4) was added to PRP for 30 minutes at room 
temperature, according to established procedures.6 Platelets were then centrifuged at 
5550 g for 3 minutes to remove excess and unbound thiazole orange, and resuspended 
in Hepes buffer pH 7.45. Samples were activated with 1 μM 2MeS-ADP in the presence 
of AF647-fibrinogen (75 μg/ml) for 15 minutes. For staining with 5’Cy5-oligo-dT, washed 
platelets in suspension (1 x 108/ml) were activated with 1 μM 2MeS-ADP in the presence 
of OG488-fibrinogen (75 μg/ml) for 15 minutes. Samples were fixed (15 minutes) with 
0.2% formaldehyde and permeabilized (10 minutes) with 0.1% saponin. 5’-Cy5-oligo-dT 
(1 μM) was incubated for 15 minutes at 37 °C. For all samples, 5’Cy5-oligo-dA (1 µM) was 
used as a negative control probe to check for specificity of the staining with 5’Cy5-oligo-
dT. Color compensation was not required as fluorescent spectra did not overlap. 
The average percentage of juvenile platelets as analyzed by the thiazole orange 
staining and the oligo-dT staining was 6.7% (± 1.9%) and 21.5% (± 5.8%) respectively. 
The discrepancy in the percentage of detected juvenile platelets can be explained by 
the higher sensitivity of the oligo-dT staining to detect mRNA in comparison to thiazole 
orange. In order to use a uniform definition of juvenile platelets, the threshold for 
juvenile platelets was based on the IPF as determined by the Sysmex XN9000 analyzer, 
which is an internationally validated method in the clinic. An alternative analysis of 
juvenile platelets, based on the negative controls of both stainings, is presented in the 
supplements (Supplemental Fig.3). 
Thrombus formation in whole blood
Whole-blood thrombus formation on microspots in a parallel-plate flow chamber 
was measured, basically as described before.7 Briefly, 0.5 μl microspots containing either 
collagen I (100 μg/ml) or fibrinogen (250 μg/ml) plus vWF (50 μg/ml) were perfused with 
citrate-anticoagulated whole blood, which was recalcified with 7.5 mM CaCl2 and 3.75 
mM MgCl2 in the presence of 40 μM PPACK immediately before the experiment. Patient 
blood samples were perfused through the chamber for 4 minutes at a wall-shear rate of 
1600 s-1, while 2MeS-ADP (0.1 μM, f.c.) was co-perfused with a second pump. Ticagrelor 
was added where indicated. Thrombi were stained with AF647-labelled fibrinogen and, 
when indicated, DiOC
6
, as described elsewhere.7 Brightfield and fluorescence microscopic 
images were captured with an EVOS fluorescence microscope, equipped with a 60x oil 
objective. Images were analysed using Metamorph (Molecular Devices, Sunnyvale CA, 
USA) and ImageJ (open access) software.7
For measurement of thrombus formation of reconstituted blood samples from 
healthy controls, mixtures of CAM- and vehicle-treated platelets (2.5 x 108/ml, final count) 
were added to washed red cells (45% hematocrit) and plasma (30-35% of total volume). 
In these experiments, the CAM-treated platelets were pre-labeled with the membrane 
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probe CellVue Maroon (1.6 μM), whereas the vehicle-treated platelets were pre-labeled 
with the membrane probe PKH26 (0.8 μM). Both probes were not transferrable from 
cell to cell (data not shown). The reconstituted whole blood was again co-perfused with 
2MeS-ADP over collagen. Microscopic DIC and confocal fluorescent images were taken 
using a Zeiss LSM7 microscope (Oberkochen, Germany).7
Statistical analysis
Statistical analysis was performed using the SPSS Statistics 22 package (Armonk, 
NY, USA). Statistical analysis was performed using a one-way-repeated-measures-ANOVA 
or with a Friedman test with a post hoc Wilcoxon signed rank test. Bonferroni correction 
was applied when comparing multiple groups.
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Variables
Patient characteristics
Age (years) 59 ± 9
Female/male (n) 3/13
Diabetes Mellitus (n) 3
Aspirin use (n) 16
Statins use (n) 13
Hematological variables
Hematocrit (L/L) 0.435 ± 0.035
Platelet count (109/L) 239 ± 81
Mean platelet volume (fL) 10.8 ± 0.7
Immature platelet fraction (IPF) Sysmex (%) 3.6 ± 1.9
Supplemental Table 1. Study characteristics. Means ± SD.
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Supplemental Figure 1. Impaired fibrinogen binding of populations of P2Y12-inhibited platelets. Mixtures 
of control platelets and CAM-treated platelets were preincubated with 1 μM ticagrelor or vehicle, and 
stimulated for 15 minutes with 20 μM 2MeS-ADP in the presence of OG488-fibrinogen. Fibrinogen binding 
was assessed by flow cytometry. Shown are representative histograms of fibrinogen binding after stimulation 
in the presence of vehicle (A) or ticagrelor (B).
CHAPTER 1
Chapter 3
66
0 50 100
A
B
% CAM treated platelets
DI
C
PK
H2
6/
Ce
llV
ue
Supplemental Figure 2. Impaired contribution to thrombus formation of P2Y12-inhibited platelets. 
Reconstituted blood with different fractions of CAM-treated platelets was perfused 4 minutes over collagen 
at 1600 s-1 in the presence of 2MeS-ADP. Uninhibited platelets were prelabeled with PKH26 (blue) and CAM-
treated platelets with CellVue Maroon (red). Shown are representative DIC (A) and dual-color fluorescence 
(B) images. Bars = 25 µm. See further, Figure 1.
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Supplemental Figure 3. Alternative analysis confirms higher reactivity of juvenile platelets and increased 
activation in time upon prasugrel offset Juvenile platelets were detected using the oligo-dT staining or 
the thiazole orange staining, as described for Figure 5. Shown are representative dot plots of oligo-dA/dT 
or thiazole orange vs. Fg-OG488/AF647. Thresholds for juvenile and mature platelets were based on the 
negative controls oligo-dA and PBS for the oligo-dT and thiazole orange staining respectively. Thresholds for 
activated platelets were based on unstimulated samples. Unstimulated juvenile platelets (blue) and activated 
juvenile platelets (green) are depicted. Representative dot plots of unstimulated (A) or ADP-activated (B) 
mature and juvenile platelets as identified by the oligo-dT staining. Representative dot plots of unstimulated 
(C) or ADP-activated (D) mature and juvenile platelets using the thiazole orange staining.
Table. Using the percentage of platelets in each quadrant of the dot plots, the activation ratio was calculated 
for both mature (Q-UL/Q-LL) and juvenile platelets (Q-UR/Q-LR) using either staining. Mean ± SEM (n =16), 
*p < 0.05, **p < 0.01, ***p < 0.001 vs. corresponding mature ratio (ANOVA with Bonferroni correction).
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Supplemental Figure 4. Increased ADP-induced α
IIb
β3 activation of juvenile platelets formed upon prasugrel 
offset. Platelets from patients during offset from prasugrel were activated and analyzed by flow cytometry. 
Juvenile platelets were identified by staining with the mRNA probe, 5’Cy5-oligo-dT. See further Figure 5. 
Washed platelets were activated with 1 μM 2MeS-ADP in the presence of OG488-fibrinogen. The cells were 
fixed and permeabilized with saponin to allow staining of mRNA by incubation with 5’Cy5-oligo-dT. Shown is 
extent of α
IIb
β
3
 activation of mRNA-positive and -negative platelets, per subject. (A) Data from 16 patients, 
medians ± IQR. (B) Data from additional patients including day 12 time points. Red dots are from patients 
with a high immature platelet fraction (IPF ≥ 7.0%).
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Supplemental Figure 5. Unchanged platelet adhesion in thrombus formation under flow upon prasugrel 
offset. Whole blood samples from patients (at indicated days after stopping prasugrel intake) were co-
perfused with 2MeS-ADP over microspots containing vWF/fibrinogen (A) or collagen type I (B), as in Figure 
6. Brightfield images were analyzed for surface area coverage of all platelets (single platelets and aggregates) 
at different offset days. Means ± SD (n = 16), ***p < 0.001 vs. day 0 (ANOVA with Bonferroni correction); #n 
= 15.
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Supplemental Figure 6. Restored thrombus formation under flow upon prasugrel offset. Whole blood 
samples from patients (at indicated days after stopping prasugrel intake) were co-perfused with 2MeS-ADP 
over microspots containing vWF/fibrinogen or collagen type I, at a shear rate of 1600 s-1 for 4 minutes. 
See also Figure 6. Staining of thrombi was with AF647-fibrinogen and the platelet membrane label DiOC
6
. 
Vehicle (control) or 10 µM ticagrelor was added to the blood. (A, B) Shown are (for a representative patient) 
fluorescence images of fibrinogen binding (red) of the thrombi formed on vWF/fibrinogen or collagen I. Bars 
= 25 μm. (C, D) Representative confocal z-stacks of thrombi on vWF/fibrinogen or collagen I stained with 
DiOC
6
 (green).
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Abstract  
Platelet- and fibrin-dependent thrombus formation is regulated by blood flow and 
exposure of collagen and tissue factor. However, interactions between these blood-borne 
and vascular components are not well understood. Here, we developed a method to 
assess whole blood thrombus formation on microspots with defined amounts of collagen 
and tissue factor, allowing determination of the mechanical properties and intrathrombus 
composition. Confining the collagen content resulted in diminished platelet deposition 
and fibrin formation at high shear flow conditions, but this effect was compensated by 
a larger thrombus size and increased accumulation of fibrin in the luminal regions of 
the thrombi at the expense of the base regions. These thrombi were more dependent 
on tissue factor-triggered thrombin generation. Microforce nanoindentation analysis 
revealed a significantly increased microelasticity of thrombi with luminal-oriented fibrin. 
At a low shear rate, fibrin fibers tended to luminally cover the thrombi, again resulting 
in a higher microelasticity. Studies with blood from patients with distinct hemostatic 
insufficiencies indicated an impairment in formation of a platelet-fibrin thrombus in the 
cases of dilutional coagulopathy, thrombocytopenia, Scott syndrome and hemophilia 
B. Taken together, our data indicate that: (i) thrombin increases the platelet thrombus 
volume; (ii) tissue factor drives formation of fibrin outside of the platelet thrombus; (iii) 
limitation of platelet adhesion redirects fibrin from bottom to top of the thrombus; (iv) 
a lower shear rate promotes thrombus coverage with fibrin; (v) the fibrin distribution 
pattern determines thrombus microelasticity; and (vi) the thrombus-forming process is 
reduced in patients with diverse hemostatic defects.
Introduction
During hemostasis, blood flow and platelet activation in combined action with 
the coagulation system determine the formation of platelet-fibrin thrombi at the injured 
vessel wall. Multiple components of the damaged endothelial and  subendothelial layers 
are known to influence the dynamics of thrombus growth and fibrin polymerization.1 
Key vascular constituents triggering this process are collagen fibers and tissue factor (TF), 
serving as potent platelet- and coagulation-stimulating agents, respectively.2 Thrombin 
that is formed on the surface of activated platelets and on injured vascular cells is a 
central player in the hemostatic process by enhancing platelet activation, producing 
activated coagulation factors and converting fibrinogen into fibrin.3 Yet, the complex role 
of thrombin in formation of a platelet-fibrin thrombus under flow is at best incompletely 
studied.
Murine in vivo models of arterial thrombus formation have shown that the 
type and severity of vascular injury are determinative for the precise triggering of this 
process. Exposure of the vasculature to FeCl3, resulting in endothelial denudation, leads 
to collagen-dependent platelet activation with an additional role of TF, particularly 
upon milder FeCl3 injury.
4-7 Thrombin and fibrin generation are elicited on procoagulant 
platelets exposing phosphatidylserine.8, 9 Platelets, furthermore, control the coagulation 
process by secreting pro- and anticoagulant proteins, whereas there is ample evidence 
for a role of platelet-exposed TF.10, 11 On the other hand, in most laser-induced injury 
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models, thrombus formation is primarily triggered by thrombin that is generated 
via vascular TF.12, 13 Severe laser injury, however, also leads to collagen exposure and 
collagen-dependent platelet activation.14, 15
Together, these in vivo findings indicate that the relative availability of platelet-
adhesive (like collagen) and coagulation-triggering (like TF) substances determines the 
buildup of a thrombus and, by implication, the roles of thrombin and fibrin herein. In 
support of this idea, different patterns of fibrin deposition have been detected in injury 
models, such as fibrin structures around a thrombus,16 and thrombin/fibrin-rich areas 
in the thrombus core region.17, 18 How the platelet- and coagulant-activities of the 
thrombogenic surface, for example, the relative abundance of collagen and TF, influence 
the buildup and composition of a platelet-fibrin thrombus has not been examined so far.
Viscoelasticy is considered to be an important hemostatic property of a fibrin-
containing thrombus. For instance, in patients with severe factor XI deficiency, a low 
density fibrin network is associated with impaired hemostasis.19, 20 However, the conditions 
that favor high elasticity of a platelet-fibrin thrombus or clot are largely unknown. The 
limited evidence available suggests that a local, high concentration of thrombin enforces 
the fibrin network,21 and that blood flow supports the alignment of stiff fibrin fibers.22, 
23 Macroscopic thromboelastic studies have not come much further than demonstrating 
that, in patients with dilutional coagulopathy, the overall clot strength is predictive for 
the risk of perioperative bleeding.24
In the present article, we investigated how the type of thrombogenic surface - 
with defined relative amounts of collagen and TF - affects the formation and composition 
of platelet-fibrin thrombi that are formed under high and low shear flow conditions. 
We developed standardized protocols, in which citrate-anticoagulated blood was flowed 
over defined collagen/TF microspots, and the deposition of platelets and fibrin(ogen) 
were assessed simultaneously. We then determined the distribution of fibrin within 
and outside the thrombus by confocal microscopy, as well as the microelasticity of the 
formed thrombi by a novel method of nanoindentation. The data reveal a surface- and 
flow-dependent thrombus buildup with a different location of fibrin.
Materials and Methods
Materials and methods are available in the Supplemental data.
Results
Collagen-TF surface determines buildup of platelet-fibrin thrombus and extent of fibrin 
formation under flow
To study the roles of platelets and coagulation in whole blood thrombus formation 
under flow, we applied a previously developed microspot method of thrombus formation 
in parallel-plate flow chambers,25 which was adapted to operate under strictly controlled 
coagulant conditions. The changes included: (i) preparation of microspots with defined 
amounts of collagen and tissue factor (TF), (ii) co-infusion of citrate-anticoagulated 
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blood with Mg2+/Ca2+ recalcification medium to obtain physiological concentrations of 
divalent cations; (iii) adequate mixing of blood with medium by pushing through a tube-
slit converter in the flow chamber, and (iv) real-time confocal recording of both platelet 
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Figure 1. Collagen-tissue factor (TF) coating determines the buildup of platelet-fibrin thrombus formed 
under flow. Citrated whole blood was perfused during recalcification over microspots with collagen (20 or 
100 ng) in the absence or presence of TF (10 pg) for 7 minutes at a wall shear rate of 1000 s-1. Blood samples 
were prelabeled with DiOC6 to label platelets (green) and with AF647-fibrinogen to monitor fibrin formation 
(red). Control samples were pretreated with hirudin (h, 3 µg/mL), where indicated. Two-color microscopic 
confocal images were recorded in real time at frequency of 1 Hz. (A) Representative fluorescence images 
from collagen/TF microspots after 7 minutes of flow (bars, 50 µm). (B, C) Time-dependent accumulation of 
(B) DiOC6-labeled platelets and (C) AF647-fibrin(ogen) during blood flow. (D) Representative stacks of thrombi 
in 3D (z-step 1 μm) of platelets (green) and fibrin(ogen) (red) on collagen/TF microspots after 7 minutes of 
flow (bars, 50 µm). (E) Fluorescence area covered by platelets and fibrin on collagen/TF microspots after 7 
minutes of flow. (F) Average thrombus size on spot as determined by morphometric image analysis. Means 
± SEM (n = 6-15), *p < 0.05.
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deposition and fibrin generated on the microspots using 3,3’-dihexyloxacarbocyanine 
(DiOC6) and Alexa Fluor (AF)647-fibrinogen as probes, which were pre-added to the 
blood samples (Supplemental Fig. 1).
Pilot data indicated that co-coating of 10 pg TF per microspot resulted in optimal 
shortening of time to fibrin formation, as checked with bright-field image recording, such 
as in agreement with published findings.26 Perfusion of blood samples at a shear rate of 
1000 s-1 over microspots enriched in collagen (100 ng per microspot) resulted in a rapid 
formation of platelet thrombi that were rich in fibrin (Fig. 1A-C). Lowering the collagen 
content (20 ng per microspot) significantly decreased platelet deposition after 7 minutes 
of perfusion (area covered, 12.3 ± 1.4 % vs. 33.8 ± 3.0 %; p = 0.005) and delayed the onset 
of fibrin formation (3 vs. 5 minutes), as compared to the high collagen microspots (Fig. 1A-
C). In the absence of TF, when coagulation is triggered via the intrinsic pathway,27 platelet 
deposition was decreased on high collagen but unaltered on low collagen, whereas fibrin 
formation was greatly delayed in either case (Supplemental Table 1). Pretreatment of the 
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Figure 2. Collagen-tissue factor (TF) coating determines distribution of fibrin through a thrombus. 
Platelet-fibrin thrombi were formed by blood flow over microspots of collagen (20 or 100 ng) plus TF (10 
pg) for 7 minutes, as described in Figure 1. Confocal images of DiOC6 (green) and AF647-fibrin(ogen) (red) 
fluorescence in 3D were captured. (A) Representative fluorescence images of optical slices at base, center 
and top of thrombus on collagen (100 ng)/TF microspots (bars, 20 μm). (B, C) Integrated fluorescence 
intensity (arbitrary units, AU) of platelet (green) and fibrin (red) fluorescence from z stacks at base (<10 μm), 
center (10-20 μm) and top (>20 μm) of thrombi formed. (D) Ratio of platelet/fibrin fluorescence intensity at 
base, center and top of thrombi. Means ± SEM (n = 6-7), *p < 0.05. 
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blood with corn trypsin inhibitor to block the intrinsic coagulation pathway resulted in 
a delayed formation of fibrin only for microspots not containing TF (data not shown). In 
the absence of collagen (only TF), neither platelets nor fibrin deposited on the surface.
Reconstruction of stacks of confocal images in 3D indicated that the platelet-fibrin 
thrombi formed on high collagen microspots were relatively small and dense, when 
compared with the more dispersed thrombi formed on low collagen microspots (Fig. 
1A, D). Persistent thrombin activity on each type of microspot was confirmed by the 
addition of a fluorogenic thrombin substrate, which was continuously cleaved (data 
not shown). Markedly, with hirudin added to the blood, platelet deposition decreased 
on high collagen microspots (surface area coverage from 33.8 to 19.1 %, p = 0.001), 
whereas on low collagen hardly any platelets were left (from 12.3 to 2.9 %, p < 0.0001). 
As expected, with hirudin present, fibrin formation was completely suppressed on either 
surface (Fig. 1E). Quantification also showed that hirudin significantly reduced the size 
of individual thrombi on the high collagen surface (from 228 ± 76 to 121 ± 16 µm2, p = 
0.007), a reduction that was even more pronounced on the low collagen surface (from 
335 ± 94 to 74 ± 21 µm2, p < 0.001) (Fig. 1F).
As microscopic images showed a gradual contraction of platelets in fibrin-
containing thrombi, we aimed to quantify this process by addition of 3 % DiOC6-labeled 
washed platelets to the blood, and then monitoring the movement of adhered platelets 
in time. It seemed that the overall displacement rate of platelets was high on microspots 
with collagen/TF during the time of fibrin formation (1.06 ± 0.11 x10-3 μm/s), whereas it 
was non-significantly changed (0.87 ± 0.10 x10-3 μm/s) in the presence of Gly-Pro-Arg-
Pro, inhibiting fibrin polymerization, and significantly lowered in the presence of hirudin 
(0.64 ± 0.05 x10-3 μm/s, p = 0.0064). Hence, under the present flow conditions, platelet 
contraction did occur in the absence of thrombin or fibrin but was enhanced by the 
formation of either. This resolves a dispute in the literature that platelet-fibrin retraction 
is considered a thrombin-dependent event28 but can still occur under conditions where 
thrombin is blocked.29
By lowering the wall shear rate from 1000 to 150 s-1, platelet deposition on high or 
low collagen was reduced (Supplemental Table 1), as expected due to a diminished role of 
von Willebrand factor.25 On the other hand, total fibrin formation did not reduce at lower 
shear rate (Supplemental Fig. 2). Co-localization analysis of fluorescence from platelets 
and fibrin indicated major extension of the fibrin fibers outside of platelet aggregates 
especially at low shear conditions (150 s-1), and to a lesser extent at the higher shear 
rate (Supplemental Fig. 2). Jointly, these data indicate that limitation of the platelet-
adhesive collagen surface resulted in an overall reduced platelet deposition, which was 
partly compensated by a larger thrombus size because of the activity of TF-triggered 
thrombin generation. Lowering of the shear rate also reduced platelet accumulation but 
in a relative way promoted fibrin formation.
Collagen-TF surface and shear rate define distribution of fibrin in a thrombus
To assess the amount and localization of thrombus-associated fibrin on different 
microspots, z stacks of confocal images of the fluorescent-labeled platelets and fibrin 
were captured at the end of high shear flow experiments (Fig. 2A). On microspots with 
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high collagen, the majority of platelet and fibrin fluorescence was located near the 
base (0-10 μm) and center regions (10-20 μm) of the thrombi. On microspots with low 
collagen, overall thrombus volume was reduced from 1.10 ± 0.20 to 0.46 ± 0.10 x106 μm3 
(p < 0.001; Supplemental Table 1). In this case, fluorescence from platelets and fibrin was 
more evenly distributed among the base, center and top regions of the thrombus (Fig. 2B, 
C). Markedly, the top regions of thrombi formed on low collagen showed a significantly 
higher ratio of fibrin to platelet fluorescence (p = 0.022), compared with those on high 
collagen (Fig. 2D). In contrast, the base regions of thrombi formed on low collagen had a 
lower fibrin/platelet ratio (p = 0.013), compared to the high collagen microspots. 
The images were also analyzed for co-localization of platelets and fibrin, in order 
to assess the appearance of fibrin outside the aggregated platelets. On high collagen 
microspots, more fibrin fibers extended outside the platelet area at the base of the 
thrombi (28.8 ± 1.9 % of fibrin-positive pixels) than at the center and top regions of the 
thrombus (8.9 ± 2.1 % and 5.3 ± 1.8 % fibrin-positive pixels, respectively; p < 0.001). 
Fibrin outgrowth was further restricted on low collagen microspots, where only 9.7 ± 
2.8 %, 2.3 ± 0.6 % and 5.2 ± 1.1 % of the fibrin fluorescence were detected outside the 
platelet aggregates, at the base, center or top regions of thrombi, respectively.
Interestingly, when compared with a high shear rate, at a low shear rate of 150 s-1, 
overall thrombus volume reduced from 1.10 ± 0.20 to 0.78 ± 0.02 x106 μm3 (p = 0.032) on high 
collagen and from 0.46 ± 0.10 to 0.29 ± 0.04 x106 μm3 (p = 0.026) on low collagen. At low shear 
rate, the majority of the fibrin was located outside of the platelet regions, which were low in 
height, such as apparent from analysis of z stacks of confocal images (Supplemental Table 1). 
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Figure 3. Collagen-tissue factor (TF) coating determines microelasticity of platelet-fibrin thrombus formed 
under flow. Platelet-fibrin thrombi were formed on microspots with collagen ± TF, as described in Figure 
1. Flow experiments were carried out at shear rate of 1000 s-1, except where indicated otherwise (150 s-1). 
After careful rinse with Hepes buffer pH 7.5, coverslips with thrombi were subjected to nanoindentation (6 
x 6 indentations/microspot). Control coverslips were used for scanning electron microscopy. (A) Schematic 
presentation of nanoindenter, featuring the indentation probe, sample and automated x-y stage. (B) 
Schematic grid pattern of preset 6 x 6 indentations per microspot with height gradient. (C) Reduced Young’s 
modulus (RedYM, kPa), a parameter inversely related to the microelasticity, in control measurements with 
a collagen-coated surface or with fibrinated plasma (n = 16). (D) RedYM assessed for thrombi formed on 
indicated collagen/TF surfaces (n = 36-72). Means ± SEM, *p < 0.05, h indicates hirudin.
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ollagen-TF surface and shear rate influence microelasticity of a thrombus
A novel method of ferrule-top nanoindentation, related to atomic force microscopy, 
was used to determine how the quantity and localization of fibrin fibers affected the 
mechanical and microelastic properties of the thrombi formed on microspots. This 
method is schematized in Fig. 3A, and described in more detail in the Supplement 
data. By gradually indenting and retracting a nanoindentation tip at multiple spots 
per coverslip, loading and unloading curves could be obtained, wherein slopes of the 
unloading curves informed on the reduced Young’s modulus (RedYM), as an inverse 
measure for the microelasticity of the sample (Supplemental Fig. 3). By applying multiple 
nanoindentations per microspot surface in a grid-like pattern, high-resolution information 
on the microelasticity of the thrombi on the surface could be obtained (Fig. 3B). Uncoated 
(not shown) or collagen-coated coverslips without thrombi gave a high RedYM of >1000 
kPa (Fig. 3C). In contrast, coverslips covered with coagulated, fibrin-containing plasma 
produced a low RedYM of 1.22 ± 0.1 kPa, thus pointing to high microelasticity of the fibrin 
network. Nanoindentation measurements of thrombi formed on high collagen (78.2 ± 
5.9 kPa) and low collagen (20.0 ± 8.1 kPa) microspots resulted in different RedYM values 
(p = 0.019), indicating that the latter had a higher microelasticity (Fig. 3D). Similarly, for 
thrombi formed on high collagen, lowering of the shear rate from 1000 s-1 to 150 s-1 
resulted in a lower RedYM (p < 0.0001) and hence a higher microelasticity (Fig. 3D). 
This suggested that intrathrombus fibrin increased the microelasticity of the sample. This 
was confirmed by nanoindentation analysis of fibrin-poor thrombi, formed on collagen 
without TF, giving high RedYM values of 133.1 ± 21.6 kPa. In the presence of hirudin to 
block thrombin activity, and hence fibrin formation, the RedYM even further increased to 
182.9 ± 29.3 kPa (Fig. 3D). Together, this indicates that the thrombi with fibrin in the top 
or with outside coverage of fibrin, being formed on low density collagen microspots or 
at low shear rate, display a higher microelasticity, when compared with thrombi in which 
fibrin is accumulated at the base.
Formation of platelet-fibrin thrombus under conditions of impaired hemostasis
Using several approaches, we further assessed the roles of platelets and other blood 
components in the formation of fibrin-containing thrombi. Considering the diminished 
clotting activity of patients with perioperative dilutional coagulopathy,30, 31 we first 
determined the consequences of blood dilution in vitro. Blood samples were flowed at 
a shear rate of 1000 s-1 over high collagen/TF microspots. In the absence of dilution, this 
resulted in a high platelet deposition and fibrin formation (see above). However, dilution 
of the blood to 80, 60 and 40 % resulted in a gradual decrease in platelet deposition after 
7 minutes of perfusion, amounting to 14 ± 2 % (p = 0.046), 10 ± 3 % (p = 0.004) and 8 ± 3 % 
(p < 0.001), respectively, in comparison with the undiluted sample. In contrast, amounts 
of fibrin only reduced at dilution to 60 and 40 % blood, which reduction was accompanied 
by a prolonged time to onset of fibrin formation (Fig. 4A, B). Comparable results were 
obtained under conditions of a low, venous shear rate of 150 s-1 (Supplemental Fig. 4). 
Reconstitution of the 40 % diluted blood with either washed platelets or red blood cells 
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caused partial improvement of both platelet deposition and fibrin formation (Fig. 4A, 
C). Interestingly, complete recovery of the thrombus-forming process was obtained by 
addition of platelets in combination with red blood cells (Fig. 4C). These data pointed to 
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Figure 4. Restoration of platelet-fibrin thrombus formation by reconstitution of diluted blood. Platelet-
fibrin thrombi were formed on microspots with collagen (100 ng) and tissue factor (TF; 10 pg), as described 
in Figure 1. Blood samples were diluted to indicated percentages with saline (keeping fixed concentrations 
of citrate, MgCl2 and CaCl2). Specific samples were reconstituted with autologous washed platelets (PLT) or 
red blood cells (RBC), added to the original counts. (A) Representative fluorescence images of DiOC6-labeled 
platelets (green) and AF647-fibrin(ogen) (red) after 7 minutes of flow using  100 % or 40 % blood with(out) 
reconstitution (bars, 50 µm). (B) Time-dependent accumulation of fluorescence from platelets (green) and 
fibrin (red) during perfusion. (C) Fluorescence area covered after 7 minutes of flow by platelets and fibrin. 
Means ± SEM (n = 5-12), *p < 0.05.
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a limiting role of platelet adhesion (enforced by marginalization with erythrocytes) not 
only for platelet aggregation but also for fibrin formation under conditions of high shear 
flow. This was confirmed with scanning electron microscopy (Supplemental Fig. 5).
As a second approach, blood was used from various patients with hemostatic 
insufficiencies and a bleeding risk. Blood samples were obtained from 3 patients with 
dilutional coagulopathy because of massive fluid infusion during surgery. In this case, 
only few platelet aggregates of small size were formed and no fibrin was generated during 
the measured time of 7 minutes (Fig. 5A). With blood samples from 2 thrombocytopenic 
patients, platelet deposition was comparably low, although measurable amounts of 
fibrin were formed (Fig. 5A, C), such in accordance with normal coagulation activity 
in this condition. A requirement for platelet procoagulant activity (phosphatidylserine 
exposure) was investigated with blood samples from a Scott patient, whose platelets 
lack this property.32 Whereas platelet deposition and aggregate size were not affected, 
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Figure 5. Impaired platelet-fibrin thrombus formation using blood from patients with impaired hemostasis. 
Blood was obtained from 7 healthy control subjects, 3 patients with dilutional coagulopathy because of 
massive fluid infusion during cardiothoracic surgery, 2 patients with acquired thrombocytopenia, 1 Scott 
syndrome, or 2 patients with hemophilia B. At least 3 blood samples were analyzed per condition. Platelet-
fibrin thrombi were formed in a standard way by blood flow at 1000 s-1 over microspots with collagen (100 
ng) and TF (10 pg), as described in Figure 1. (A) Representative images of DiOC6-labeled platelets (green) and 
AF647-fibrin(ogen) (red) after 7 minutes (bars, 50 µm). (B) Time-dependent accumulation of platelet and 
fibrin fluorescence during blood perfusion. (C) Fluorescence area covered by fibrin after 7 minutes of flow. 
Means ± SD (n = 6-9), *, significantly different from reference range of control blood samples.
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fibrin formation was essentially absent in the Scott blood samples. Similarly, impaired 
coagulation, as in blood from 2 patients with hemophilia B (~5 % factor IX), led to normal 
platelet aggregation under flow, but an impaired fibrin formation (Fig. 5A, C).
Because the flow of thrombocytopenic blood over high collagen microspots still 
gave limited fibrin formation, the intrathrombus localization of fibrin could be analyzed 
in more detail. Analysis of z stacks of confocal images indicated that fibrin and platelets 
were similarly distributed throughout the thrombi (Fig. 6A). Yet, the ratio of fibrin to 
platelets was higher in the top regions of thrombi (Fig. 6B), with only limited fibrin 
extending from the platelet aggregates at base areas (12 ± 8 % of fibrin-positive pixels). 
This fibrin distribution pattern, concentrated in platelet regions, persisted even after 
prolongation of the perfusion time to 12 minutes (Fig. 6C). After 12 minutes, at high and 
low collagen microspots, fibrin deposition outside the platelet regions at the thrombus 
base gradually increased to 34 ± 14 % and 6 ± 1 %, respectively. Jointly, these results 
pointed to platelet control of fibrin formation and distribution in thrombi formed on 
collagen/TF surfaces, relying on phosphatidylserine exposure.
Discussion
This study shows that, under conditions of high shear blood flow and coagulation, 
platelet deposition and platelet-dependent fibrin formation are decreased when collagen 
as a platelet-activating substrate becomes limited. Although fewer thrombi are formed 
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Figure 6. Altered fibrin distribution within thrombus formed by thrombocytopenic blood. Platelet-fibrin 
thrombi were formed by blood flow over microspots with collagen (20 or 100 ng) and tissue factor (TF; 10 
pg), as described in Figure 1. Confocal images of DiOC6 (green) and AF647-fibrin(ogen) staining (red) in 3D 
were captured. (A) Integrated fluorescence intensity (arbitrary units, AU) of platelet (green) and fibrin (red) 
fluorescence from z stacks at base (>10 μm), center (10-20 μm) and top (>20 μm) regions of thrombi after 7 
minutes of blood perfusion on high collagen/TF. (B, C) Ratio of platelet/fibrin staining at base, center and top 
of thrombi after 7 minutes on high collagen (B) or after 12 minutes (C) of blood perfusion on low and high 
collagen. Means ± SD (n = 3), *p < 0.05 vs. base.
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on microspots with low collagen, we see a partly compensating effect in that thrombus 
size is increased and the contribution of thrombin to thrombus growth is relatively more 
important. Nanoindentation measuring viscoelastic properties of the sample indicates 
that the thrombi formed on low collagen possess enhanced microelasticity because of 
fibrin accumulation in the luminal region of thrombi. Interestingly, redistribution of fibrin 
from the base to the luminal region of thrombi is also observed under conditions of 
thrombocytopenia. Hence, a limitation of either the platelet-activating surface or the 
platelet number leads to reductions in platelet deposition and fibrin accumulation, which 
effects are accompanied by an altered fibrin distribution throughout the thrombus. Blood 
flow at low shear rate similarly enhances microelasticity by reducing platelet deposition 
and increasing the formation of a fibrin coat surrounding the thrombi.
Model of thrombus buildup, determining fibrin distribution and microelasticity
Platelet adhesion to collagen is known to result in a sustained rise in cytosolic 
calcium and phosphatidylserine exposure. This procoagulant surface greatly promotes 
the assembly of coagulation factors culminating in the formation of factor Xa and 
thrombin.2 Earlier, in flowing mouse blood, we have established that in the presence 
of collagen and TF this platelet-dependent factor Xa formation is essential for the 
propagation of fibrin formation and for boosting platelet phosphatidylserine exposure.3 
The present results allow to extend this coagulation-platelet activation cross talk to the 
human system, in that we find that human deficiency in factor IX (hemophilia B patient) 
or deficiency in platelet phosphatidylserine exposure (Scott syndrome patient) results in 
almost complete abolition of fibrin formation under flow conditions.
Although in the past years progress has been made in determining the mechanical 
properties of fibrin fibers formed under static conditions, little is known about the elasticity 
of platelet-fibrin thrombi formed under flow. Recently, a new method of nanoindentation 
has been used to assess the microelasticity of clotted murine platelet-rich plasma.33 In 
this study, we have used this technique to measure the physical characteristics of human 
thrombi formed at high and low shear rates and find that thrombi with a high fibrin content 
in the thrombus top region are highest in microelasticity. Jointly, our results indicate that 
not so much the fibrin content, but rather the fibrin distribution through a thrombus 
determines its elastic properties. We hypothesize that the high microelasticity of thrombi 
with luminal-oriented fibrin ameliorates the hemostatic process. In agreement with this, 
thromboelastometry studies have indicated that a high clot elasticity associates with less 
bleeding in patients with hemostatic insufficiencies.20, 34 If platelet adhesion is limited (low 
collagen), we see a relatively high fibrin content in the top region of an apparently ‘loose’ 
thrombus. On the other hand, at high platelet adhesion (high collagen), fibrin appears to 
be primarily formed at the base region of thrombi. Summarizing these data as in Figure 
7, we conclude that: (i) the presence of thrombin increases platelet-thrombus volume 
independent of the shear rate; (ii) the presence of TF drives fibrin formation outside of 
the thrombus; (iii) limitation of platelet adhesion redirects fibrin from the bottom to the 
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top of the thrombus; (iv) lowering of the shear rate results in a more fibrin rich thrombus; 
and (v) the thrombus microelasticity is determined by the distribution pattern of fibrin. 
Comparison to in vivo models
These findings provide an extension of the hemostatic thrombus model, based on 
in vivo observations, presented by the groups of Brass and Diamond, in which thrombin 
activity is confined to the dense thrombus core.18, 35, 36 Previous in vivo studies have shown 
that, upon laser-induced injury of arterioles, where exposed TF drives the thrombotic 
process, fibrin concentrates near the vessel wall and in the vascular-oriented part of 
the thrombus.6, 12, 14 Our findings suggest that this vascular-oriented fibrin distribution 
pattern points to a relatively high abundance of platelet-adhesive substrates. These 
substrates can be collagens, as well as other vascular components, such as laminins 
and von Willebrand factor. In other words, it seems that the ‘strength’ of the platelet-
adhesive surface controls the platelet packing density during thrombus buildup, and 
thereby the thrombin retention and fibrin distribution pattern. Confirmative evidence 
for this hypothesis comes from in vivo studies using PAR4-deficient mice, in which fibrin 
was found to redistribute through the whole thrombus as a consequence of diminished 
platelet activation.16
A different pattern of fibrin distribution occurs under low shear flow conditions, 
where relatively more (microelastic) fibrin is formed, appearing as a coat that covers 
the thrombi. This might be explained by a reduction in the flow-dependent removal of 
thrombin and fibrin monomers.37 In accordance with our results, it has been shown that the 
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Figure 7. Schematic representation of thrombus buildup on collagen/TF surfaces. Platelet-fibrin thrombi 
were formed by blood perfusion over microspots with indicated amounts of collagen and TF at indicated 
shear rates, as described in Figure 1. In specific blood samples, thrombin was inhibited with hirudin (+ h). 
Multiple parameters of thrombus formation were assessed; for full data see Supplemental Table 1. Cartoons 
illustrate key characteristics of thrombi in terms of: width (scale 1-5), height (scale 1-3), fibrin inside platelet 
thrombus (sphere size: 1-4), and fibrin outside platelet thrombus (size of shell). Presentation is for three 
thrombus zones: A, <10 μm from microspot surface; B, 10-20 μm; C, >20 μm.
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thrombi formed in mesenteric venules after laser injury are surrounded by a fibrin cap.38 
 
Effects of hemostatic insufficiencies
Under conditions of (perioperative) dilution, we find that platelet deposition 
is more sensitive to blood dilution than fibrin formation, which is impaired already 
at 60 % blood. This contrasts to static measurements of macroscopic clot strength by 
thromboelastometry, which seemed to be less sensitive to dilution effects.30 Single-
pass flow perfusion likely makes the difference here because under flow the deposited 
platelets provide a rate-limiting surface for the formation of thrombin and subsequent 
fibrin, whereas the same flow removes procoagulant factors and hence restricts fibrin 
formation.37 Remarkably, in reconstitution experiments, the addition of both platelets 
and red blood cells was required for complete reversal of dilution effects. By implication, 
this indicates that under conditions of flow and sufficient margination of platelets by 
red blood cells, a coagulant activity of >60 % is required for unrestricted generation of 
fibrin. These findings are supported by hydrodynamic simulations indicating that platelet 
interactions with the vessel wall are promoted by an increasing hematocrit.39
A limitation of the present study is the absence of vascular cells such as endothelial 
cells, which can also provide a procoagulant surface for the formation of thrombin.40 
On the other hand, current overviews indicate that collagen (TF)-based in vitro flow 
studies compare well with in vivo arterial thrombosis models, when evaluating the 
functional effects of genetic knockout in mice.41, 42 Hence, we consider the present test 
of formation of platelet-fibrin thrombi under flow as a valid method to determine the 
hemostatic capacity of a blood sample. For fibrin localization we used fluorescently 
labeled fibrinogen and therefor the distinction between fibrinogen and fibrin cannot be 
made unambiguously. We minimized the contribution of fibrinogen to the fibrin signal 
by threshold settings and the presence of fluorescent fibrin fibers was always confirmed 
from bright-field images. The advantage is that this method prevents underestimation 
of the fibrin signal as a consequence of poor permeation in the thrombus when using a 
fibrin antibody.
In summary, we conclude that under conditions of flow and coagulation the 
amount and localization of fibrin are regulated by the relative abundance of triggers 
for platelet adhesion/activation (e.g. collagen) and coagulation (TF), and that the fibrin 
distribution is determinative for the clot microelasticity. Thrombin herein influences 
thrombus growth as well as fibrin formation, depending on its local concentration.
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Significance
Activation of blood platelets as well as the coagulation system is required for 
a normal hemostatic response. While it is known that platelet- and fibrin-dependent 
thrombus formation is regulated by blood flow, the blood composition and vascular 
triggers such as collagen and tissue factor, the interactions between these blood-
borne and vascular components are not well understood. Our data imply that the 
relative abundance of vascular triggers of platelet adhesion/activation (collagen) 
at one side and of coagulation (tissue factor) at the other side is determining 
for both thrombus growth and thrombus composition, in particular regarding 
the distribution of fibrin. Furthermore, we show that the fibrin distribution is 
determinative for the thrombus microelasticity as assessed by nanoindentation. 
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Supplemental data
Methods
Healthy volunteers and patients
Blood was taken from healthy volunteers and patients after informed consent was 
obtained in accordance with the Declaration of Helsinki. Studies were approved by the 
local medical ethics committee (METC 10-3-023). All donors were free from antiplatelet 
and anticoagulant medication for at least 2 weeks. Blood was taken from healthy control 
donors and from two patients with hemophilia B (both 5 % factor IX), a patient with 
Scott syndrome (deficient anoctamin 6 expression),1 two patients with immune-induced 
thrombocytopenia (platelet count 85 × 109/L and 22 x 109/L), or from three patients with 
dilutional coagulopathy due to massive fluid infusion during cardiothoracic surgery (4.5-
5 L), collected in the operating theatre. At least three blood samples were analyzed for 
all conditions.
Blood collection and preparation
Blood was collected in 1:10 (v/v) 3.2 % trisodium citrate for whole blood perfusion 
experiments and the preparation of washed red blood cells, or in 1:6 (v/v) acidic citrate 
dextrose (ACD, 80 mM trisodium citrate, 52 mM citric acid and 180 mM glucose) for the 
isolation of washed platelets. Platelets and red blood cells were isolated as described.2 
Cell count was determined using a thrombocounter (Coulter Electronics, High Wycombe, 
United Kingdom).
Formation of platelet-fibrin thrombi under conditions of coagulation and flow
Thrombus formation under flow conditions was determined by perfusion of citrated 
whole blood over a collagen/tissue factor (TF) coated glass coverslip in a transparent 
parallel-plate perfusion chamber (width 3 mm, depth 50 μm, length 300 mm).3 Coverslips 
were coated with microspots containing 20 or 100 ng Horm type I collagen (Nycomed 
Pharma, Munich, Germany) in the absence or presence of 10 pg recombinant human TF 
(Innovin; Dade Behring, Deerfield IL, USA). After coating, surfaces were blocked with 1 % 
bovine serum albumin (BSA; Sigma, St. Louis MO, USA) in Hepes buffer pH 7.45 (10 mM 
Hepes, 136 mM NaCl, 2.7 mM KCl, 2 mM MgCl2), and used within 4 hours. Immediately 
before use, blood samples were pre-labeled with the membrane probe DiOC6 (f.c. 0.5 
µg/mL, Anaspec, Reeuwijk, The Netherlands) to identify platelets (green) and with Alexa 
fluor (AF)647-fibrinogen (f.c. 16.5 µg/mL, Molecular Probes, Life Technologies, New York 
NY, USA) to detect fibrinogen and fibrin (red). Using two pulse-free micro-pumps (Model 
11 Plus, 70-2212, Harvard apparatus, Holliston MA, USA) and a Y-shaped flattened mixing 
tube, blood samples in 1 mL plastic syringe (Becton Dickinson, Franklin Lakes NJ, USA) 
were mixed with coagulation medium (Hepes buffer pH 7.45 supplemented with 32 mM 
MgCl2 and 63 mM CaCl2) also in 1 mL syringe at a volume ratio of 10:1 (push mode). This 
resulted in complete mixing and physiological (mM) concentrations of Ca2+ and Mg2+.4 
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Where indicated, blood samples were pre-treated with 3 µg/mL hirudin (Refludan; 
Schering, Berlin, Germany) to block formed thrombin. Blood perfusion over microspots 
in the flow chamber was at a wall shear rate of 150 or 1000 s-1 for at least 7 minutes.
For assessing platelet contraction in a thrombus, citrated blood samples were 
spiked with 3% of autologous, washed DiOC6-labeled platelets. Where indicated, spiked 
blood samples were pre-treated with Gly-Pro-Arg-Pro (GPRP) or hirudin.
Two-color confocal fluorescence microscopy and image analysis
During or after blood perfusion, two-colored images were recorded using a fast 
line-scanning Zeiss LSM7 system, equipped with OPSS lasers and a 40× oil-immersion 
objective (numerical aperture 1.30) (Carl Zeiss, Oberkochen, Germany). Confocal 
fluorescence images (16 bit, 1024 × 1024 pixels, single channel plus overlay) were 
obtained at both 488 and 635 nm excitation. Fluorescence was detected with an ultra-
sensitive CCD line camera after selection by optical emission filters of 495-555 nm and 
665-750 nm (pinhole 1 AU). For time series, fluorescence images were taken at 1 s 
intervals; for z stacks, fluorescence images were taken at 1 μm z-steps.
Image analysis of morphometry and fluorescence was performed with Live7 
Metamorph software, version 7.5.0.0 (MDS Analytical Technologies, Sunnyvale, Canada) 
and ImageJ (version 1.48g: Rasband, NIH, Bethesda, MD, USA), as described elsewhere.5 
For the quantification of fibrin and platelet fluorescence, images were thresholded to 
eliminate background. Integrated fluorescence intensity as well as percentage area 
covered were calculated per image. For co-localization of two-color fluorescence, binary 
images were created based on threshold to determine overlap percentages. As a standard, 
integrated fluorescence intensity was compared to surface area coverage of fluorescence 
features. Considering the overall similarity of these two analyses (Supplemental Fig. 1), 
for most conditions data of surface area coverage are given only.
For the quantification of (fluorescent) fibrin formation, threshold levels of 
fibrinogen binding to platelets was determined under conditions where coagulation 
was inhibited. Image intensities above this threshold were considered as originating 
from fibrin fibers. The presence of fluorescent fibrin fibers was always confirmed from 
brightfield images. Times to onset of fibrin formation were the moments at which the 
fluorescence threshold was passed, as confirmed by visual inspection of brightfield 
images.
For measurement of platelet contraction in a thrombus, time series of DiOC6-
labeled images were collected during flow. Movement towards each other of labeled 
platelets within thrombi was analyzed off-line via tracking analysis, as described.6 In 
brief, individual images of time-lapse series were thresholded to a binary images. Using 
the Mtrack2 plugin displacement was measured by including objects (platelets) of <5 
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pixels which were present >60 seconds. Objects were rejected when the displacement 
was >25 pixels s-1 (indicating noise or platelets not part of one thrombus).  Calculated was 
per condition the average movement of platelets in time (µm/s).
 
Dilution and reconstitution of whole blood samples
Citrated blood was diluted in vitro with saline medium, consisting of 154 mM 
NaCl, 10.8 mM trisodium citrate, 2 mM CaCl2 and 2 mM MgCl2, in order to keep equal 
concentrations of free Ca2+ and Mg2+ in all diluted samples.2 Washed platelets and/or red 
cells were added to diluted blood samples to restore original cell counts, as described 
before.2 Amounts of fluorescent labels, DiOC6 and AF647-fibrinogen, were adjusted 
according to the extent of dilution and reconstitution.
Measurement of thrombin generation on microspots in flow chamber
Fluorogenic thrombin substrate Z-Gly-Gly-Arg-AMC (f.c. 0.5 mM, Thrombinoscope, 
Maastricht, The Netherlands) was added to blood samples where indicated, and used 
to measure thrombin generation on preformed thrombi under static conditions.7 Real-
time fluorescence accumulation due to substrate cleavage was recorded at 447/30 
nm emission every 30 seconds for at least 5 minutes, using an inverted fluorescence 
microscope equipped with an Olympus 60 × oil-immersion objective (numerical 
aperture 1.35), equipped with a 360 nm led cube (EVOS, Life Technologies, Bleiswijk, The 
Netherlands).5 Temporal analysis of fluorescence was performed using ImageJ.
Determination of microelasticity of thrombi on microspots by nanoindentation technology
Microelasticity of formed thrombi on coverslips was analyzed with a recently 
developed Piuma nanoindenter (Optics11, Amsterdam, The Netherlands), which 
features a calibrated nanoindentation probe consisting of a cantilever fabricated on 
top of a ferruled optical fibre. Recent developments in indentation probe fabrication 
have resulted in probes that can measure soft (biological) materials, e.g. cartilage and 
vascular models. These probes measure the material hardness in the Pascal to kilo-
Pascal range.8 In atomic force microscopy a cantilever tip is used that is repelled from the 
surface by minute forces. In contrast, in nanoindentation methods a spherical, cylinder 
or Berkovich shaped tip is used that is forced into the sample. The employed Optics11 
Piuma Nanoindenter system has been validated before with biological samples.9-11
In brief, a probe with a defined cantilever of 1.39 N/m and calibrated spherical tip 
of 56.5 μm was gradually brought into contact with the sample surface, up to a depth 
of maximum 10 % of the sample thickness.12 The counter-force of the sample on the tip 
results in cantilever bending, which is linear with the load on the cantilever. The result is 
a load-displacement curve of both loading (indenting) and unloading (retraction) of the 
probe. The probe, fixed on a closed-loop z-piezoelectric translator, was equipped with 
an integrated strain gage sensor and controlled by a closed-loop controller. From the 
slope of the unloading curve, the maximum load and the indentation area (tip surface 
area), a reduced Young’s modulus (RedYM) can be calculated as a proxy measure of 
microelasticity.13 The modulus is the amount of force per unit area (stress), needed to 
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reach a certain amount of deformation (unit = Pa). Hence, a higher RedYM indicates that 
the given material is harder to deform. This measurement outcome is similar to atomic 
force microscopy.14
As a conservative rule of thumb, the indentation value is independent of the 
height and size of a sample, provided that the indentation depth is smaller than the 
sample radius and <10 % of the sample height.12, 15 With these criterions met for the 
present conditions, the RedYM reflects the elastic modulus of platelet-fibrin thrombi. The 
attractiveness of the nanoindentation technique is that the mechanoelastic properties of 
a microscopic sample can directly be determined without any further sample knowledge. 
A drawback is the lack of visual feedback of the probe location above the thrombus 
sample. To overcome this, we have indented all samples (old and new conditions) 36 
times in a grid-like pattern. With an optical magnifier, we further confirmed that the right 
spots on the sample were indented.
Coverslips with thrombi were carefully washed and incubated with Hepes buffer pH 
7.45. The diameter of the contact area of indentation tip with thrombi was ~20 μm2. Per 
microspot, 6 x 6 indentations were performed following a gridding pattern with a step-
size of 50 μm. All indents were depth controlled (1 μm to a maximum of 5 μm). Loading 
and unloading times were set at 3 seconds, data were collected for 1 second per step. The 
unloading curves were used to calculate slopes using the compliance method of Oliver 
and Pharr in order to calculate the RedYM.13, 16 This is a measure of the microrigidity of 
the indented spot, which is inversely related to the microelasticity. A high RedYM reflects 
high microrigidity or stiffness of the indented sample and, hence, low microelasticity. 
Of the grid nanoindentations, only curves reflecting thrombi on glass were included. As 
negative and positive controls bare collagen surfaces and macroscopic fibrin clots were 
used, which showed a low and high microelasticity, respectively. Furthermore, scanning 
electron microscopy pictures were obtained for direct comparison of the dimensions of 
tip and thrombi.
Scanning electron microscopy
Thrombi were formed on microspots in a perfusion chamber, as described above, 
and prepared for scanning electron microscopy. In short, after disassembly of the 
perfusion chamber, coverslips were removed and gently washed with Hepes buffer pH 
7.45. Fixation was with 2.5 % glutaraldehyde in 0.1 M K-phosphate buffer pH 7.4 at  4 °C. 
Following a rinsing step with 0.1 M phosphate buffer, samples were dehydrated in graded 
ethanol series, then critical point dried, mounted with silver paint on specimen stubs, 
and coated with gold. Thrombi were visualised with a Philips XL30 scanning electron 
microscope at 10 kV (Eindhoven, The Netherlands).
Statistics
Statistical significance of differences between two independent groups was 
determined using the independent samples t test. Differences with p values <0.05 were 
considered significant. Error bars indicate inter-individual variability, except for patient 
data, where the variation of independent measurements is shown; values outside 
reference ranges of controls (mean ± 2SD) were considered to be different.
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Supplemental Figure 1. Quantification of platelet-fibrin thrombus formation on collagen/TF surfaces. 
Citrated whole blood was perfused during recalcification over microspots with collagen (100 ng) and TF 
(10 pg) for 7 minutes at a wall shear rate of 1000 s-1. Blood samples were pretreated with DiOC6 to label 
platelets (green) and with AF647-fibrinogen (red). (A, B) Analysis of integrated fluorescence intensity (open) 
and surface area coverage above background (close) from deposited platelets (A) and fibrin (B). Note high 
similarity of either analysis parameter. 
Supplemental Figure 2. Effect of wall shear rate in platelet-fibrin thrombus formation on collagen-tissue 
factor surfaces. Platelet-fibrin thrombi were formed by blood perfusion over microspots with collagen (100 
ng) and TF (10 pg), as in Figure 1. Wall shear rate was 150 or 1000 s-1. (A) Representative images after 7 
minutes of flow of DiOC6-labeled platelets (green) and AF647-fibrin(ogen) (red) (bars, 50 µm). (B) Time-
dependent deposition of fluorescent-labeled platelets and fibrin during blood perfusion. (C) Quantification 
of platelet-fibrin co-localization at indicated shear rates. Means ± SEM (n = 5-10), *p < 0.05.
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Supplemental Figure 3. Nanoindentation load-displacement curves for the assessment of microelasticity 
of platelet-fibrin thrombi. Platelet-fibrin thrombi were formed by blood perfusion over microspots with 
collagen ± TF, as in Figure 1. Microspot surfaces were subjected to nanoindentation, as in Figure 4. Shown are 
representative load-displacement curves for thrombi formed on (A) 100 ng collagen, (B) 100 ng collagen plus 
10 pg TF, or (C) 20 ng collagen plus 10 pg TF. Indicated is the loading curve during indentation, the maximum 
load and the unloading curve with slope (= RedYM). The RedYM represents a measure of the microrigidity of 
the sample, which is inversely related to microelasticity.
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Supplemental Figure 4. Effects of blood dilution on formation of platelet-fibrin thrombus at low shear rate. 
Platelet-fibrin thrombi were formed by perfusion of blood over microspots with collagen (100 ng) and TF (10 
pg) at low shear rate of 150 s-1 for 7 minutes. Whole blood samples were undiluted or diluted to indicated % 
with saline (see Figure 5). (A) Time-dependent accumulation of fluoresence from platelets (green) and fibrin 
(red) during blood perfusion. (B) Fluoresence area covered by platelets and fibrin after 7 minutes of flow. 
Means ± SEM (n = 6), *p < 0.05.
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Supplemental Figure 5. Scanning electron microscopy of platelet-fibrin thrombus formed on different 
surfaces. Platelet-fibrin thrombi were formed by perfusion of blood over microspots with collagen ± TF at 
shear of 150 or 1000 s-1. Thrombi on microspots were fixed, stained and visualised with a scanning electron 
microscope at 10 kV. Representative (n = 3) images are shown from thrombi formed on: (A) 20 ng collagen 
+ TF; (B) 100 ng collagen + TF; (C) 100 ng collagen; (D) 100 ng collagen + TF, with hirudin in blood; (E) 100 ng 
collagen + TF, perfusion at 150 s-1; (F) 100 ng collagen + TF, 40 % whole blood (bars, 20 μm). Upper part shows 
schematic representation of the spherical nanoindentation cantilever to scale.
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Thrombus fibrin distribution and microelasticity 
Collagen 100 Collagen 100 +TF Collagen 20 + TF
150 s-1 1000 s-1 150 s-1 1000 s-1 150 s-1 1000 s-1
SAC* (%) platelets 9.04 ± 1.7 27.0 ± 2.2 19.1 ± 3.2 33.8 ± 3.0 5.62 ± 0.7 12.3 ± 1.4
fibrin 0.73 ± 0.7 1.19 ± 0.1 49.9 ± 6.8 29.8 ± 4.0 4.30 ± 1.7 5.76 ± 1.1
Fibrin 
area 
outside 
thrombus 
(% of 
total)
0-10 mm 
(base)
48.8 ± 9.7 36.3 ± 8.4 83.1 ± 0.3 28.8 ± 1.9 69.6 ±3.0 9.7 ± 2.8
10-20 mm 
(center)
54.0 ± 18.0 55.5 ± 8.2 91.4 ± 2.1 8.9 ± 2.1 55.8 ± 5.4 2.3 ± 0.6
>20 mm  
(top)
54.1 ± 13.9 75.5 ± 14.0 76.9 ± 4.8 5.3 ± 1.8 57.5 ± 1.3 5.2 ± 1.1
Thrombus 
volume  
(x 106 
mm3)
platelets 0.15 ± 0.02 0.28 ± 0.04 0.16 ± 0.02 0.79 ± 0.1 0.15 ± 0.02 0.40 ± 0.1
fibrin 0.03 ± 0.007 0.02 ± 0.01 0.72 ± 0.03 0.76 ± 0.2 0.20 ± 0.03 0.24 ± 0.07
total 0.16 ± 0.02 0.28 ± 0.04 0.78 ± 0.02 1.10 ± 0.2 0.29 ± 0.04 0.46 ± 0.1
Ratio 
fibrin/
platelets
0-10 mm 
(base)
0.86 ± 0.07 0.84 ± 0.02 0.97 ± 0.02 1.21 ± 0.1 0.88 ± 0.01 0.97 ± 0.1
10-20 mm 
(center)
1.09 ± 0.1 1.20 ± 0.1 1.07 ± 0.02 0.87 ± 0.04 0.98 ± 0.01 0.93 ± 0.08
>20 mm  
(top)
NA NA NA 1.07 ± 0.1 1.18 ±0.01 1.27 ± 0.1
Supplemental Table 1. Collagen-tissue factor surface determines platelet-fibrin thrombus buildup under 
flow. Citrated whole blood was perfused during recalcification over microspots with collagen (20 or 100 ng) 
with(out) TF (10 pg) for 7 minutes at a wall shear rate of 150 or 1000 s-1. Blood samples were pretreated 
with DiOC6 to label platelets and with AF647-fibrinogen to monitor fibrin formation. Two-color confocal 
microscopic images were recorded in real time at a frequency of 1 Hz. For determination of thrombus 
volume, confocal z stacks were recorded after 7 minutes of perfusion (z-step 1 μm). *SAC, surface area 
covered; NA, not applicable due to relatively low thrombus height. Means ± SEM (n = 6-15).
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Abstract
Background and aim: Blood dilution after transfusion fluids leads to diminished 
coagulant activity monitored by rotational thromboelastometry, assessing elastic fibrin clot 
formation, or by thrombin generation testing. We aimed to determine the contributions of 
blood cells (platelets, red blood cells) and plasma factors (fibrinogen, prothrombin complex 
concentrate) to fibrin clot formation under conditions of hemodilution in vitro or in vivo. 
Methods: Whole blood or plasma diluted in vitro was supplemented with platelets, 
red cells, fibrinogen or prothrombin complex concentrate (PCC). Thromboelastometry 
was measured in whole blood as well as plasma; thrombin generation was 
determined in parallel. Similar tests were performed with blood from 48 patients, 
obtained before and after massive fluid infusion during cardiothoracic surgery. 
Results: Addition of platelets or fibrinogen, in additive and independent ways, 
reversed the impaired fibrin clot formation (thromboelastometry) in diluted whole 
blood. In contrast, supplementation of red blood cells or prothrombin complex 
concentrate was ineffective. Platelets and fibrinogen independently restored clot 
formation in diluted plasma, resulting in thromboelastometry curves approaching 
those in whole blood. In whole-blood from patients undergoing dilution during 
surgery, elastic clot formation was determined by both the platelet count and the 
fibrinogen level. Thrombin generation in diluted (patient) plasma was not changed 
by fibrinogen, but improved markedly by prothrombin complex concentrate. 
Conclusions: In dilutional coagulopathy, platelets and fibrinogen independently, but not red 
blood cells or vitamin K-dependent coagulation factors, determine thromboelastometry 
parameters measured in whole-blood and plasma. Clinical decisions for transfusion 
based on thromboelastometry should take into account the platelet concentration.
Introduction
It is still a matter of debate how insufficiencies of the hemostatic system lead to 
bleeding under conditions of massive fluid infusion during cardiothoracic surgery. Fluid 
infusion diminishes a variety of processes, including platelet activity, coagulation factor 
levels, thrombin generation and fibrin clot formation. The latter process is monitored by 
rotational thromboelastometry or thromboelastography, which are frequently used to 
monitor patients during surgery.1-3 Elastic fibrin clot formation can be measured in whole 
blood samples, thus providing a rapid point-of-care method for goal-directed coagulation 
management of surgery or trauma patients with, for example, fibrinogen concentrate.4
Recently, we have shown that combined plasma measurement of thrombin 
generation and fibrin clot formation results in a better prediction of the bleeding risk 
after major surgery than the use of either test alone.5 The rationale is that thrombin 
generation monitors the rate and extent of formed thrombin, as a central controlling 
enzyme of the coagulation cascade.6 On the other hand, thromboelastometry, being more 
sensitive for fibrinogen7,8 and platelets,8,9 reports on the more advanced stage of elastic 
fibrin clot formation. In patients with bleeding during major surgery or experiencing 
trauma, impaired hemostasis can be restored by administration of fibrinogen10-12 or 
vitamin K-dependent coagulation factors (prothrombin complex concentrate, PCC).10,13,14 
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Both types of concentrates are also effective in large animal models of injury-induced 
bleeding,15-17 suggesting that normalization of part of the coagulation factors helps to 
stop bleeding after dilution.
Vitamin K-dependent coagulation factors, platelets and fibrinogen all contribute 
to the process of elastic clot formation by providing enzymatic activity, strength and 
mass of a clot, respectively. However, it is still unresolved how, under conditions of 
dilutional coagulopathy, reduced levels of these blood components interact to limit fibrin 
clot formation, nor is it clear how red blood cells are involved in this process. In the 
present paper we aimed to determine these interactions. Using thromboelastometry, we 
measured fibrin clot formation in whole blood and plasma under conditions of dilution 
in vitro or in vivo, and assessed the effects of reconstitution of blood cells (platelets, 
red blood cells) and plasma coagulation factors (fibrinogen, PCC). The results show 
that the clot-forming process is controlled by platelets and fibrinogen in additive and 
independent ways, implicating that the platelet count is an important functional variable, 
independently of fibrinogen, in whole-blood thromboelastometry under condition of in 
vivo dilution in patients undergoing cardiothoracic surgery.
Materials and Methods
Materials
Bovine serum albumin (BSA) and apyrase were obtained from Sigma (St. Louis MO, 
USA). Human thrombin calibrator and thrombogram software were from Thrombinoscope 
(Maastricht, The Netherlands), thrombin substrate Z-Gly-Gly-Arg aminomethyl coumarin 
(Z-GGR-AMC) was from Bachem (Bubendorf, Switzerland). Thromboelastometry 
International (Munich, Germany) supplied the corresponding hardware, software and 
cuvettes.
 Fibrinogen concentrate (Haemocomplettan P) and prothrombin complex 
concentrate (PCC, Beriplex) were from CSL-Behring (Marburg, Germany). PCC contains 
the vitamin K-dependent coagulation factors, prothrombin and factor VII, IX and X, 
and the anticoagulant factors, protein C and S, and antithrombin/heparin; 1 U/mL 
PCC refers to 100% prothrombin. Recombinant tissue factor (Innovin) was from Dade 
Behring (Deerfield IL, USA). Phospholipid vesicles containing phosphatidylserine, 
phosphatidylcholine and phosphatidylethanolamine (20:60:20) were purchased from 
Avanti (Alabaster AL, USA) and prepared by ultrasonication.18 All other reagents came 
from sources described before.5
Blood donors
The studies were approved by the local medical ethics committee (MEC 07-2-114). 
Healthy donors and patients gave full informed consent for blood donation, according to 
the Helsinki declaration. Healthy subjects had not taken antithrombotic medication for 
at least two weeks. For in vitro dilution experiments, blood was obtained from 15 healthy 
subjects by venipuncture using a 1.2 mm needle, allowing the blood to drip freely into 
open tubes (first 2-3 mL were discarded). The collection tubes contained either 1/10 
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volume of trisodium citrate (0.129 M) for the preparation of platelet-free plasma; or 1/6 
volume of acidic citrate dextrose (ACD: 80 mM trisodium citrate, 52 mM citric acid and 
180 mM glucose) for the isolation of washed platelets.
 Blood samples were obtained from 48 patients before and after a 
cardiopulmonary bypass (CPB) procedure. This sample size is based on the results of 
an earlier study, where the effects of in vivo dilution on elastic fibrin clot formation in 
only plasma were determined.19 Patients were admitted in the hospital in the period of 
October to December 2010. Patients had stopped taking anticoagulant drugs at least 1 
week before the procedure. Blood samples were collected into 0.129 M trisodium citrate 
(1:10) Vacuette tubes (Greiner, Alphen a/d Rijn, The Netherlands) at two time points: (i) 
after induction of anesthesia, but prior to the CPB procedure and heparin administration; 
(ii) after surgery and infusion of protamine to neutralize heparin, when the activated 
clotting time (ACT) was normalized. In samples from 4 patients coagulation times pointed 
to the presence of residual traces of heparin. In these cases, assays were repeated in the 
presence of 10 µg/mL polybrene, i.e. a concentration not influencing the assay parameters 
(data not shown). None of the patients developed surgical complications other than 
bleeding during the time span of blood sampling. Transfusion of blood products during 
surgery was guided on the basis of low blood cell counts, prolonged aPTT, and/or clinical 
observation of bleeding. Whole blood thromboelastometry was measured immediately 
after collection; plasma samples were stored for later measurements.
Preparation of plasma, washed platelets and red blood cells
Platelet-free plasma was obtained from citrate-anticoagulated blood, by 
centrifuging twice at 2630 g for 10 min.20 Plasma samples were immediately snap-frozen 
into liquid nitrogen, and stored at -800 C until further use. Washed platelets were prepared 
from ACD-anticoagulated blood, and suspended in Hepes buffer pH 7.45 (10 mM Hepes, 
136 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 0.1% glucose and 0.1% BSA), as described.
19 
Platelet count was determined with a thrombocounter (Coulter Electronics, Luton, UK). 
For the isolation of red blood cells, citrate-anticoagulated blood was centrifuged at 240 g 
for 15 min, after which the red cell layer was supplemented with Hepes buffer pH 7.45 in 
a 1:2 volume ratio. Red cells were then centrifuged at 2630 g for 10 min, suspended with 
Hepes buffer pH 7.45 (2:1), and washed again, which yielded a highly purified suspension 
of red cells (99.9%).
Dilution of whole blood or plasma and reconstitution experiments
Whole blood or plasma was diluted in vitro with saline medium, consisting of 137 
mM NaCl, 12.9 mM trisodium citrate, 2 mM CaCl2 and 2 mM MgCl2, in order to keep 
equal concentrations of free Ca2+ and Mg2+ in all diluted samples. Coagulation factor 
levels in plasma were determined, as described.5 Percentage values of plasma are given 
as final concentrations (relative to citrate-anticoagulated plasma taken as 100%). In all 
reconstitution experiments, replacement of plasma by added supplements was taken 
into account when calculating the final extent of dilution. Red blood cells were added at 
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1:10 volume ratio. Where indicated, factor concentrates in saline were added to plasma 
samples from healthy subjects or patients, and incubated for 10 min before starting the 
experiment.
Rotational thromboelastometry
In samples from the same donors, elastic fibrin clot formation was measured 
in whole blood and plasma (citrate-anticoagulated) by thromboelastometry, using 
equipment and cuvettes from TEM International. Coagulation was triggered with 10 
pM tissue factor and a surplus of CaCl2.
19 Plasma samples were supplemented with 
phospholipid vesicles (4 μM, final concentration) or washed platelets from one healthy 
donor (100-250 ×109/L, final count). Runs were performed in duplicate or, when >5% 
variation was observed, in triplicate. Curves were analyzed for slope of elastic clot 
formation (α-angle), maximum strength of the clot (maximal clot firmness, MCF) and the 
time to the onset of clot formation (clotting time, CT).
Thrombin generation
Thrombin generation in plasma was measured, using the calibrated automated 
thrombogram (CAT) method.19 Plasma samples were supplemented with either 
phospholipid vesicles (4 μM) or washed platelets from a single healthy donor (100-250 × 
109/L). Assays were run in 96-well U-bottom plates (Milford, MA, USA) in the presence of 
fluorogenic substrate Z-GGR-AMC (2.5 mM) and CaCl2 (16.7 mM, final concentrations). 
Coagulation was triggered with 10 pM tissue factor. Measurements were performed 
in triplicate. First-derivate curves of thrombin generation were obtained by using 
Thrombogram software.20 Curves were analyzed for maximal rate of thrombin generation 
(thrombin peak height), thrombin-generating capacity (endogenous thrombin potential, 
ETP) and the time until thrombin formation (lag time). Samples containing added 
PCC were analyzed for 10 min after triggering coagulation, to ensure adequate curve 
calibration.
Statistical analysis
Data are given as means ± SD. The Shapiro-Wilk test was used to test for normal 
distribution of the data. Statistical analysis was performed, as appropriate, using the 
Mann-Whitney U test.  Patient data were not normally distributed and are given as 
medians with interquartile ranges. The Wilcoxon matched pairs signed ranked test was 
used for comparing pre- and post-surgical values. Determinants of thromboelastometry 
curves were identified by multiple linear regression analysis. P-values <0.05 were 
considered statistically significant. The program GraphPad Prism 6.0 (GraphPad Software, 
San Diego, CA, USA) was used for graphical purposes and relevant statistics; the SPSS 20 
(IBM, Armonk, NY, USA) package was used for regression analysis and statistical testing.
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Results
Determinants of thromboelastometry and thrombin generation curves for whole blood 
and plasma upon in vitro dilution
Blood samples from healthy subjects were diluted in vitro, reconstituted with various 
blood components, and analyzed for elastic fibrin clot formation by thromboelastometry. 
Coagulation was triggered via the extrinsic pathway with recombinant human tissue 
factor at an optimal concentration of 10 pM.19 To keep cationic concentrations constant, 
citrate-anticoagulated blood samples were diluted with saline medium, containing 
equimolar concentrations of citrate, CaCl2 and MgCl2. The MCF, as a curve parameter 
determining the overall clotting capacity, was half-maximal at 30% blood, while the 
α-angle, detecting the rate of elastic clot formation, was half-maximal at 20% blood 
(Fig. 1A). The clotting time (CT) was prolonged from <40% blood (Fig. 1B). Strikingly, 
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Figure 1: Determinants of thromboelastometry in diluted whole blood. Whole blood samples from healthy 
subjects were diluted with saline medium (see methods) to the indicated percentage. Levels of hemostatic 
factors in the undiluted blood (plasma) were: platelets 220-250 ×109/L; red blood cells 33-37% hematocrit; 
fibrinogen 3.0-3.5 g/L, prothrombin 100%. (A, B) Effect of blood dilution on maximal clot firmness (MCF), 
α-angle and clotting time (CT) of thromboelastometry curves. (C, D) Whole blood diluted to 40% was 
supplemented (final concentrations) with prothrombin complex concentrate (PCC 1 U/mL, equivalent to 
100% prothrombin), red blood cells (RBC, 37% hematocrit), autologous platelets (PLT, 250 ×109/L) and/or 
fibrinogen concentrate (FC, 3.0 g/L.). Values of MCF, α-angle and CT are given in comparison to the control 
condition with undiluted blood (100%). Means ± SD (n = 5-8), *p < 0.05 vs. no addition.
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Figure 2: Determinants of thromboelastometry and thrombin generation in diluted plasma. Normal 
plasma (fibrinogen 3.2 g/L, prothrombin 100%) was diluted with saline medium.  Samples were replenished 
(final concentrations) with fibrinogen concentrate (FC, 3.0 g/L) or prothrombin complex concentrate (PCC, 
100% prothrombin). Final plasma dilution of all samples was 40%. Coagulation was triggered with 10 pM 
tissue factor in the presence of either procoagulant phospholipid vesicles (PV, 4 µM) or platelets (PLT, 100 
×109/L). (A, C) Representative thromboelastometry curves with phospholipid vesicles or platelets. (B, D) 
Representative thrombin generation curves with phospholipid vesicles or platelets. (E-H) Effect of added 
fibrinogen or PCC on parameters of thromboelastometry (E) and thrombin generation curves (F-H). Means 
± SD (n = 5-6), *p < 0.05 vs. no addition.
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after dilution of blood to 40% (as in patients undergoing major surgery with bleeding), 
neither the MCF nor the α-angle changed by addition of PCC or red blood cells (Fig. 1C). 
Addition of red blood cells to raise the hematocrit from 10 to 35% (at 40% plasma) did 
not influence thromboelastometry curve parameters (data not shown, but see below). In 
contrast, re-addition of either platelets (to 250 ×109/L) or fibrinogen concentrate (to 3.0 
g/L) to the diluted blood markedly restored parameters of fibrin clot formation (Fig. 1C). 
Only addition of platelets normalized the CT (Fig. 1D).
 Given the inability of red cells to affect thromboelastometry curves, further 
experiments were performed with isolated plasma, as this allowed simultaneous 
measurements of elastic clot formation and thrombin generation. Coagulation was 
triggered again with 10 pM tissue factor, while phospholipid vesicles (4 µM) or autologous 
platelets (100-250 ×109/L) were added to provide a phospholipid surface for coagulation 
activity.19 In the presence of phospholipid vesicles, thromboelastometry curves remained 
low in slope (α-angle) and amplitude (MCF). Plasma dilution to 40% resulted in further 
lowering of the curves (Fig. 2A), and in diminished thrombin generation (Fig. 2B). 
Supplementation of fibrinogen concentrate, but not of PCC, antagonized the dilution 
effect on thromboelastometry (Fig. 2A, E). In contrast, only PCC markedly antagonized 
the dilution effect on thrombin generation (Fig. 2B, F-H). This analysis underscored the 
fibrinogen level as a major variable (independently of platelets) in elastic clot formation.
In the presence of platelets (100 ×109/L), the rate and maximal amplitude of 
elastic clot formation were markedly higher and reached the maximal levels detected 
in whole blood (Fig. 2C, E), thus pointing to an additive effect of platelets to the 
thromboelastometry curves. In this case, plasma dilution to 40% only moderately 
diminished the thromboelastometry curves. In measurements of thrombin generation 
with platelets, plasma dilution was of limited effect on thrombin peak height, total 
amount of thrombin (ETP) or lag time (Fig. 2F-H).
Dose-response studies were performed to better define the effects of fibrinogen 
and PCC in diluted plasma. For thromboelastometry curves, added fibrinogen up to 3-4 g/L 
(final concentration) caused a dose-dependent increase in MCF and α-angle, regardless 
of whether PCC was added or not (Fig. 3A, B). Added fibrinogen did not affect the CT, 
while only the highest concentration of PCC caused a slight prolongation in CT (Fig. 3C). 
Addition of PCC resulted in a dose-dependent increase in thrombin generation, reaching 
300% of the normal thrombin peak height and ETP level. At none of the doses, fibrinogen 
influenced parameters of thrombin generation (Fig. 3D, E). However, PCC at high doses 
prolonged the lag time to thrombin formation (Fig. 3F), which can be explained by the 
presence of anticoagulant proteins in this concentrate. Together, these data indicate 
that, in diluted whole blood and plasma, fibrin clot formation relies on the amounts of 
platelets and fibrinogen, whereas the thrombin generation process is regulated by the 
levels of vitamin K-dependent coagulation factors, as present in PCC.
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In thromboelastometry, effects of varying the levels of both platelets and fibrinogen 
were then compared. These blood components were added in various combinations to 
diluted plasma, while keeping the final extent of dilution constant. The three-dimensional 
plot of Fig. 4A indicates that, up to 250 ×109 platelets/L and 2.7 g fibrinogen/L, the 
MCF increased with higher levels of both platelets and fibrinogen (Fig. 4A). Even at the 
highest fibrinogen concentrations, the MCF raised with the platelet count. This is also 
apparent from a plot of the α-angle, although this parameter reached a maximal value 
at lower fibrinogen and platelet levels (Fig. 4B). Regression analysis revealed that the 
platelet count contributed more strongly to the MCF than the fibrinogen level; with a 
standardized regression coefficient β of 0.760 and 0.498, respectively (Suppl. Table 1). 
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Figure 3: Dissimilar effects of fibrinogen and prothrombin complex concentrate on thromboelastometry 
and thrombin generation in diluted plasma. Normal plasma was diluted with saline medium and replenished 
with fibrinogen concentrate (FC, 1.4-2.4 g/L) and/or prothrombin complex concentrate (PCC, 0.1-1.6 U/mL). 
Final plasma dilution in all samples was 40%. Coagulation was triggered with 10 pM tissue factor in the 
presence of phospholipid vesicles. Effects of addition of different amounts of FC with or without PCC (0.5/1.4 
U/mL) on MCF (A), α-angle (B) and CT (C) of the thromboelastometry curves. Effects of addition of different 
amounts of PCC with or without FC (2.4 g/L) on peak height (D), ETP (E) and lag time (F) of the thrombin 
generation curves. Means ± SD (n = 3-6).
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Furthermore, the relative contribution of fibrinogen to MCF appeared to be independent 
of the platelet count, i.e. standardized regression coefficients for fibrinogen were >0.89. 
This was also true for the α-angle.
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Figure 4: Combined contribution of fibrinogen and platelets to thromboelastometry. Plasma was diluted 
as in Fig. 3; fibrinogen levels were adjusted to 1.1-2.7 g/L, while platelets were added at 25-250 ×109/L. 
Thromboelastometry curves were analyzed, as described. Graphs show effect of fibrinogen and platelet 
variation on MCF (A) and α-angle (B). See also Suppl. Table 1.
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Predictive variables of whole blood thromboelastometry and thrombin generation in 
patients undergoing hemodilution during surgery
To assess the clinical relevance of these different roles of platelets and fibrinogen in 
thromboelastometry, blood and plasma samples were studied from patients undergoing 
cardiothoracic surgery and in vivo dilution by massive fluid infusion. Blood samples 
were analyzed from 48 patients, with mean age of 67 (range 51-75) years, of whom 33 
underwent coronary artery bypass grafting and 10 replacement of the aortic or mitral 
valve (Suppl. Table 2). Total fluid volume transfused during the surgery procedure was 
4.6 ± 1.4 L (mean ± SD). A minority (12 patients) needed transfusion with 2.2 ± 1.5 units 
packed red cells. Blood samples were obtained from the patients before and after the 
surgical procedure. All patients received heparin (344 ± 77 mg) after collection of the first 
blood sample, and the heparin was antagonized with protamine (269 ± 51 mg) before the 
second blood collection. Plasma samples were checked for absence of residual heparin 
activity.
In the group of patients, the platelet count dropped with 45%, the hematocrit level 
reduced with 25%, and the aPTT significantly prolonged from 30.0 (median) to 35.0 sec 
(Table 1). Plasma levels of prothrombin, antithrombin and factor X reduced with 41-46%, 
while fibrinogen decreased from 3.50 (median) to 1.90 g/L. In remaining plasma samples 
from a subgroup of 7 patients, levels of other coagulation factors were determined; 
factors VII, VIII and IX were reduced by 46%, 32% and 38%, respectively. Overall, this 
pointed to a dilution of ~40% of most blood components due to fluid infusion.
Whole blood samples pre- and post-surgery from all patients were analyzed by 
thromboelastometry upon triggering with tissue factor (Table 2). As expected, curves 
of clot formation narrowed significantly, in that the MCF decreased from median 66.0 
(62.0-70.0) to 55.0 (48.0-60.0) mm, while the α-angle decreased from 76.0 (74.0-79.0) 
Parameter Pre-surgery Post-surgery Δ
Platelets (x109/L) 199 (159-227) 110 (83.3-140)** -44.7%
Hematocrit (ml/ml) 0.32 (0.30-0.36) 0.24 (0.23-0.26)** -25.0%
Hemoglobin (mM) 6.70 (6.10-7.50) 5.00 (4.68-5.53)** -25.4%
aPTT (s) 30.0 (28.0-30.0) 35.0 (32.0-38.0)** 16.7%
Prothrombin (%) 103 (87.0-118) 55.5 (43.5-64.0)** -46.1%
Antithrombin (%) 98.0 (90.5-109) 57.5 (52.0-65.8)** -41.3%
Factor X (%) 86.0 (74.5-109) 47.5 (42.3-58.0)** -44.8%
Fibrinogen (g/L) 3.50 (2.90-4.30) 1.90 (1.50-2.30)** -45.7%
Table 1: Hematological parameters of patients before and after cardiothoracic surgery. Blood was obtained 
from 48 patients before and after a CPB procedure. Inactivation of heparin was checked in all post-CPB 
samples. Mean changes (∆) due to the surgery procedure are indicated in percentages. Medians with 
interquartile ranges (n = 48). **p < 0.001 vs. pre-surgery.
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to 70.5 (63.4-71.80) degrees. Both the CT and clot formation time (CFT) significantly 
prolonged. During the 30 minutes of measurement, no signs of fibrin degradation were 
observed (not shown).
Multiple regression analysis demonstrated that in pre-surgery as well as in post-
surgery samples, the platelet count and fibrinogen level were significant predictors of 
whole blood thromboelastometry. Standardized regression coefficients indicated that 
platelet count and fibrinogen level contributed similarly to the variation in MFC (Table 3). 
In contrast, variation in red blood cell count (hematocrit) or prothrombin level did not 
significantly add to this variation in either pre-surgery or post-surgery samples (p > 0.1).
Thromboelastometry and thrombin generation were also determined in 
plasma samples prepared from pre- and post-surgery blood (Table 4). Post-surgery 
thromboelastometry curves, obtained with plasma containing phospholipid vesicles, 
showed a consistent reduction in MCF (-46%) and α-angle (-11%) and a prolongation of the 
CT (+30%). These parameters also changed with platelets present. Analysis of thrombin 
generation measurements indicated a marked dilution effect post-surgery on thrombin 
peak height (-28%) and ETP (-7%), particularly when assessed with phospholipids. 
Exclusion of the data from patients, who had received red blood cells (n=12), resulted 
in similar changes of thromboelastometry and thrombin generation data (not shown).
To determine the potential for normalization, post-surgery plasma samples were 
supplemented with fibrinogen concentrate and PCC. These concentrates were added 
at amounts corresponding to the expected effect of transfusion of 2 units fresh frozen 
plasma,5 i.e., 0.4 g/L fibrinogen plus 0.11 U/mL PCC. This addition significantly increased 
MCF in the presence of phospholipids from 16.5 (12.5-20.0) to 21.0 (17.0-25.0) mm, but 
left the parameter unchanged in the presence of platelets (Table 4). The same addition 
caused a 25-33% increase in thrombin generation (thrombin peak height and ETP), both 
with phospholipids and platelets.
Parameter Pre-surgery Post-surgery Δ
MCF (mm) 66.0 (62.0-70.0) 55.0 (48.0-60.0)** -16.7%
α-angle (˚) 76.0 (74.0-79.0) 70.5 (63.4-72.8)** -7.2%
CT (s) 112 (98.0-143) 135 (117-156)* 20.5%
CFT (s) 70.0 (57.0-85.0) 104 (88.0-138)** 48.6%
Table 2. Parameters of thromboelastometry in whole blood from patients before and after surgery. 
Thromboelastometry was determined in whole blood from 48 patients pre- and post-surgery, as described 
in the methods section. Data are medians with interquartile ranges. *p < 0.05, **p < 0.001 vs. corresponding 
pre-surgery.
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b SE b β p-value partial 
correlation
Pre-surgery
Step 1
Constant 45.59 3.985 <0.001
Fibrinogen 2.655 0.986 0.382 0.011 0.424
Platelets 0.054 0.018 0.422 0.005 0.460
Step 2
Constant 44.07 9.627 <0.001
Fibrinogen 3.031 1.079 0.436 0.009 0.450
Platelets 0.062 0.021 0.485 0.006 0.471
Hematocrit 7.989 23.92 0.047 0.741 0.060
Prothrombin -0.042 0.044 -0.152 0.348 -0.169
Post-surgery
Step 1
Constant 33.805 2.505 <0.001
Fibrinogen 5.783 1.296 0.507 <0.001 0.608
Platelets 0.080 0.021 0.439 <0.001 0.552
Step 2
Constant 27.95 7.122 <0.001
Fibrinogen 5.491 1.502 0.481 0.001 0.543
Platelets 0.080 0.025 0.440 0.003 0.498
Hematocrit 21.06 25.14 0.084 0.408 0.147
Prothrombin 0.024 0.073 0.048 0.749 0.057
Table 3. Predicting variables of thromboelastometry in whole blood from patients before and after surgery. 
Fibrin clot formation was measured in whole blood from 48 patients pre- and post-surgery. Predicting 
variables of thromboelastometry MCF were obtained by linear, multiple regression analysis. Abbreviations: 
b indicates unstandardized regression coefficient; SE b, standard error of b; β, standardized regression 
coefficient.
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The MCF of whole blood thromboelastometry with pre- and post-surgery samples 
was dependent on the fibrinogen level (partial correlation coefficients 0.917 and 0.890, 
respectively, p < 0.001). Notably, the MCF from curves obtained with whole blood samples 
correlated significantly with the MCF measured with plasma plus phospholipids (R = 0.83, 
p < 0.001) or with plasma plus platelets (R = 0.75, p < 0.001) (Fig. 5). On the other hand, 
the various parameters of thromboelastometry curves (whole blood or plasma) did not 
correlate with those of thrombin generation (p > 0.2). Together, this indicated that the 
predictive variables of thromboelastometry curves of patient whole blood and plasma 
were similar, but differed from those predicting thrombin generation curves.
Parameter Pre-surgery Post-surgery Δ Post + FC/PCC
Thromboelastometry
phospholipid vesicles
MCF (mm) 30.5 (26.0-37.0) 16.5 (12.5-20.0)** -46% 21.0 (17.0-25.0)**
α-angle (˚) 79.0 (77.0-81.0) 70.0 (63.0-74.0)** -11% 74.0 (71.0-78.0)**
CT (s) 89.0 (83.0-103) 116 (100-132)** 30% 90.5 (77.0-105)**
Platelets
MCF (mm) 73.0 (71.0-76.0) 65.0 (62.0-69.0)** -11% 63.5 (59.0-66.0)
α-angle (˚) 79.0 (77.0-80.0) 77.0 (75.0-78.0)** -2.5% 76.5 (74.0-79.0)
CT (s) 104 (93.0-135) 111 (97.0-127) 6.7% 95.5 (85.0-112)**
Thrombin generation in plasma
phospholipid vesicles
Peak height (nM) 297 (249-325) 213.6 (179-232)** -28% 269.5 (230-295)**
ETP (nM x min) 1159 (997-1313) 1083 (922-1252)** -6.6% 1415 (1291-1563)**
Platelets
Peak height (nM) 144.5 (114-168) 133.6 (113-151)* -7.5% 167.1 (147-191)**
ETP (nM x min) 1282 (1094-1412) 1159 (1041-1358)* -9.6% 1536 (1423-1805)**
Table 4: Comparison of thromboelastometry and thrombin generation tests in patient plasmas before and 
after surgery. Plasma samples from patients, before and after surgery, were supplemented with either 4 
µM phospholipid vesicles or 100 ×109 platelets/L, as indicated. Coagulation was triggered with 10 pM tissue 
factor. Parallel plasma samples post-surgery were supplemented with fibrinogen concentrate (FC, 0.4 g/L, 
f.c.) and prothrombin complex concentrate (PCC, 0.11 U/mL, f.c.). Medians with interquartile ranges (n = 48). 
*p < 0.05, **p < 0.001 vs. pre-surgery samples, or vs. no addition.
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Discussion
In this paper, we studied principal sources of variation of the processes of elastic 
fibrin clot formation (thromboelastometry) and thrombin generation under conditions 
of in vitro or in vivo dilution. Coagulation in all cases was fully activated with tissue 
factor.21 It appeared that, in whole blood or plasma diluted in vitro to 40%, both the 
platelet count and fibrinogen concentration determine the kinetics and extent of fibrin 
clot formation in additive ways, with no more than limited contributions of red blood 
cells and vitamin K-dependent coagulation factors. In other words, certain (threshold) 
values of thromboelastometry parameters could be obtained by supplementation of 
platelets and fibrinogen at different relative amounts, but not by red blood cells. On the 
other hand, the best way to restore impaired thrombin generation in diluted plasma was 
by increasing the levels of vitamin K-dependent coagulation factors.
In the present paper we find that, under conditions of hemodilution, 
thromboelastometry parameters in whole blood are not improved by raising the 
hematocrit. A limited contribution of red blood cells is also apparent from the observation 
that curve parameters were similar in whole blood and in platelet-containing plasma 
(without red blood cells). Other authors, using undiluted blood have reported a negative 
contribution of the hematocrit on thromboelastometry parameters.22-24 Comparing with 
the present results, this suggests that under high viscous conditions, as in undiluted 
blood, red blood cells interfere with the formation of an elastic platelet-fibrin clot, while 
this interference becomes smaller under less viscous conditions.
The recognition that platelets and fibrinogen in additive ways contribute to 
thromboelastometry parameters sheds new light on our earlier conclusion19 that platelets 
can partly compensate for the dilutional effect on elastic clot formation. The apparently 
independent contribution of platelets and fibrinogen most likely reflects differences in 
0
20
40
60
80
100
40 50 60 70 80 90
0
20
40
60
80
100
MCF plasma/phospholipids (mm) MCF plasma/platelets (mm)
M
CF
 w
ho
le
 b
lo
od
 (m
m
)
M
CF
 w
ho
le
 b
lo
od
 (m
m
)
40 60200
pre-surgery post-surgery pre-surgery post-surgery
R=0.83 (p < 0.001) R=0.75 (p < 0.001)
A B
Figure 5: High correlation of thromboelastometry MCF values in whole blood and plasma samples. 
Thromboelastometry was measured in whole blood and plasma with phospholipids or platelets (100 × 
109/L) from 48 patients. MCF was derived from the thromboelastometry curves. (A) MCF in whole blood vs. 
plasma/phospholipids, (B) MCF in whole blood vs. plasma/platelets. Correlation coefficients and p-values 
are given of combined pre- and post-surgery data. 
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function in this process, i.e. providing elasticity to the fibrin clot by contraction (platelets) 
and by determining the mass of a fibrin clot (fibrinogen).25 This suggestion is supported 
by the finding that also in blood samples from patients subjected to in vivo dilution, the 
platelet count and fibrinogen level are independent variables of the clot-forming process.
Marked differences were found, when comparing the effects of factor concentrates 
on thromboelastometry and thrombin generation under conditions of dilution in 
vitro or in vivo. Supplementation of fibrinogen concentrate, but not of PCC, in a dose-
dependent way restored elastic fibrin clot formation, as detected by an increased MCF 
and α-angle, without affecting thrombin generation. Interestingly, the CT was hardly 
changed by PCC addition to whole blood or plasma, which agrees with published findings 
that the CT prolongs when coagulation factors fall below 35% of normal.26 Conversely, 
supplementation of PCC, but not of fibrinogen concentrate, restored thrombin generation. 
These data indicate that, although thromboelastometry is often viewed as an integrated 
global measure of coagulation, its sensitivity to reduced levels of vitamin K-dependent 
coagulation factor is limited.
Human and large animal studies indicate that both types of factor concentrates can 
improve hemostasis and reduce blood loss after major trauma.4,15-17 In porcine models, 
infusion of a factor concentrate, not containing anticoagulant proteins, in contrast to 
fibrinogen concentrate, promoted disseminated intravascular coagulation and thus 
caused a prothrombotic condition.27,28 In vitro analysis indeed indicates that the absence 
of anticoagulant factors in such concentrates promotes thrombin generation.29 In the 
present study, we find a prolonged CT (thromboelastometry) and lag time (thrombin 
generation) in the presence of a high concentration of PCC, which hence reflects the 
presence of anticoagulant factors that delay the formation of thrombin.
In patient plasmas after surgery, parameters of thrombin generation were less 
strongly reduced than those of thromboelastometry. Impairment in thrombin generation 
is demonstrated by the reduction in thrombin peak level as well as by the prolongation of 
the CT. Comparison of the curve parameters learned that the thrombin peak height was a 
better responsive indicator for dilution than the ETP. The latter agrees with other papers 
reporting on effects of in vitro dilution in thrombin generation.21,30
Taken together, we conclude that the platelet count and fibrinogen level, in 
additive ways, but not the amount of red blood cells, determine the extent of elastic 
fibrin clot formation in diluted whole blood or plasma. Thrombin generation in diluted 
plasma, on the contrary, is dependent on vitamin K-dependent coagulation factors. By 
implication, clinical decisions for transfusion with fibrinogen or plasma that are based on 
thromboelastometry should take into account the platelet concentration.
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What is known on this topic
• Fibrinogen is a key determinant of elastic fibrin clot formation, assessed by whole-
blood thromboelastometry or thromboelastography
What this paper adds
• Platelets and fibrinogen contribute in additive and independent ways to elastic fibrin 
clot formation under conditions of in vitro or in vivo dilution.
• In dilutional coagulopathy, platelets and fibrinogen, but not red blood cells or vitamin 
K-dependent coagulation factors, determine thromboelastometry parameters 
measured in whole-blood and plasma.
• Clinical decisions for transfusion of fibrinogen or plasma based on thromboelastometry 
should take into account the platelet concentration.
• In diluted plasma, thrombin generation is more dependent on vitamin K-dependent 
coagulation factors than elastic clot formation. 
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Supplemental data
b SE b β p-value
MCF
Plt 25 constant 30.82 1.850 <0.001
fibrinogen 9.700 0.943 0.924 <0.001
Plt 50 constant 39.54 2.087 <0.001
fibrinogen 9.663 1.064 0.906 <0.001
Plt 75 constant 46.16 1.451 <0.001
fibrinogen 9.064 0.739 0.945 <0.001
Plt 100 constant 50.28 1.608 <0.001
fibrinogen 8.839 0.820 0.931 <0.001
Plt 250 constant 62.84 1.562 <0.001
fibrinogen 6.667 0.796 0.892 <0.001
Alpha
Plt 25 constant 48.80 2.961 <0.001
fibrinogen 9.925 1.509 0.840 <0.001
Plt 50 constant 61.20 1.300 <0.001
fibrinogen 5.431 0.662 0.888 <0.001
Plt 75 constant 64.74 1.096 <0.001
fibrinogen 4.981 0.559 0.903 <0.001
Plt 100 constant 67.64 1.288 <0.001
fibrinogen 4.232 0.656 0.835 <0.001
Plt 250 constant 76.34 1.040 <0.001
fibrinogen 1.610 0.530 0.582 0.007
Supplemental Table 1: Relative contribution of platelets and fibrinogen to thromboelastometry curves.
PRP was reconstituted to the indicated platelet number (x109/L) and the relative contribution of fibrinogen 
to the MCF and alpha angle was analyzed by linear regression analysis. Abbreviations: b, unstandardized 
regression coefficient, SE b, standard error of b; β, standardized regression coefficient (n=5).
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Supplemental Table 2: Patient and surgery characteristics. Means ± SD (n=48).
Characteristic
Male/female (n) 32/16
Mean age in years (range) 67 (51-75)
Medication prior to surgery (n)
• aspirin 
• coumarin 
• fraxiparine 
28
2
5
Type of surgery (n)
• coronary artery bypass graft 
• valve replacement 
• other
33
10
5
Heparin during surgery + protamine (n) 48
Perfusion time (min) 91 ± 31
Type of transfusion (n)
• red blood cells
• fresh frozen plasma
• fluids
12
0
48
Transfused fluids:
• priming fluid (L)
• cardioplegia (L) (n=11)
• colloids/crystaloids (L)
• total (L)
1.4 ± 0.4
1.9 ± 0.8
1.8 ± 0.8
4.6 ± 1.4
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As stated in Chapter 1, the overall goal of the studies was to better understand 
the consequences of an acquired impairment or recovery in platelet function in various 
physiological and clinical settings. This required further investigation on the activation 
processes of platelets, either isolated or in whole blood, during the process of thrombus 
formation. In the next paragraphs, I will discuss how the findings of this thesis have 
led to new insights into the causes of structural and functional heterogeneity between 
platelets. Subsequently, I will confer mechanisms by which an acquired low platelet 
count or platelet dysfunction can lead to impaired hemostasis, and how these can be 
overcome. In the last section, I will describe new insights arising from the synthesis study 
describing the hemostasis and thrombosis balance in genetically modified mice.
Heterogeneity in platelet structure and function
It has been recognized for more than a decade that substantial differences exist 
among platelets.1-3 The review Chapter 2 describes in detail how and why platelets from 
a given subject are heterogeneous in terms of structural characteristics (e.g., platelet size 
and receptor densities) and functional features (e.g., forming populations of aggregating, 
procoagulant and coated platelets). Given the life span of human platelets of 7-10 days,4 
both younger (juvenile or reticulated) and older platelets are circulating. It has been 
proposed that the juvenile platelets are larger in size and are more reactive towards 
agonists than older platelets.5,6 Most of the evidence has come from studies in which 
juvenile platelets were (weakly) labeled with thiazole orange, an mRNA probe with a 
debated specificity.7 In Chapter 3, we introduced a new method to identify juvenile 
platelets, namely by staining with fluorescently labeled oligo-dT, which directly binds 
to the poly-A tail of mRNA species. Using this probe we were able to demonstrate a 
regain of function in the newly formed platelets from patients, who stopped taking the 
irreversible P2Y12 receptor antagonist prasugrel. Hence, in this specific setting we found a 
higher reactivity of (unblocked) juvenile platelets than their older counterparts. Whether 
these juvenile platelets are larger was not apparent from the flow cytometric analysis.
Although juvenile platelets were more reactive, by themselves they were unable 
to compensate for the impairment in thrombus and fibrin formation due to a low platelet 
count despite a relatively high number of juvenile platelets (immune thrombocytopenia, 
Chapter 4). While we find that during antiplatelet therapy and the offset period, 
irreversible P2Y12 inhibition impairs the reactivity of the juvenile platelets, several other 
studies have shown a positive correlation between the percentage of juvenile platelets 
and on-treatment platelet reactivity.8-10 Thereby, it was suggested that, due to a high 
platelet turnover, juvenile platelets are incompletely inhibited by antiplatelet therapy 
and, thus, contribute to high on-treatment platelet reactivity.8,10 However, our data in 
Chapter 3 are not supportive of this hypothesis, in that the reactivity of juvenile platelets 
during the initial days of the offset period was still low and only gradually increased in 
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time. This observation agrees with the evidence from other authors that the intrinsic 
structural properties of juvenile platelets, rather than a high turnover, explain a high on-
treatment activity.11
According to their presumed functions, activated platelets can be separated into 
the - partly overlapping - populations of adhesive, aggregating, procoagulant and coated 
platelets. Each of these populations is characterized by a specific set of surface markers 
and can be distinguished in a thrombus (Figure 1).1,12,13 How individual platelets transform 
into one of these populations is not fully clear. In Chapter 2 we reviewed the current 
understanding of platelet heterogeneity and the characteristics of platelet populations. 
We postulate that both the genetic make-up (inherited from megakaryocytes) and the 
vascular environment of a platelet determine its activation profile, and hence direct 
them to a specific population.
A population with unique properties is that of procoagulant platelets.14 These 
platelets are characterized by surface exposure of negatively charged phosphatidylserine 
(PS) at the outer leaflet of the plasma membrane, which property greatly enhances 
their interaction with vitamin K-dependent coagulation factors.15,16 In Chapter 5 we 
investigated how in particular the PS-exposing platelets are implicated in the extracellular 
shedding of glycoprotein (GP) receptors, mediated by the membrane-linked proteases 
ADAM10 and ADAM17.17,18 We discovered that shedding of both GPIbα (by ADAM17) 
and GPVI (by ADAM10) is predominantly confined to the PS-exposing population 
(Figure 1), regardless of the type of stimulus, i.e. the Ca2+-elevating receptor ligands 
CRP-XL/thrombin or the apoptosis-inducing compound ABT-737.19 Kinetic experiments 
furthermore indicated that PS exposure can precede glycoprotein shedding. However, 
PS exposure (or platelet swelling) is not required for platelet ADAM activity, as shedding 
of GPIbα in Scott platelets, which are devoid of PS exposure, was unaltered. The Scott 
platelets are deficient in both membrane phospholipid scrambling and swelling, because 
of a lack of the Ca2+-dependent ion channel anoctamin-6 (gene ANO6 or TMEM16F).20,21 
Together, these findings indicate that ADAM activation in platelets occurs via regulatory 
mechanisms that are similar but not identical to those of PS exposure. Thus, glycoprotein 
shedding and PS exposure appear to be two independent events. This is in contrast to 
a recent report demonstrating a necessity for PS exposure to induce ADAM activity in 
lymphocytes.22
In Chapter 5, we also studied the signaling pathways leading to ADAM-mediated 
glycoprotein shedding. Inhibitor experiments indicated that both caspase activity (with 
ABT-737) and prolonged elevation in cytosolic Ca2+ (with CRP-XL/thrombin or Ca2+-
ionophore) with a secondary role for protein kinase C activation could trigger shedding of 
GPIbα and GPVI. However, these pathways were not mutually exclusive, as the chelation 
of Ca2+ in ABT-737-stimulated platelets partly diminished GPIbα shedding. This is in line 
with an earlier publication from our laboratory, showing the existence of a population of 
apoptotic platelets that shows increased levels of cytosolic Ca2+.23
Another relevant finding was that cleavage of GPIbα and GPVI lowers the 
adhesion tendency of the platelets and, conversely, increases their procoagulant activity. 
It appeared that those platelets that had lost their GPIbα and GPVI receptors showed 
a decreased binding of VWF, but an increased binding of prothrombin and factor Xa. 
As a consequence, the platelets with cleaved receptors mediated a faster onset of 
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fibrin formation under flow. Specific blockade of GPIbα shedding also increased the 
procoagulant activity, suggesting a predominant role of GPIbα in the control of this 
process.
At first sight a loss of glycoprotein receptors in procoagulant platelets is 
counterintuitive, because the literature reports that both GPIbα and GPVI can act as 
receptors for thrombin and fibrin, respectively, i.e. two major players of the coagulation 
cascade.24-26 Our data thus implicate that the platelet population that is most supportive 
of coagulation cannot steer this process via GPIbα and GPVI. Accordingly, other 
populations must account for the GPIbα- and GPVI-dependent effects of thrombin and 
fibrin, respectively: for instance, the populations of adhesive and aggregated platelets. 
In Chapter 4 we find that, at conditions where platelet adhesion is limited, thrombus 
formation is highly dependent on thrombin, whilst fibrin accumulates in the thrombus 
top. One might speculate that in such situations the relative importance of GPIbα and 
GPVI as coagulant receptors increases. Glycoprotein-dependent binding of thrombin and 
fibrin may also facilitate the formation of procoagulant and coated platelet elsewhere in 
the thrombus.
Acquired impairment of hemostasis: effects of reduced platelet count or dysfunction
Given the central role of platelets as mediators of hemostasis, both an adequate 
platelet count (platelet mass) and platelet function is needed to prevent bleeding.27,28 In 
Chapter 2 we present the concept that platelets can be negatively or positively primed 
by their physiological environment, with positive priming becoming more important at 
conditions where the thrombosis risk increases. By changing the environment, not only 
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Figure 1. Proposed model of platelet priming and heterogeneity in thrombus formation. Platelets are 
positively or negatively primed by genetic and environmental factors and as such can show differential 
responses to vascular injury. This translates into the formation of a heterogenous thrombus with a distinct 
localization of the different platelet types and their specific responses (e.g. receptor shedding located 
specifically at the procoagulant platelets) within the thrombus. As such also the pattern of fibrin formation 
and thereby, the elasticity of the thrombus is affected.
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anti-platelet but also anticoagulant therapies will affect the priming of platelets, and 
thereby alter their responsiveness. As a result, platelets can become hypo- or hyper-
responsive (Figure 2).
Chapter 6 provides an illustration of how disease and treatment can affect platelet 
mass, function and priming. In this chapter, we investigated platelet and coagulant 
functions in patients, who had been diagnosed with a hematological malignancy and 
were treated with chemotherapy. As a consequence of disease and chemotherapy, 
these patients develop severe thrombocytopenia and are hence at increased risk for 
bleeding, ultimately with a necessity of platelet transfusion.29 Our data indicate that, 
after a couple of weeks of chemotherapy treatment, the remaining platelets of the 
patients are dysfunctional in multiple aspects. To a varying extent, these platelets display 
defective integrin activation, granule secretion and Ca2+ signaling. As the direct effect 
of chemotherapeutic exposure to the circulating platelets was minimal, it is concluded 
that the impairment in platelet function likely originates at the level of megakaryocytes. 
The high variability in platelet responses among patients could not be explained by 
the diagnosis or type of chemotherapy. This would argue for a variable susceptibility 
of the megakaryocytes. From patient to patient, the anti-proliferative effects of 
chemotherapeutics, e.g. inhibition of DNA replication and cell cycle progression, might 
differently affect the process of megakaryopoiesis.30 Furthermore, even megakaryocytic 
precursor cells have a different sensitivity to chemotherapeutics.31 This implies that the 
extent of damage inflicted to the megakaryocytes and derived platelets is determined by 
the chemotherapeutic agents administered and the stage of megakaryopoiesis.
Given the cytotoxic nature of chemotherapy, we investigated whether the 
dysfunction of the patient platelets was due to apoptosis. This was also driven by data 
that integrin activation and secretion are impaired in apoptotic platelets.32 However, we 
could not find indications of ongoing apoptosis in platelets from the patients. For instance, 
no caspase activity was detected, and caspase inhibition did not affect PS exposure. 
Rather, we found strong evidence that mitochondrial dysfunction could account for the 
diminished platelet responsiveness.
Under normal conditions, the energy demand increases upon platelet activation. 
As platelets rely on glycolysis and mitochondrial respiration for sufficient ATP production, 
an impairment in mitochondrial respiration can result in decreased platelet reactivity.33 
Our data suggest that, in the patient platelets, the mitochondrial function is inadequate 
to support the higher energy demand needed for activation, with as a result lower 
platelet responsiveness. Mitochondrial dysfunction can also explain the increased PS 
exposure in the patient platelets, given the observation that mitochondria normally have 
a suppressive function in PS exposure.34 Along the same line, a deficiency in glucose 
metabolism can enhance PS exposure.35
Impaired platelet responsiveness appeared to be a main determinant of disturbed 
hemostasis in patients treated by chemotherapy (Chapter 6). On the other hand, the 
combined lowering of coagulation factors and platelets accounts for the increased 
bleeding risk in patients with dilutional coagulopathy during major surgery (Chapter 
7). Here, we investigated the contribution of the plasmatic and cellular components 
of blood to the hemostatic potential, as measured by elastic fibrin clot formation 
(rotational thromboelastometry) and thrombin generation (assessed by the calibrated 
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automated thrombin generation test). The method of rotational thromboelastometry or 
thromboelastography is frequently used to monitor the hemostatic capacity of the blood 
from patients during major surgery.36 Advantages of this point-of-care technique are that 
only small blood volumes are needed and that the measurement time is short.37,38 Our in 
vitro data suggest that upon dilutional coagulopathy – dilution of whole blood or plasma 
with crystalloids to 40% – fibrin clot formation could be normalized by reconstitution 
with either platelets or fibrinogen. On the other hand, administration of prothrombin 
complex concentrate (containing a mixture of pro- and anti-coagulation factors) or red 
blood cell concentrate was ineffective. In blood samples from patients taken before and 
after hemodilution, we found that only the platelet count and the fibrinogen level were 
relevant predictors of clot strength. Thrombin generation though could be restored by 
the addition of prothrombin complex concentrate, in which case addition of fibrinogen 
or platelets was without effect.
In Chapter 4, we used a whole blood perfusion assay to investigate thrombus 
and fibrin formation in blood obtained from patients with dilutional coagulopathy. Both 
thrombus and fibrin formation were severely impaired in these blood samples. In this test 
system – in contrast to rotational thromboelastometry – it appeared that reconstitution 
of both platelets and red blood cells was needed to achieve normal thrombus and fibrin 
formation at 40% dilution. The role of red blood cells herein, likely, is to improve platelet 
marginalization and adhesion to the microfluidic chamber surface.39 Importantly, this 
platelet marginalization effect of (transfused) red blood cells, considered to be relevant 
for hemostasis (see Chapter 1), is not detected in other, static assays. Taken together, this 
work clearly indicates that the ‘hemostatic benefit’ of various blood products is often 
dependent on the type of test used. Accordingly, not every test outcome necessarily 
detects or reflects the actual bleeding risk of a patient.
Normalization of hemostasis: recovery of platelet count and function
Given that platelets, as anucleate cellular fragments, have only a low ability to 
synthesize proteins,40,41 the production of new platelets will be needed to repair any 
dysfunction (Figure 2). In Chapter 3, we investigated platelet function during one month 
after cessation of the irreversible P2Y12 antagonist prasugrel. We could demonstrate 
that the formation of juvenile platelets was needed for a recovery of P2Y12 signaling and 
platelet responses. However, surprisingly, this recovery was only partial during the first 
days after prasugrel discontinuation, and it only gradually increased during the offset 
period. These findings point to the presence of a ‘reservoir’ of inhibited P2Y12 receptors 
in the megakaryocytes, which during the initial days of offset still produce P2Y12-inhibited 
platelets.
This resembles the situation of chemotherapy-treated cancer patients, who also 
produce platelets with a megakaryocyte-inherited dysfunction (Chapter 6). Usually, the 
thrombocytopenia lasts for two to three weeks and then platelet count reverts to normal 
when chemotherapeutic treatments are stopped.29 Markedly, before the platelet count 
restores, the megakaryocyte ploidy increases,42 and the fraction of reticulated platelets 
rises.43,44 Our data indicate that an increase in platelet count – after discontinuation 
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of chemotherapy – is accompanied by a normalization of function of the (reticulated) 
platelets. This suggests that the restoration process starts with a normalization of 
megakaryopoiesis.
In case of active or expected bleeding, the common treatment protocol in the 
Netherlands is a transfusion with pooled platelet concentrate.45,46 In Chapter 6, we found 
that platelet transfusion to patients receiving chemotherapy resulted in an improved 
platelet activity in thrombus and fibrin formation. These results are in agreement 
with other reports.47,48 Since the platelet concentrates used for transfusion purposes 
are stored for several days (median six days), this might be accompanied by a loss of 
mitochondrial function.49 However, no sign of this was found, since the mitochondrial 
membrane potential – a sensitive indicator for platelet quality50 – was comparable to 
that of freshly isolated platelets from healthy volunteers.
Inactivation in megakaryocytesInactivation in circulation
aspirin
prasugrel
chemotherapy
thrombopoiesis
megakaryopoiesis
production of 
ﬂawed/inhibited 
platelets
reticulated
platelets
donor platelets
hemodilution
Thrombin
Prothrombin
Prothrombin
Thrombin
Impairment of platelet function Recovery of platelet function
Prothrombin
FVII FIX
FX
Protein C
Protein S
Formation of new active platelets Transfusion of blood components
mitochondria
Figure 2. Mechanisms of impairment and recovery of platelet function. Impairment of platelet function can 
result from a direct inhibition of the platelets themselves during circulation and/or an indirect inhibition at 
the level of the megakaryocytes. Further, dilution of plasmatic and cellular components can affect platelet 
functionality as well. As platelets are anucleate cells, recovery of platelet function is dependent on the 
production of new platelets by megakaryocytes. When immediate improvement of hemostasis is required, 
transfusion of blood components can aid in the recovery of thrombus and fibrin formation. 
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Genetic alterations in hemostasis and thrombosis
Chapter 8 describes a synthesis paper to compile the outcomes of published in vivo 
and in vitro studies on effects of gene depletion in mouse on arterial thrombus formation. 
This paper provides insight into the roles of 401 mouse genes in experimentally induced 
thrombosis with or without prolonged bleeding times. In particular, the synthesis 
approach enabled us to compare various methods employed to study in vivo and in vitro 
thrombus formation. Given that a conventional meta-analysis showed major limitations 
in numbers of studies to be included, we developed a three- and a five-point scoring 
scale in order to evaluate and combine results from individual published studies. The 
score normalization was used for a newly developed consistency analysis in order to 
determine the strength of the data from literature. This led to the identification of 19 
genes, which regulated murine arterial thrombus formation, but were not implicated 
in tail bleeding. Remarkably, genes (proteins) that are currently targeted in the clinic by 
anti-platelet or anti-coagulant drugs are not included in this list, which is in agreement 
with increased incidence of bleeding seen with all these drugs. There is high interest in 
the development of new antithrombotic drugs that have a better antithrombotic efficacy 
without enhancing bleeding, e.g. by targeting receptors like GPVI (one of the 19 genes 
identified) or PAR1 (not expressed on mouse platelets).51,52
Another relevant outcome was that, in general, published results from in vivo 
thrombosis models (including thromboembolism) correlated well with those of in vitro 
flow chamber models, in particular for the collagen-dependent methods. This is of 
translational interest, since also with human blood, flow chamber tests are considered 
as a suitable initial screening tool for evaluating the efficacy of established and novel 
antithrombotic drugs.53,54
Altogether, the findings of this thesis point to multiple interacting roles of the 
different blood components – platelets, red blood cells and plasma – in hemostatic 
reactions from platelet aggregation and thrombus formation to fibrin clot formation. 
Regarding platelets, it has become clear that different populations are formed with 
distinct properties and distinct interactions with other blood components. Although 
thrombocytopenia and platelet dysfunction often coincide, both conditions are relevant 
in a hemostatic imbalance. 
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 Platelets play crucial roles in thrombosis and hemostasis. In an injured vessel 
wall they rapidly adhere, become activated and aggregate into a thrombus clot to halt 
bleeding. Similarly, following rupture of an atherosclerotic plaque, platelets activate, 
aggregate and form an intra-arterial thrombus. Alterations in platelet activation and/
or count can hence disturb the processes of thrombus and clot formation, with 
consequences for thrombosis or hemostasis. In this thesis, my emphasis is on acquired 
modes of platelet dysfunction and the underlying mechanisms of these.
 Chapter 1 provides relevant background information on the regulation of platelet 
activation and thrombus formation. Highlighted are key platelet receptors responsible for 
adhesion to the vessel wall and, furthermore, the evidence for response heterogeneity 
between platelets. Also introduced are the clinical concepts how thrombosis is prevented 
by dual antiplatelet therapy, with bleeding as a side effect; as well as the conditions for 
platelet transfusion. In the review Chapter 2, a novel concept is presented how inter-
platelet heterogeneity can link to priming of platelets towards increased or decreased 
activation properties. Platelet heterogeneity can be observed at multiple levels. Structural 
heterogeneity can result from variability between individual megakaryocytes and from 
ageing of platelets in the circulation. Within a thrombus, response heterogeneity 
is enhanced by the specific location of the platelet in the thrombus and unequal 
distribution of receptor agonists, such collagen, ADP and thrombin. Regarding priming, 
during their time in circulation platelets will be exposed to a wide range of molecules 
that either increase or reduce the responsiveness. It is considered that, in pathological 
conditions, where the physiological balance between positive and negative priming 
factors is disturbed, platelets can become either hyper- or hypo-responsive. This can 
lead to an increased risk of thrombosis or bleeding, respectively. As a consequence of an 
underlying pathology, platelets can even be activated in the circulation, and subsequently 
appear as non-responsive, when assayed with in vitro tests. Therefore, we conclude that 
measurement is needed of both in vivo markers of platelet activation and in vitro activity 
of platelets, for a better understanding of the possible risks for thrombosis or bleeding.
 In order to prevent recurrent thrombotic events, patients who suffered a 
myocardial infarction will receive dual antiplatelet therapy for one year, consisting of 
the cyclo-oxygenase inhibitor aspirin and an irreversible inhibitor of the ADP receptor 
P2Y12, prasugrel. In Chapter 3 we investigated how the platelet activation properties 
recovered in patients, who stopped prasugrel intake after one year of treatment. Platelet 
responsiveness to ADP was hence tested at 0, 1, 2, 5 and 30 days after the cessation 
of drug intake. We found that after 5 days platelet responses to ADP were markedly 
improved, but still in part inhibited. In vitro addition of ticagrelor - a reversible P2Y12 
antagonist - suppressed the regained ADP responsiveness after >2 days, thus providing 
evidence for a gradual recovery of P2Y12-induced signaling. Interestingly, during the first 
days after discontinuation of prasugrel, we identified a separate population of platelets 
with fully regained responsiveness to ADP. Staining with the mRNA probes, thiazole 
orange or 5’-Cy-oligo-dT, showed that this population consisted of so-called juvenile 
platelets, i.e. newly released from the megakaryocytes residing in the bone marrow. 
Although the reactivity of the juvenile platelets was higher than that of older platelets, 
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interestingly, the reactivity of both populations continued to increase during the whole 
offset period, suggesting a prolonged inhibitory effect of prasugrel intake on P2Y12 
receptors of megakaryocytes.
 In Chapter 4 we determined the interactions between immobilized collagen 
and tissue factor for platelet- and fibrin-dependent thrombus formation under flow 
conditions. It appeared that, alongside collagen that is required for platelet adhesion, 
the tissue factor-triggered generation of thrombin is a controlling factor determining 
the platelet-thrombus volume. In particular at low flow rates, the thrombin generated 
on procoagulant platelets drives the formation of fibrin fibres outside of the thrombus 
area. Furthermore, under conditions where platelet adhesion is a limiting factor, we find 
fibrin fibres redistributed from the bottom to the top of a thrombus. This chapter also 
elucidates the effects of the flow shear rate on the localization of fibrin and on the micro-
elasticity of the fibrin-thrombus.
 The glycoproteins (GP), GPIbα and GPVI, are key surface receptors for platelet 
adhesion to von Willebrand factor and collagen, respectively. Both receptors are known to 
be susceptible to cleavage of their extracellular domains by the platelet membrane-bound 
extracellular proteases, ADAM10/17, in a process called receptor shedding. In Chapter 
5 we investigated the signaling pathways underlying ADAM10/17 mediated receptor 
shedding as well as the implications of this process for platelet functions. Interestingly, we 
found heterogeneity in extent of shedding between populations of (activated) platelets. 
Platelets with phosphatidylserine exposure due to a high intracellular calcium level or a 
high caspase activity appeared to preferentially cleave the glycoproteins GPIbα and GPVI. 
Phosphatidylserine exposure also coincided with glycoprotein shedding in platelets of a 
thrombus. However, as the platelets from a Scott syndrome patient, which are unable to 
expose phosphatidylserine, still showed unchanged ADAM mediated cleavage of GPIbα 
we concluded that phosphatidylserine exposure was not a prerequisite for shedding. 
Given the procoagulant effect of phosphatidylserine exposure, we subsequently 
investigated how receptor shedding affected the procoagulant potential of platelets. 
Remarkably, we found that this was increased by enhancing the binding of prothrombin 
to platelets and by accelerating fibrin formation.
 In Chapter 6 we identified and characterized the dysfunction of platelets acquired 
by chemotherapy treatment in patients, who were diagnosed with a hematological 
malignancy and developed thrombocytopenia. We found that platelets from these 
patients show impaired integrin activation, granule secretion and spreading, when 
stimulated via their ADP, thrombin or collagen receptors. Markedly, the severity of the 
platelet dysfunction was not related to the disease type, the type of chemotherapy, 
or the platelet count. Moreover, platelet dysfunction was not explained by apoptosis, 
nor was the spontaneous phosphatidylserine exposure in the absence of agonists, 
since no caspase activity could be detected. Rather, mitochondrial impairments were 
associated with the compromised platelet responses as patient platelets showed a lower 
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mitochondrial O2 consumption and a decreased mitochondrial membrane potential. 
Transfusion of the patients with platelet concentrates led to an overall recovery of 
responsiveness, thrombus formation and platelet-dependent fibrin formation.
 As a consequence of substantial blood loss due to trauma or major surgery, 
infusion of crystalloids and/or colloid fluids is necessary for patients to maintain fluid and 
electrolyte homeostasis. However, the infusion also leads to dilution of the hemostatic 
factors and ultimately to an increased risk of bleeding, a condition known as dilutional 
coagulopathy. In Chapter 7 we investigated how addition of fibrinogen, platelets, red blood 
cells or prothrombin complex concentrate altered clot formation and thrombin generation 
in plasma samples resembling those of dilutional coagulopathy. We demonstrate that, in 
this case, fibrinogen as well as platelets can normalize the elastic clot formation assessed 
by thromboelastometry. In contrast, the impaired thrombin generation was particularly 
normalized by the addition of prothrombin complex concentrate. These results could be 
confirmed with blood obtained from patients before and after major fluid infusion. Here, 
again, it appeared that the platelet count and fibrinogen level were main predictors 
of the whole blood thromboelastometry outcome, in contrast to the hematocrit and 
prothrombin level. Clinical decisions on transfusion with fibrinogen or plasma, based 
on thromboelastometry measurements alone, should therefore take into account the 
platelet count.
 In Chapter 8, a synthesis paper is presented of published in vivo and in vitro studies 
of murine arterial thrombosis and tail bleeding. In total 1407 studies were included, 
resulting in a comprehensive analysis of the roles of 401 mouse genes in thrombosis 
and hemostasis. By developing a scoring system of the pro- and antithrombotic effects 
of genetic modification, we found high correlations between gene effects of the most 
commonly used in vivo and in vitro models. Moreover, this synthesis identified 19 genes 
that solely affect arterial thrombosis without a role in bleeding. By constructing a network 
of human orthologues of murine genes that affect thrombosis and/or bleeding, we could 
identify multiple novel genes with a possible role in thrombosis and hemostasis. A role 
of several of these new genes was validated by studying thrombus formation in vitro 
using blood from eight genetically modified mouse models. This synthesis approach can 
provide a guide for the identification of new antithrombotic targets in the future.
 In Chapter 9, the most important findings of this thesis are discussed in view of 
the current literature. It is reasoned that knowledge is needed of not only the platelet 
count, but also of the activation properties of the different platelet populations, in order 
to make an appropriate assessment of the hemostatic imbalance of patients with an 
(acquired) risk of thrombosis or bleeding.
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Bloedplaatjes spelen een cruciale rol bij zowel hemostase als trombose. Wanneer 
een bloedvatwand beschadigd raakt, leidt dat tot snelle aanhechting en activering van 
de bloedplaatjes. Het gevolg hiervan is een trombus van geaggregeerde plaatjes, die 
een bloeding kan stelpen. Ook na het scheuren van een arteriële atherosclerotische 
plaque worden plaatjes geactiveerd, en zij vormen dan een trombus die de arterie 
kan afsluiten. Als gevolg hiervan kunnen dus veranderingen in ofwel plaatjesactivering 
ofwel plaatjesaantal leiden tot een abnormale trombusvorming, en daarmee tot een 
verstoorde hemostase of verhoogde tromboseneiging. In dit proefschrift zijn dergelijke 
veranderingen onderzocht, met een nadruk op relevante verworven vormen van 
plaatjesdysfunctie en de mechanismen die daarvoor verantwoordelijk kunnen zijn.
Hoofdstuk 1 biedt relevante achtergrondinformatie over de regulatie van 
plaatjesactivering en trombusvorming. Uitgelicht zijn de voornaamste plaatjesreceptoren, 
zoals de receptoren die zorgen voor adhesie aan de vaatwand. Verder zijn de belangrijkste 
aanwijzigingen in kaart gebracht voor heterogeniteit tussen verschillende plaatjestypen. 
Om het klinische belang te benadrukken van een adequate onderdrukking van 
plaatjesactiviteit bij (arteriële) trombose beschrijft dit hoofdstuk ook de mogelijkheden 
tot preventie middels duale antiplaatjestherapie, die echter regelmatig bloedingen als 
bijwerking hebben. In Hoofdstuk 2 is een nieuw concept gepresenteerd over hoe de 
heterogeniteit tussen plaatjes van invloed kan zijn op het (on)gevoeliger maken (priming) 
van deze cellen voor stimulerende of inhiberende signalen. Deze heterogeniteit kan 
meerdere oorzaken hebben. Heterogeniteit in de samenstelling van plaatjes kan het 
gevolg zijn van verschillen tussen individuele megakaryocyten in het beenmerg, maar ook 
van een geleidelijke plaatjesveroudering. Binnen een trombus wordt de heterogeniteit 
tussen plaatjes ook bepaald door hun precieze locatie en daarmee samenhangend de 
ongelijke verdeling van plaatjesagonisten zoals collageen, ADP en trombine. Wat betreft 
het begrip priming worden plaatjes in de circulatie blootgesteld aan een scala van 
moleculen die hun responsiviteit stimuleren of juist remmen. Beargumenteerd is dat 
onder pathologische omstandigheden, waarin de fysiologische balans tussen positieve 
en negatieve priming-factoren verstoord is, de plaatjes van een patiënt hyper- danwel 
hypo-responsief kunnen worden. Dit kan leiden tot een verhoogd risico op trombose of 
bloeding. Als gevolg van een aandoening kunnen plaatjes in de circulatie zelfs geactiveerd 
worden en vervolgens dysfunctioneel raken, zoals dan blijkt uit in vitro testen. Op grond 
hiervan concluderen wij dat voor een goed begrip van de mogelijke risico’s op trombose 
of bloedingen er metingen nodig zijn van zowel markers van de plaatjesactivering in vivo 
als de activiteit van geïsoleerde plaatjes in vitro.
Om een herhaalde trombose te voorkomen krijgen patiënten die een myocardinfarct 
hebben gehad een jaar lang duale antiplaatjestherapie, die bestaat uit de cyclo-oxygenase 
remmer aspirine en een irreversibele remmer van de P2Y12 receptor voor ADP, prasugrel. 
In Hoofdstuk 3 hebben we onderzocht hoe de plaatjesactivering herstelt in patiënten, die 
stoppen met prasugrel-behandeling. Daarvoor zijn de plaatjesresponsen op ADP gemeten 
op 0, 1, 2, 5 en 30 dagen na de laatste prasugrel-inname. Duidelijk werd dat op 5 dagen 
na stoppen de plaatjesrespons op ADP sterk verbeterd is, maar toch nog gedeeltelijk 
geremd. De herwonnen respons op ADP kon onderdrukt worden met ticagrelor – een 
reversibele P2Y12 antagonist. Dit bevestigde dus een gradueel herstel van de signalering 
via P2Y12 receptoren. Al op enige dagen na het stoppen van prasugrel-inname konden we 
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een afzonderlijke populatie van plaatjes identificeren, waarvan hun responsiviteit op ADP 
grotendeels hersteld was. Door plaatjes te labelen met een mRNA marker zoals thiazole-
oranje of 5’-Cy-oligo-dT, konden we aantonen dat de hoog-reactieve populatie bestond 
uit zogenaamde juveniele plaatjes, dat wil zeggen plaatjes die recent uit het beenmerg 
zijn vrijgekomen. Hoewel de reactiviteit van de juveniele plaatjes hoger was dan die 
van de oude (geremde) plaatjes, bleef de reactiviteit van beide populaties toenemen 
tijdens de periode na het stoppen van de inname van prasugrel. Dit suggereert dat het 
plaatjes-onderdrukkend effect van prasugrel verlengd wordt door remming van de P2Y12 
receptoren van megakaryocyten in het beenmerg.
In Hoofdstuk 4 is nagegaan hoe een oppervlak met collageen met/zonder 
weefselfactor bepalend is voor plaatjesadhesie, trombusvorming en ontstaan van een 
fibrinestolsel onder stromingscondities. Uit het onderzoek bleek dat naast collageen 
dat de plaatjesadhesie initieert, de trombine die ontstaat middels weefselfactor 
bepalend is voor de grootte van de gevormde plaatjes-fibrinestolsels. Met name bij lage 
stromingscondities stimuleerde trombinegeneratie op het oppervlak van procoagulante 
plaatjes de vorming van fibrinevezels buiten de trombus. Daarnaast bleek dat onder 
omstandigheden, waarbij de plaatjesadhesie beperkt is, de fibrinevezels herverdelen 
van de onderkant naar de top van de trombus. Dit hoofdstuk beschrijft verder hoe de 
stromingssnelheid en de lokalisatie van fibrine bepalend zijn voor de microelasticiteit 
van een trombus.
 De glycoproteïnen (GP) GPIbα en GPVI zijn belangrijke receptoren op het oppervlak 
van plaatjes voor hechting aan respectievelijk von Willebrand factor en collageen. Bekend 
is dat beide receptoren gevoelig zijn voor het knippen van hun extracellulaire domein 
door de extracellulaire proteasen ADAM10/17, welke zich ook op het plaatjesoppervlak 
bevinden. Dit knipproces wordt receptor shedding genoemd. In Hoofdstuk 5 hebben 
wij onderzocht welke signaleringspaden in plaatjes ten grondslag liggen aan deze 
ADAM10/17-gemediëerde receptor-shedding. Ook hebben we de gevolgen bepaald van 
het shedding-proces voor de functionaliteit van plaatjes. Een belangrijke bevinding was 
dat de shedding van zowel GPIbα als GPVI heterogeen verloopt, namelijk op bepaalde 
populaties van (geactiveerde) plaatjes. Vooral geactiveerde plaatjes met expositie van 
fosfatidylserine als gevolg van een hoge intracellulaire calciumconcentratie of een 
hoge caspase-activiteit bleken actief in het ADAM-gemedieerde knippen van GPIbα 
en GPVI. Ook voor plaatjes in een trombus viel de glycoproteïne shedding samen met 
fosfatidylserine-expositie. Echter gezien de onveranderde shedding van GPIbα in plaatjes 
van een patiënt met Scott syndroom, die dysfunctioneel zijn in fosfatidylserine-expositie, 
kon de conclusie getrokken worden dat fosfatidylserine-expositie geen vereiste is voor 
receptor-shedding. Gezien het procoagulante effect van fosfatidylserine-expositie, 
hebben we vervolgens onderzocht hoe shedding het stollingsvermogen van plaatjes 
beïnvloedt. Opmerkelijk vonden we een verhoogd stollingspotentiaal, omdat bij plaatjes 
met shedding de binding van stollingsfactoren toeneemt en de fibrinevorming versnelt.
 Hoofdstuk 6 had als doel identificatie van de verworven dysfunctie van plaatjes 
in patiënten, die gediagnostiseerd zijn met een hematologische maligniteit, en na 
chemotherapie behandeling een trombocytopenie ontwikkelen. Aangetoond kon worden 
dat de plaatjes van deze patiënten een verminderde activering van integrines, een lage 
secretie van granula, en een defecte spreiding vertoonden, wanneer ze gestimuleerd 
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werden met ADP, trombine of collageen. Typisch was dat de mate van plaatjesdysfunctie 
niet gerelateerd was aan de diagnose, het type chemotherapie of het plaatjesaantal. 
Bovendien kon noch de plaatjes-dysfunctie noch de spontane fosfatidylserine-
expositie van plaatjes verklaard worden door actieve apoptose, aangezien geen 
activiteit van de apoptose-marker caspase gedetecteerd kon worden. Echter de lage 
plaatjesfunctie was geassocieerd met een verminderde activiteit van de mitochondriën. 
De patiënten-plaatjes vertoonden namelijk een verminderde zuurstofconsumptie en 
een verlaagd membraanpotentiaal in de mitochondriën. Transfusie van de patiënten 
met plaatjesconcentraat leidde tot een algeheel verbeterde plaatjesresponsiviteit, 
trombusvorming en plaatjes-afhankelijke fibrinevorming.
 Toediening van kristalloïde en colloïde vloeistoffen is noodzakelijk om een 
goede vocht- en elektrolytenbalans te behouden, met name wanneer er bij een patiënt 
substantieel bloedverlies optreedt als gevolg van trauma of ingrijpende chirurgie. 
Echter deze vloeistof-infusie leidt ook tot een verdunning van hemostatische factoren 
in het bloed, en kan daarmee aanleiding geven tot een verhoogd bloedingsrisico. 
Deze conditie staat bekend als verdunningscoagulopathie. In Hoofdstuk 7 hebben 
wij onderzocht hoe in verdunde plasmamonsters de extra additie van fibrinogeen, 
bloedplaatjes, rode bloedcellen of protrombine complex concentraat (PCC) leidt tot een 
verbeterde trombinegeneratie en stolselvorming. Dit onderzoek werd uitgevoerd met 
plasmamonsters, die qua samenstelling vergelijkbaar waren met die van patiënten met 
verdunningscoagulopathie. In dit hoofdstuk konden we aantonen dat zowel fibrinogeen 
als plaatjesconcentraat een normaliserend effect heeft op de fibrinestolselvorming, 
zoals gemeten met tromboelastometrie. Anderzijds werd de lage trombinegeneratie het 
beste genormaliseerd door toevoeging van PCC. Deze conclusies werden bevestigd voor 
bloedmonsters verkregen van operatiepatiënten, bij wie het bloed verdund was door 
vloeistofinfusie tijdens de ingreep. Ook in deze metingen bleek dat het plaatjesaantal 
en de fibrinogeenconcentratie de belangrijkste voorspellende variabelen waren van de 
volbloed tromboelastometrie-test. Ook nu waren hematocriet en het protrombine-niveau 
veel minder relevant. In de klinische beslisregels omtrent transfusie van ofwel fibrinogeen 
ofwel plasma, die tegenwoordig vaak gebaseerd worden op tromboelastometrie-
metingen, zou daarom ook het plaatjesaantal opgenomen moeten worden.
 In Hoofdstuk 8 is een vergelijkende kwantitatieve analyse beschreven van een 
groot aantal gepubliceerde studies naar arteriële trombose en staartbloeding in genetisch 
gemodificeerde muizen. In totaal zijn 1407 studies vergeleken, waarmee inzicht verkregen 
werd in de rol van 401 muizengenen bij arteriële trombose, trombo-embolisme en 
hemostase. Middels een scoringsprocedure voor de pro- en antitrombotische effecten 
van genetische modificatie konden we een hoge correlatie vaststellen van de uitkomst 
van de meest gebruikte in vivo en in vitro trombosemodellen. Sterkte-analyse resulteerde 
in 19 muizengenen die een positieve rol spelen bij arteriële trombose, maar geen effect 
hebben op bloeding. Na samenstellen van een netwerk van humane ortologe eiwitten 
van die muizengenen die trombose en/of hemostase beïnvloeden, konden we meerdere 
nieuwe eiwitten en genen identificeren die mogelijk betrokken zijn bij deze processen. 
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Van een aantal van deze konden we een betrokkenheid valideren, door bestudering 
van de trombusvorming in vitro. Deze synthese-aanpak kan een toekomstige leidraad 
vormen voor de identificatie van nieuwe antitrombotische targets.
 In Hoofdstuk 9 zijn de meest belangrijkste bevindingen van dit proefschrift 
bediscussieerd in het licht van de huidige literatuur. Verder is beredeneerd dat zowel het 
plaatjesaantal als de activeringseigenschappen van de verschillende plaatjespopulaties 
bekend dient te zijn om tot een beoordeling te komen van de hemostatische disbalans 
van patiënten met een (verworven) risico op trombose of bloedingen.
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To valorize: to assign value or merit to
Recent years more emphasis has been put on assigning social and/or economical 
value to scientific findings.1 However, the direct contribution to society is not as clear-cut 
for all scientific developments. To be able to improve the patient’s quality of life or to 
ameliorate treatment, first a better understanding of the underlying physiological and 
pathological mechanisms has to be gained. Here, basic research is essential. 
Platelets are an integral part of the hemostatic system. Upon vascular damage, 
platelets quickly respond by forming a platelet plug, which is stabilized by the formation 
of fibrin. Aberrant functionality of platelets can result in an imbalance in the hemostatic 
system and thereby contribute to thrombosis or hemorrhage. Arterial thrombosis underlies 
the development of cardiovascular disease, the number one cause of death globally, 
according to the World Health Organization.2 Here, antiplatelet drugs are an essential 
part in the treatment of cardiovascular disease.3 A downfall of antiplatelet therapy is the 
increased risk of hemorrhage.4 The high occurrence of bleeding complications as a result 
of antithrombotic therapy again underlines the delicate hemostatic balance, indicating 
the need for more insight into the processes of hemostasis and thrombosis to provide 
optimal treatment. 
In this thesis two novel techniques are presented. In Chapter 3, we describe a new 
approach for the detection of juvenile platelets, i.e. the oligo-dT staining. The number 
of juvenile platelets is an indication of the platelet turnover, i.e. production of new 
platelets and degradation/consumption of circulating platelets. In different pathological 
conditions one or both processes can be affected. Knowledge of merely platelet count 
is insufficient to distinguish between a defect in platelet production or in degradation/
consumption. Here, the measurement of the number of juvenile platelets can be of great 
use. The current approach to detect juvenile platelets relies on the usage of thiazole 
orange to label mRNA, which is especially detectable in newly formed platelets.5 Since 
thiazole orange shows aspecific staining of the dense granules, results can be confounded 
by granular content.6 Although the procedures for oligo-dT staining are more laborious, 
the oligo-dT staining might be a suitable replacement for thiazole orange due to the 
higher specificity. The second novel technique is described in Chapter 4, in which a 
new integrative whole blood perfusion assay is presented that allows the simultaneous 
assessment of both platelet and coagulant functions under flow conditions. Most current 
assays only study either platelet function or coagulant activity under static conditions. 
However, platelets promote coagulation by providing a procoagulant surface for the 
assembly and activation of coagulation factors, which leads to enhanced generation of 
thrombin. Thrombin in turn is an important platelet activator. Using this novel whole 
blood perfusion assay, reciprocal effects of thrombus and fibrin formation (coagulation) 
can be studied, providing a better reflection of the patients’ hemostatic potential. 
In case immediate improvement of hemostasis is required, such as in conditions 
with a high risk of bleeding, transfusion of blood components is one of few treatment 
options available.7 However, transfusion of blood products entails several severe 
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side effects such as allergic reactions, infections and incidentally acute lung injury.7 
Furthermore, transfusion of blood products is associated with high costs. Currently, a 
substantial part of platelet concentrates (67%) is administered to patients with severe 
thrombocytopenia as a consequence of hematological malignancies and chemotherapy 
treatment.8,9 For the prevention of bleeding these patients receive prophylactic platelet 
transfusions on guidance of the platelet count, i.e. when the platelet count drops 
below 10 x109/L.8 However, in this patient population platelet count shows only a weak 
correlation with bleeding.10 In Chapter 6 we demonstrated that platelets from severely 
thrombocytopenic cancer patients treated with chemotherapy are highly dysfunctional 
in multiple aspects. We also showed variability in platelet responsiveness between 
patients, which was independent of platelet count. The next step would be to study 
whether platelet responsiveness is linked to the occurrence of bleeding. This may not 
only lead to better prevention of bleeding but also to a more efficient transfusion practice 
wherein only those patients will receive platelet concentrates that are likely to benefit. 
Ultimately this will reduce the number of platelet transfusions and thereby the negative 
side effects and high costs associated with it.  
Patients, who suffer from severe blood loss due to trauma or surgery, may require 
fluid infusion to maintain electrolyte and fluid homeostasis. However, due to the large 
volumes of fluid infused, hemostatic factors are diluted as well, resulting in a condition 
better known as dilutional coagulopathy. In order to correct the dilution of the hemostatic 
factors, transfusion of blood products is necessary. In Chapter 4 and 7, the contribution 
of multiple blood components to thrombus and fibrin formation was investigated. We 
demonstrated that the addition of fibrinogen and platelets ameliorated clot formation, 
while addition of prothrombin complex concentrate improved thrombin generation. The 
addition of red blood cells only proved to be beneficial for thrombus formation when 
thrombus formation was studied under flow using the whole blood perfusion assay. This 
highlights the importance of the incorporation of flow when studying thrombus and fibrin 
formation. Assays that are currently used in the clinic to monitor clot formation (e.g. 
thromboelastometry) measure platelet function and/or coagulant capacity under static 
conditions. Where thromboelastometry assesses hemostasis globally11 and thrombin 
generation determines the coagulant capacity in the absence or presence of platelets12, 
both assays lack the incorporation of shear stress. Here, whole blood perfusion assays 
such as described in Chapter 4, can be of great added value to determine the need and 
effect of transfusion in a clinical setting. 
In order to gain more insight into thrombosis and hemostasis, in vivo studies are of 
great importance. Chapter 8 presents a synthesis of all published studies on thrombosis 
and hemostasis in genetically altered mice. By combining the results of all studies, 
several important observations could be confirmed and made. Firstly, in vitro models 
for thrombus formation correlated well to in vivo models for thrombosis. Thereby, in 
vitro whole blood perfusion models can partly replace and refine animal models. 
Secondly, by constructing a network of all genes, new genes that are highly likely to affect 
thrombosis and hemostasis, could be detected. Using this network, also new genes could 
be identified that affected thrombosis but not bleeding and are thereby, possible new 
targets for antithrombotic therapy. 
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